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01 generaL inTroduCTion
Parts of this introduction are based on: 
Hair cortisol, stress exposure, and mental health in humans: A 
systematic review. 
Staufenbiel, S.M., Penninx, B.W.J.H., Spijker, A.T., Elzinga, B.M., & van 
Rossum, E.F.C. (2013). 
Psychoneuroendocrinology, 38(8), 1220-1235.
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Chapter 1
1 tHe HyPotHalamic-Pituitary-aDrenal (HPa) aXis
The hypothalamic-pituitary-adrenal axis (HPA axis) is a complex and dynamic system 
of direct infl uences and feedback interactions between three endocrine glands: the 
hypothalamus, the pituitary gland, and the adrenal glands. In response to stimuli from 
the central nervous system, neurons in the paraventricular nucleus of the hypothalamus 
secrete corticotrophin releasing hormone (CRH) and vasopressin [1]. CRH and vasopres-
sin stimulate the biosynthesis and secretion of adrenocorticotropic hormone (ACTH), 
which in turn acts on the adrenal cortex and stimulates production and release of 
glucocorticoid (GC) hormones. In humans, the main GC is cortisol [1]. Figure 1 gives a 
schematic overview of this mechanism.
figure 1. Schematic overview of the reg-
ulation of the HPA axis activity including 
the negative feedback loop. Picture adapt-
ed from Sweis, 2012 [2]. Abbreviations: 
CRH, corticotrophin releasing hormone; 
ACTH, adrenocorticotropic hormone; 
CORT, cortisol.
1.1 regulation of the HPa axis
In daily life, the regulation of the HPA axis is crucial for proper body and brain function-
ing as cortisol regulates numerous basal processes such as fat and glucose metabolism, 
blood pressure, infl ammatory and immune responses, and thereby aids the organism to 
fl exibly adjust to environmental challenges [3]. The three main regulatory mechanisms 
will be discussed in the subsequent sections.
1.1.1 Chronobiological Rhythms
Circulating cortisol levels of healthy persons are known to be infl uenced by diff erent 
chronobiological rhythms, i.e. the ultradian rhythm, the circadian rhythm, and seasonal 
rhythms. The ultradian rhythm is caused by oscillatory neurons in the hypothalamus, 
releasing CRH (and thereby stimulating ACTH and cortisol release) approximately 
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every 1-2 hours in a pulsatile fashion [4]. The pulsatile secretion is thought to prevent 
down-regulation of the HPA axis while maintaining its ability to respond to stressors [5]. 
While the frequency of these pulses is constant, the amplitude can vary and thereby 
allows the production of the subsequent circadian rhythm [6]. In the circadian rhythm, 
the cortisol levels rise steadily after 4.00 am, and peak approximately 30 to 40 minutes 
after awakening. This phenomenon of a morning rise is called the cortisol awakening 
response (CAR). The purpose of the CAR is uncertain, however, it has been suggested to 
be linked to the hippocampus’ preparation of the HPA axis in regard to the upcoming 
day [7]. The cortisol levels then decrease throughout the day, with a small second peak 
at early afternoon. The nadir is reached around 3.00 am. The circadian rhythm serves the 
purpose of helping the body adjust to its activities of the day and night cycles. Figure 2 
depicts the circadian rhythm of hourly measured plasma cortisol in healthy individuals.
The seasonal rhythm presents itself by higher morning and evening salivary cortisol 
levels during winter months [8], however, reasons behind the eff ect of season are not 
well understood until now [8, 9].
figure 2. Circadian rhythm of cortisol secretion in healthy individuals. Picture adapted from Kandel, 2012 [10].
1.1.2 Negative Feedback
Apart from stimulatory regulation as described above, the HPA axis also knows inhibitory 
regulation, i.e. negative feedback. The negative feedback is initiated by the circulating 
cortisol levels and occurs at both the pituitary and the hypothalamic levels, demonstrat-
ing an inhibitory action on CRH and ACTH production and thereby decreasing cortisol 
production and secretion. The so-called negative feedback loop is also shown in Figure 
1. This negative feedback can be fast, delayed, or slow feedback [11]. The fast (or rate-
sensitive) feedback occurs within seconds to minutes and depends on the rate of GC 
change in plasma, e.g. following stress-induced rises or administration of exogenous 
steroids, and results in rapid inhibition of ACTH secretion. The delayed (or intermediate) 
feedback acts within 30 minutes to hours and can aff ect responses in pituitary and hy-
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pothalamic cells. The suppression of secretion of CRH and ACTH is directly proportional 
to the concentration of GCs previously reached in the plasma. The slow feedback results 
from constant GC exposure for days to weeks and affects both basal as well as stimulated 
pituitary and hypothalamic activity [11]. Which kind of feedback is activated seems to 
depend on the rise of cortisol and the timing and duration of the stressor.
1.1.3 Stress
The third regulatory mechanism is stress. Upon appearance of a physical or psychosocial 
stressor (e.g. infection, pain, or fear), the HPA axis increases its activity to maintain the 
adaptive ability required for dealing with the stressors.
The concept of stress has evolved since the late 19th century. The term “stress” is often 
used for both a stressor and the reaction of the body to the stressor. In 1936, Selye 
coined the concept of stress and later defined stress as “a non-specific response of the 
body to any demand placed in it” [12]. He further differentiated the concept of stress 
into eustress and distress, which are positively and negatively connoted interpretations 
of a stressor, respectively; eustress is mostly short-termed and enhances performance, 
whereas distress can go on for longer periods and most often has an adverse influence 
on body and mind. Therefore, it is usually “distress” what is commonly meant when talk-
ing about “stress”. Indeed, a stressor is regarded harmful when there is a discrepancy 
between the demands of a stressor, and the perceived ability to cope with it. Lazarus 
developed a 2-stage appraisal view of stress and suggested that an individual’s stress 
level is directly affected by their cognitive appraisal of a situation [13]. During the pri-
mary appraisal, the situation is assessed to be a threat or not, and during the secondary 
appraisal, the individual evaluates whether they have the ability to effectively cope with 
the situation. In this way, secondary appraisal interacts with the primary appraisal to 
determine the emotional reaction to the situation. Indeed, the cognitive appraisal has 
been found to account for 20—30% of the stress response [14].
The stress response consists of three phases: stress reaction, recovery, and adaptation 
[15]. In reaction to basically all stressors, two classes of hormones are released; catechol-
amines and glucocorticoids, and the speed and magnitudes of both parts depend on 
the specific stressor [16]. Catecholamines such as noradrenaline or adrenaline exert 
their effects via the nervous system within seconds, thereby enabling immediate physi-
cal reactions associated with the flight-or-fight response (also known as acute stress 
reaction). Glucocorticoids such as cortisol act via the hormonal route and support the 
activity of catecholamines over the course of minutes or hours. The increased secretion 
of catecholamines and cortisol can result in temporarily increased availability of energy 
by increased muscle strength, increased memory function, increased immunity, and 
decreased sensitivity to pain [3]. This increased release is under normal circumstances 
terminated by cortisol itself via the negative feedback-loop. During the recovery phase, 
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containment of the stress reaction takes place, as well as encoding of information. Dur-
ing the adaptive phase, the experience is consolidated in memory to ensure adaptive 
behavior in the future. The adaptive stress response can turn maladaptive when chroni-
cally stimulated and can become more damaging than the stressor itself (especially 
if the stressor is purely psychological) [17]. The initiation as well as the termination of 
the stress response is susceptible to dysregulation; as these processes can be delayed, 
excessive, flattened, or prolonged [15, 18].
1.2. Dysregulation of the HPa axis
As described above, there are several regulatory mechanisms regarding the HPA axis; 
however, dysregulations can also occur. The HPA axis dysregulation can result in hypo-
cortisolism and hypercortisolism. Dysregulation can vary from extreme dysregulation to 
subtle dysregulation, and it can be caused both endogenously and exogenously.
Two well-known, extreme examples of hypo- and hypercortisolism are Addison’s 
Disease (AD) and Cushing’s Disease (CD), in which there is an under- and an overproduc-
tion of cortisol, respectively. In AD, also known as primary adrenal insufficiency, the de-
struction or dysfunction of the adrenal cortex leads to adrenal insufficiency and hence, 
hypocortisolism. Adrenal insufficiency can also be secondary (caused by impairment of 
the pituitary) or tertiary (due to impairment of the hypothalamus). Symptoms of adrenal 
insufficiency are unspecific, involving severe abdominal pains, vomiting, profound 
muscle weakness and fatigue, weight loss, hypotension, kidney failure, but also depres-
sion, and changes in mood and personality [19, 20]. In CD, a pituitary adenoma increases 
the secretion of ACTH, stimulating the synthesis of cortisol by the adrenal glands. The 
extremely high levels of cortisol lead to Cushing`s Syndrome (CS), which is a collection 
of signs and symptoms due to prolonged exposure to cortisol. Hypercortisolism can be 
primary, secondary, or tertiary, depending on whether it originates from the adrenal 
glands, the pituitary, or the hypothalamus. These signs and symptoms include weight 
gain, striae, fat accumulation in the face (moon face) and/or the neck (buffalo hump), 
hypertension, hirsutism, acne, menstrual irregularities, fatigue, osteoporosis, impaired 
immunological function, and also memory and attention dysfunction and symptoms of 
anxiety and (psychotic) depression [21-23].
The above described conditions are diseases with extreme HPA axis dysregulations 
that can present with psychopathological comorbidities. A subtle chronic dysregula-
tion of the HPA axis is thought to play a role in several psychopathological disorders; 
however, it is not known whether the dysregulation is cause or consequence of the 
psychopathological disorders. Both hypo- and hyperactivity of the HPA axis have been 
found in different psychiatric populations, for example in patients with depressive 
and anxiety disorders [24-26], or with personality disorders [27]. Abnormal CAR and/
or disturbed negative feedback mechanisms as shown by the dexamethasone suppres-
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sion test (DST) have been linked to diagnoses of depressive and anxiety disorders [25, 
26, 28]. These interactional findings are furthermore emphasized by the intriguing fact 
that, in general, a normalization of the HPA axis activity is considered a prerequisite for 
convalescence [29].
As mentioned above, apart from endogenous dysregulations, the HPA axis is also 
susceptible to exogenous influences. The most common cause of CS is iatrogenic CS, 
caused by treatment with GC medications. These medications are prescribed e.g. for 
their anti-inflammatory effects, for their immunosuppressive effects, as well as physi-
ological replacement in case of insufficient cortisol production. They can be applied in 
different forms, including pills, injections, nasal sprays, inhalation medication, topical 
ointments, and eye drops.
2. measurement of cortisol
As mentioned before, cortisol is produced in the adrenal cortex. From there, it is released 
into the systemic circulation. In blood, a high amount of cortisol (80-90 %) is bound 
to cortisol-binding globuline (CBG) and to albumin (6-15 %). The remaining, unbound 
cortisol (4-5 %) is biologically active. Several methods have been developed to measure 
cortisol levels.
One important distinction in this area is the measurement of short-term cortisol levels 
from the measurement of long-term cortisol levels, as both methods capture different 
aspects of cortisol. Research using short-term circulating cortisol levels provides valu-
able information about cortisol dynamics and stress reactivity, while studies on hair 
cortisol assess a completely different phenomenon of the HPA axis, namely that of long-
term (i.e. months to years) total cortisol exposure.
2.1. short-term measurements of cortisol
The short-term cortisol measurements consist of the measurement of cortisol in blood 
serum, saliva, or urine. These analyses offer the possibility to explore the dynamics and 
the concentrations of acutely (serum, saliva) or short-term (urine) circulating cortisol 
concentrations. The cortisol levels obtained by these techniques show considerable 
intra- and interindividual differences, which are caused by cortisol’s circadian rhythm as 
well as its pulsatile secretion [30], daily variation, and reactivity to acute transient stress, 
such as nervousness or rush [31]. These techniques further call for invasive or frequent 
sampling and in particular urinary and salivary samples are prone to measurement error 
and sloppiness as the samples are often collected by the participants themselves, with-
out supervision [32]. These are confounding variables that hamper the comparability of 
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existing studies in this area. In addition, these techniques do not cover the long-term 
effect of stress exposure very well.
2.2. long-term measurement of cortisol
The short-comings of the measurement of short-term cortisol have led to the develop-
ment of a new method to measure cortisol exposure in humans; the extraction of cortisol 
from human hair, with first evidence provided in 2004 [33]. Since then, several research 
groups have been focusing on this promising technique with some of its numerous 
advantages being the non-invasiveness, the standardized sampling, and, maybe most 
intriguing, the possibility to use hair as a retrospective biomarker of cortisol exposure. 
As hair grows approximately one centimeter per month [34], hair analysis offers the pos-
sibility to show the average long-term activity of the HPA axis, and to compare several 
hair segments/months with each other, including segments before the presence of a 
stressful event.
For the analysis, a strand of hair is cut from the posterior vertex position of the scalp. 
Cortisol of the hair segment of interest is extracted by methanol and further analyzed by 
either immunoassays or liquid chromatography tandem-mass spectrometry (LC-MS/MS) 
[35, 36]. The analysis using immunoassays such as radioimmunoassay (RIA) or enzyme-
linked immunosorbent assay (ELISA) is limited to the measurement of one steroid of 
interest in question, whereas analysis with LC-MS/MS allows the measurement of several 
steroids in one sample, thereby enabling the creation of steroid profiles. Both methods 
are depicted in Figure 3.
figure 3. The process of sample collection, preparation, and analysis. With permission from Wester [37].
3. aPPlicability of long-term cortisol researcH
Hair cortisol research is a rapidly emerging research area and has successfully been 
applied to studies of patients with varying physical and psychological symptoms, i.e. 
chronic stress and stress-related disorders and diseases (e.g. obesity and mental illness). 
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Hair cortisol research has also shown useful as a diagnostic tool for (cyclic) CS, as it offers 
the opportunity to create timelines in hair and therefore catch episodes of disease that 
are otherwise difficult to detect [38].
3.1. chronic stress
When a stressor regularly resurfaces and/or does not disappear, the stress response can-
not be terminated but continues. Individuals that undergo this prolonged stress reaction 
are therefore hypothesized to have higher cortisol concentrations in their body than 
individuals who are not exposed to chronic stress. As the increased release of cortisol 
for a prolonged period is associated with allostatic load and its deleterious effects, the 
objective assessment of chronic stress(ors) is an important prerequisite to help identify 
individuals at risk for the adverse effects of elevated cortisol, to help them reduce stress 
and to prevent further adversities.
Chronic stress is supposed to be reflected in hair cortisol concentrations. Indeed, a 
number of studies have examined the association between long-term stress exposure 
and hair cortisol, covering a range of different stressors such as endurance sport [39], 
shift work [40], unemployment [41], recent major life events (e.g. death of a close rela-
tive, serious illness, etc) [42, 43], or severe chronic pain [44], and have shown increased 
long-term cortisol levels in individuals subjected to chronic stress. Therefore, in a broad 
area of research, recent and/or ongoing stress generally seems to be associated with 
increased hair cortisol. This is in line with research on short-term cortisol measured 
with the known methods by blood, saliva, and urine, which has also reported increased 
cortisol levels in chronically stressed individuals [45, 46].
3.2. stress-related Disorders: mental Health aspects
Stress-related disease or stress-related disorder is a general term for any pathological 
condition caused by somatic or mental stress, i.e. by a period of relative hypercorti-
solism. Common examples of stress-related diseases and disorders are hypertension, 
bruxism, gastrointestinal problems, migraine, asthma, depression, anxiety, and obesity. 
Related to the presence of stress-related diseases is the assessment of stress-related 
psychological measures, which rely on individual experiences and interpretations. In 
general, the inclusion of the personal perception is an important part of stress research. 
It is an established assumption that the impact of stressful events is not only caused by 
the intensity of this event but also influenced by individual and contextual factors [47, 
48]. Coping style, composed of temperament, personality, and acquired skills, has been 
shown to influence HPA axis reactivity [49, 50]. Therefore, the assessment of these fac-
tors is important in stress research. For the assessment of stress, either objective criteria 
(such as the presence or absence of a predefined stressor) or subjective criteria can be 
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applied. The subjective impression of stress is often assessed by means of questionnaires 
which patients fill in on their own.
Previous reports on stress-related disorders have consistently associated more stress-
related physical features (such as increased BMI) with higher long-term cortisol concen-
trations [51-53]. Interestingly, the results are inconsistent when it comes to stress-related 
psychological aspects. This “lack of psychoendocrine covariance” is explainable by the 
divergence in time due to lag effects caused by different onsets and offsets of the ob-
served stress responses [54], by the fact that most studies used a hair sample reflecting 
the average cortisol exposure of three months whereas the commonly used perceived 
stress scale (PSS) includes only the previous four weeks [47], or by problems that arise 
with retrospective subjective assessment like recall bias or social desirability bias [55]. 
Furthermore, it has been proposed that psychoendocrine covariance may change over 
time in response to severe stressors, thereby reflecting the long-term alterations of HPA 
axis activity and individual psychological responses associated with a specific disorder 
[54]. However, the lack of association could also mean that perceived stress has less 
validity to increase hair cortisol concentrations than a medical diagnosis.
The role of the HPA axis in mental disorders has been explored thoroughly for several 
decades, with studies both contradicting each other as well as adding to better under-
standing. Research in the context of acutely circulating cortisol levels has also yielded 
inconsistent results concerning unipolar and bipolar depression. Increased serum [56] 
and saliva [26, 57] cortisol levels as well as decreased serum and saliva cortisol levels [58] 
and no difference in salivary cortisol levels [59] were reported, differences which could 
partly be due to different subtypes of these disorders [60]. A normalization of the HPA 
axis activity is considered a prerequisite for clinical improvement [29], and a normaliza-
tion of acutely circulating cortisol has indeed been found in patients who remit [61-63]. 
First studies on long-term cortisol levels have looked into this association [53, 64, 65].
Anxiety disorders present in a variety of manifestations and are considered a blanket 
term for disorders including generalized anxiety disorder (GAD), panic disorder (with 
or without agoraphobia), agoraphobia, specific phobia, social phobia, obsessive-com-
pulsive disorder (OCD), posttraumatic stress disorder (PTSD), and acute stress disorder 
[66]. Anxiety disorders have often been linked with abnormal dynamics of the HPA axis 
and cortisol concentrations [25, 67]. First studies on the association between long-term 
cortisol concentrations and anxiety disorders have been conducted [68-70].
3.3. cortisol-related Diseases: somatic Health aspects
Diseases that are characterized by extremely high or low cortisol levels, such as CD and 
AD, have been described above. Increased cortisol levels have also been reported in 
other medical conditions. A high level of cortisol (as seen in CS) is often marked by (ab-
dominal) obesity. This observation led to the hypothesis that also a modest increase in 
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cortisol exposure may contribute to overweight and obesity in the general population. 
Obesity has been associated with increased cortisol output, as determined by urinary 
free cortisol. Positive correlations have been reported between long-term cortisol val-
ues and body mass index (BMI) as well as waist circumference [51, 71, 72], in adult and 
paediatric cohorts [73]. Obesity is in some cases accompanied by other cardiometabolic 
risk factors such as elevated blood pressure, elevated fasting plasma glucose, high se-
rum triglycerides, and low high-density lipoprotein (HDL) levels. If three or more of these 
five medical conditions cluster, it is generally referred to as Metabolic Syndrome (MetS). 
The presence of MetS, in turn, is associated with the risk of developing cardiovascular 
disease (CVD) and diabetes mellitus [74]. First cross-sectional studies have shown that 
higher long-term cortisol levels were associated with increased presence of MetS [72] 
and with an adverse cardiovascular risk profile [75].
Apart from diseases associated with endogenously increased or decreased cortisol 
levels, cortisol can also be used in the treatment of different diseases. Hydrocortisone, 
prescribed for adrenal insufficiency (AI), is chemically identical to cortisol and is taken 
orally three times daily to mimic the circadian rhythm. First studies have used long-term 
cortisol levels as a measure to assess long-term systemic levels of administered hydro-
cortisone in AI patients [76-78], with the results indicating that long-term cortisol levels 
may be used to identify overtreatment with hydrocortisone.
4. aim anD outline of tHis tHesis
The main aim of this thesis was to examine the associations between long-term cortisol 
as measured in scalp hair and different aspects of stress-related diseases and disorders. 
For this, the thesis could incorporate data from various smaller and large-scaled patient 
cohort samples, including the Netherlands Study of Depression and Anxiety (NESDA), 
the Bipolar Stress Study, patients from the Obesity Center CGG of the Erasmus Medical 
Center, and patients from the outpatient clinic of the department of Endocrinology of 
the Leiden University Medical Center.
Our first objective was to examine which factors influence long-term corticosteroid 
levels in persons without current psychopathology to determine which covariates need 
to be taken into account when studying long-term corticosteroid measures. In chapter 
2, we therefore describe which sociodemographic, health and lifestyle, and hair (treat-
ment) characteristics affect long-term corticosteroid levels measured in scalp hair. In 
chapter 3, we investigate the associations between long-term corticosteroid levels and 
depressive and anxiety disorders and their characteristics. In chapter 4, we describe 
the effects of stressful life events, mood, and social support on long-term cortisol levels 
in patients with a bipolar disorder. In chapter 5, we describe our results of a study 
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designed to evaluate the long-term cortisol levels in three groups, i.e. in normal-weight, 
over-weight, and obese participants. In chapter 6, we compare long-term cortisol levels 
of patients with primary and secondary adrenal insufficiency on hydrocortisone replace-
ment therapy with long-term cortisol levels of control patients with a pituitary disease 
but no hydrocortisone replacement therapy, and with long-term cortisol levels of 
healthy controls. We also investigate possible determinants of long-term cortisol levels 
in patients treated with hydrocortisone, i.e. sociodemographic, health and lifestyle, and 
hair (treatment) characteristics. In chapter 7, we analyze whether long-term cortisol 
levels of patients with primary and secondary adrenal insufficiency on hydrocortisone 
replacement therapy correlate with quality of life (QoL). In the general discussion (chap-
ter 8), the results of the various study are discussed and placed within the context of 
other research groups working on the subject of long-term corticosteroids and stress-
related diseases and disorders. chapter 9 provides a summary.
019
Chapter 1
references
 1. Papadimitriou, A. and K.N. Priftis, Regulation of the hypothalamic-pituitary-adrenal axis. Neuro-
immunomodulation, 2009. 16(5): p. 265-71.
 2. Sweis, B.M., HPA Axis. 2012.
 3. Marieb, E.N. and K. Hoehn, Human anatomy & physiology. 7 ed. 2007, San Francisco: Benjamin 
Cummings.
 4. Lightman, S.L., et al., The significance of glucocorticoid pulsatility. Eur J Pharmacol, 2008. 583(2-
3): p. 255-62.
 5. Monfort, S.L., J.L. Brown, and D.E. Wildt, Episodic and seasonal rhythms of cortisol secretion in 
male Eld’s deer (Cervus eldi thamin). J Endocrinol, 1993. 138(1): p. 41-9.
 6. Veldhuis, J.D., et al., Amplitude, but not frequency, modulation of adrenocorticotropin secretory 
bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J Clin Endocrinol 
Metab, 1990. 71(2): p. 452-63.
 7. Law, R., et al., The cortisol awakening response predicts same morning executive function: results 
from a 50-day case study. Stress, 2015. 18(6): p. 616-21.
 8. Vreeburg, S.A., et al., Associations between sociodemographic, sampling and health factors and 
various salivary cortisol indicators in a large sample without psychopathology. Psychoneuroen-
docrinology, 2009. 34(8): p. 1109-20.
 9. Walker, B.R., et al., Seasonal variation in glucocorticoid activity in healthy men. J Clin Endocrinol 
Metab, 1997. 82(12): p. 4015-9.
 10. Kandel, E.R., et al., Principles of Neural Science. 5th ed. 2012: McGraw-Hill Professional.
 11. Jacobson, L., Hypothalamic-pituitary-adrenocortical axis regulation. Endocrinol Metab Clin North 
Am, 2005. 34(2): p. 271-92, vii.
 12. Selye, H., The stress of life. 1956, New York McGraw-Hill.
 13. Lazarus, R.S. and S. Folkman, Stress, appraisal, and coping. 1984, New York: Springer Pub. Co.
 14. Gaab, J., et al., Psychological determinants of the cortisol stress response: the role of anticipatory 
cognitive appraisal. Psychoneuroendocrinology, 2005. 30(6): p. 599-610.
 15. Oitzl, M.S., et al., Brain development under stress: Hypotheses of glucocorticoid actions revisited. 
Neuroscience and Biobehavioral Reviews, 2010. 34(6): p. 853-866.
 16. Pacák, K. and M. Palkovits, Stressor specificity of central neuroendocrine responses: Implications 
for stress-related disorders. Endocrine Reviews, 2001. 22(4): p. 502-548.
 17. Sapolsky, Why zebras don’t get ulcers - The acclaimed guide to stress, stress-related diseases, and 
coping. 2004, New York: Owl Books.
 18. McEwen, B.S., Mood disorders and allostatic load. Biological Psychiatry, 2003. 54(3): p. 200-207.
 19. Ten, S., M. New, and N. Maclaren, Clinical review 130: Addison’s disease 2001. J Clin Endocrinol 
Metab, 2001. 86(7): p. 2909-22.
 20. Cleghorn, R.A. and C.J. Pattee, Psychologic changes in 3 cases of Addison’s disease during treat-
ment with cortisone. J Clin Endocrinol Metab, 1954. 14(3): p. 344-52.
 21. Nieman, L.K., et al., The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice 
Guideline. J Clin Endocrinol Metab, 2008. 93(5): p. 1526-40.
 22. Dorn, L.D., et al., The longitudinal course of psychopathology in Cushing’s syndrome after correc-
tion of hypercortisolism. J Clin Endocrinol Metab, 1997. 82(3): p. 912-9.
 23. Loosen, P.T., et al., Psychiatric phenomenology in Cushing’s disease. Pharmacopsychiatry, 1992. 
25(4): p. 192-8.
020
 24. Olff, M., et al., HPA- and HPT-axis alterations in chronic posttraumatic stress disorder. Psychoneu-
roendocrinology, 2006. 31(10): p. 1220-1230.
 25. Vreeburg, S.A., et al., Salivary Cortisol Levels in Persons With and Without Different Anxiety Disor-
ders. Psychosomatic Medicine, 2010. 72(4): p. 340-347.
 26. Vreeburg, S.A., et al., Major Depressive Disorder and Hypothalamic-Pituitary-Adrenal Axis Activity 
Results From a Large Cohort Study. Archives of General Psychiatry, 2009. 66(6): p. 617-626.
 27. Lieb, K., et al., Increased diurnal salivary cortisol in women with borderline personality disorder. 
Journal of Psychiatric Research, 2004. 38(6): p. 559-565.
 28. Yehuda, R., et al., The ACTH response to dexamethasone in PTSD. American Journal of Psychiatry, 
2004. 161(8): p. 1397-1403.
 29. Holsboer, F., The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 
2000. 23(5): p. 477-501.
 30. Lightman, S.L., et al., The significance of glucocorticoid pulsatility. European Journal of Pharma-
cology, 2008. 583(2-3): p. 255-262.
 31. Hellhammer, J., et al., Several daily measurements are necessary to reliably assess the cortisol rise 
after awakening: State- and trait components. Psychoneuroendocrinology, 2007. 32(1): p. 80-86.
 32. Kudielka, B.M., J.E. Broderick, and C. Kirschbaum, Compliance with saliva sampling protocols: 
Electronic monitoring reveals invalid cortisol daytime profiles in noncompliant subjects. Psycho-
somatic Medicine, 2003. 65(2): p. 313-319.
 33. Raul, J.S., et al., Detection of physiological concentrations of cortisol and cortisone in human hair. 
Clinical Biochemistry, 2004. 37(12): p. 1105-1111.
 34. Wennig, R., Potential problems with the interpretation of hair analysis results. Forensic Science 
International, 2000. 107(1-3): p. 5-12.
 35. Manenschijn, L., et al., Evaluation of a method to measure long term cortisol levels. Steroids, 2011. 
76(10-11): p. 1032-1036.
 36. Gow, R., et al., An assessment of cortisol analysis in hair and its clinical applications. Forensic 
Science International, 2010. 196(1-3): p. 32-37.
 37. Wester, V.L. and E.F. van Rossum, Clinical applications of cortisol measurements in hair. Eur J 
Endocrinol, 2015. 173(4): p. M1-10.
 38. Manenschijn, L., et al., A novel tool in the diagnosis and follow-up of (cyclic) Cushing’s syndrome: 
measurement of long-term cortisol in scalp hair. J Clin Endocrinol Metab, 2012. 97(10): p. E1836-
43.
 39. Skoluda, N., et al., Elevated hair cortisol concentrations in endurance athletes. Psychoneuroendo-
crinology, 2012. 37(5): p. 611-617.
 40. Manenschijn, L., et al., Shift Work at Young Age Is Associated with Elevated Long-Term Cortisol 
Levels and Body Mass Index. Journal of Clinical Endocrinology & Metabolism, 2011. 96(11): p. 
E1862-E1865.
 41. Dettenborn, L., et al., Higher cortisol content in hair among long-term unemployed individuals 
compared to controls. Psychoneuroendocrinology, 2010. 35(9): p. 1404-9.
 42. Karlén, J., et al., Cortisol in hair measured in young adults - a biomarker of major life stressors? 
BMC Clin Pathol, 2011. 11(1): p. 12.
 43. Staufenbiel, S.M., et al., Recent negative life events increase hair cortisol concentrations in pa-
tients with bipolar disorder. Stress, 2014. 17(6): p. 451-9.
 44. Van Uum, S.H.M., et al., Elevated content of cortisol in hair of patients with severe chronic pain: A 
novel biomarker for stress. Stress-the International Journal on the Biology of Stress, 2008. 11(6): 
p. 483-488.
021
Chapter 1
 45. Hackney, A.C. and A. Viru, Twenty-four-hour cortisol response to multiple daily exercise sessions 
of moderate and high intensity. Clinical Physiology, 1999. 19(2): p. 178-182.
 46. Wong, I.S., et al., Job Strain and Shift Work Influences on Biomarkers and Subclinical Heart Disease 
Indicators: A Pilot Study. Journal of Occupational and Environmental Hygiene, 2012. 9(8): p. 467-
477.
 47. Cohen, S., T. Kamarck, and R. Mermelstein, A global measure of perceived stress. J Health Soc 
Behav, 1983. 24(4): p. 385-96.
 48. Mason, J.W., A re-evaluation of the concept of “non-specificity” in stress theory. Journal of Psychi-
atric Research, 1971. 8(3): p. 323-33.
 49. Binder, E.B. and F. Holsboer, Low Cortisol and Risk and Resilience to Stress-Related Psychiatric 
Disorders. Biological Psychiatry, 2012. 71(4): p. 282-283.
 50. Hammerfald, K., et al., Persistent effects of cognitive-behavioral stress management on cortisol 
responses to acute stress in healthy subjects - A randomized controlled trial. Psychoneuroendo-
crinology, 2006. 31(3): p. 333-339.
 51. Manenschijn, L., et al., Shift work at young age is associated with elevated long-term cortisol 
levels and body mass index. J Clin Endocrinol Metab, 2011. 96(11): p. E1862-5.
 52. Feller, S., et al., Predictors of hair cortisol concentrations in older adults. Psychoneuroendocrinol-
ogy, 2014. 39: p. 132-40.
 53. Kuehl, L.K., et al., Hair cortisol and cortisol awakening response are associated with criteria of the 
metabolic syndrome in opposite directions. Psychoneuroendocrinology, 2015. 51: p. 365-70.
 54. Schlotz, W., et al., Covariance between psychological and endocrine responses to pharmacologi-
cal challenge and psychosocial stress: A question of timing. Psychosomatic Medicine, 2008. 70(7): 
p. 787-796.
 55. Stalder, T., et al., Cortisol in hair, body mass index and stress-related measures. Biological Psychol-
ogy, 2012. 90(3): p. 218-223.
 56. Gillespie, C.F. and C.B. Nemeroff, Hypercortisolemia and depression. Psychosomatic Medicine, 
2005. 67: p. S26-S28.
 57. Cervantes, P., et al., Circadian secretion of cortisol in bipolar disorder. Journal of Psychiatry & 
Neuroscience, 2001. 26(5): p. 411-416.
 58. Strickland, P.L., et al., Bio-social origins of depression in the community - Interactions between 
social adversity, cortisol and serotonin neurotransmission. British Journal of Psychiatry, 2002. 180: 
p. 168-173.
 59. Manenschijn, L., et al., Long-term cortisol in bipolar disorder: Associations with age of onset and 
psychiatric co-morbidity. Psychoneuroendocrino, in press.
 60. Gold, P.W. and G.P. Chrousos, Organization of the stress system and its dysregulation in melan-
cholic and atypical depression: high vs low CRH/NE states. Molecular Psychiatry, 2002. 7(3): p. 
254-275.
 61. Hennings, J.M., et al., Clinical characteristics and treatment outcome in a representative sample 
of depressed inpatients - Findings from the Munich Antidepressant Response Signature (MARS) 
project. Journal of Psychiatric Research, 2008. 43(3): p. 215-229.
 62. Aperia, B., Hormone Pattern and Posttreatment Attitudes in Patients with Major Depressive Disor-
der Given Electroconvulsive-Therapy. Acta Psychiatrica Scandinavica, 1986. 73(3): p. 271-274.
 63. Deshauer, D., et al., Salivary cortisol secretion in remitted bipolar patients and offspring of bipolar 
parents. Bipolar Disorders, 2006. 8(4): p. 345-349.
022
 64. Dettenborn, L., et al., Introducing a novel method to assess cumulative steroid concentrations: 
increased hair cortisol concentrations over 6 months in medicated patients with depression. 
Stress, 2012. 15(3): p. 348-53.
 65. Wei, J., et al., Analysis of hair cortisol level in first-episodic and recurrent female patients with 
depression compared to healthy controls. J Affect Disord, 2015. 175C: p. 299-302.
 66. American Psychiatric Association, Diagnostic and statistical manual of mental disorders: DSM-IV-
TR. 4th ed. 2000, Washington, DC: American Psychiatric Association.
 67. Pervanidou, P. and G.P. Chrousos, Neuroendocrinology of post-traumatic stress disorder. Neuro-
endocrinology: Pathological Situations and Diseases, 2010. 182: p. 149-160.
 68. Groer, M.W., et al., Relationship of PTSD Symptoms With Combat Exposure, Stress, and Inflamma-
tion in American Soldiers. Biol Res Nurs, 2014.
 69. Steudte, S., et al., Decreased hair cortisol concentrations in generalised anxiety disorder. Psychia-
try Res, 2011. 186(2-3): p. 310-4.
 70. Steudte, S., et al., Increased cortisol concentrations in hair of severely traumatized Ugandan 
individuals with PTSD. Psychoneuroendocrinology, 2011. 36(8): p. 1193-200.
 71. Manenschijn, L., et al., Evaluation of a method to measure long term cortisol levels. Steroids, 2011. 
76(10-11): p. 1032-6.
 72. Stalder, T., et al., Cortisol in hair and the metabolic syndrome. J Clin Endocrinol Metab, 2013. 98(6): 
p. 2573-80.
 73. Veldhorst, M.A., et al., Increased scalp hair cortisol concentrations in obese children. J Clin Endo-
crinol Metab, 2014. 99(1): p. 285-90.
 74. Kaur, J., A comprehensive review on metabolic syndrome. Cardiol Res Pract, 2014. 2014: p. 943162.
 75. Manenschijn, L., et al., High long-term cortisol levels, measured in scalp hair, are associated with 
a history of cardiovascular disease. J Clin Endocrinol Metab, 2013. 98(5): p. 2078-83.
 76. Gow, R., et al., Hair cortisol content in patients with adrenal insufficiency on hydrocortisone 
replacement therapy. Clin Endocrinol (Oxf ), 2011. 74(6): p. 687-93.
 77. Noppe, G., et al., Elevated hair cortisol concentrations in children with adrenal insufficiency on 
hydrocortisone replacement therapy. Clin Endocrinol (Oxf ), 2014. 81(6): p. 820-5.
 78. Manenschijn, L., M. Quinkler, and E.F. van Rossum, Hair cortisol measurement in mitotane-treated 
adrenocortical cancer patients. Horm Metab Res, 2014. 46(4): p. 299-304.
023
02 deTerminanTs of Hair CorTisoL and Hair CorTisone 
ConCenTraTions in aduLTs
Staufenbiel, S.M., Penninx, B.W.J.H., de Rijke, Y.B., van den Akker, 
E.L.T., & van Rossum, E.F.C. (2013). Psychoneuroendocrinology, 60, 
182-194.
024
abstract
background
The analysis of hair cortisol concentrations (HairF) is a promising new tool for the as-
sessment of long-term cortisol. With the development of multiple steroid analyses by 
means of liquid chromatography tandem-mass spectrometry (LC-MS/MS), the analysis 
of cortisone in hair (HairE) has also been facilitated. However, the influence of various 
types of determinants on HairF and HairE is still largely unknown. This study systemati-
cally assesses the influence of sociodemographic, health, lifestyle, and hair (treatment) 
characteristics on HairF and HairE.
methods
Data of 760 psychiatrically healthy participants (71.8% female, mean age 45.89 years) of 
the Netherlands Study of Depression and Anxiety (NESDA) were used. HairF and HairE 
were measured in the proximal 3 cm of scalp hair, using LC-MS/MS.
results
HairF and HairE strongly correlated. In simple linear regressions, HairF and HairE were 
higher in older age, in presence of diabetes mellitus, and in men compared to women. 
More frequent washing of the hair was associated with lower HairF and HairE. Darker 
hair colours were associated with higher HairF and HairE. An effect of season and of 
use of oral contraceptives was found for HairF. After full mutual adjustment, only age, 
presence of diabetes mellitus, hair washing frequency, and season remained significant 
determinants of HairF.
conclusions
This large-scale study shows that HairF and HairE are upregulated in older age and 
in the presence of diabetes mellitus. This suggests that these levels are important for 
somatic health and should be taken into account when using hair corticosteroid analysis 
in future studies.
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introDuction
The hypothalamic-pituitary-adrenal (HPA) axis has been subjected to a wide array of 
research questions, with one of the main interest areas being one of its end products, 
the hormone cortisol.
Until a decade ago, cortisol had predominantly been measured in saliva, serum or 
urine, which allows analyzing the dynamics of cortisol production for up to 24 hours. 
Then, a new technique was developed to measure long-term cortisol levels in scalp hair, 
allowing quantifying the average cortisol production for a period ranging from one 
month to several months or even years [1, 2]. The number of studies on hair cortisol 
concentrations (HairF) substantially increased throughout the past years [3]. While HairF 
tend to remain stable in health, increased as well as decreased HairF have been associ-
ated with a range of pathological and psychological conditions such as cardiovascular 
disease, obesity, Cushing’s disease, and mood and anxiety disorders [4-8].
Determinants of HairF have been described before [9-11]. Two of these studies [9, 10] 
investigated simple associations of different socioeconomic and health variables with 
HairF, whereas one study [11] reported socioeconomic and health-related determinants 
of HairF in older adults using partial and full mutual adjustment. The first two studies 
showed associations of HairF with age (higher HairF in young and old age), sex (men 
show higher HairF than females), metabolic syndrome (MetS) (higher HairF in presence 
of MetS), and weight-related anthropometric measures (increasing HairF with increas-
ing body mass index (BMI). The third study confirmed these simple associations and 
reported positive associations with smoking, diabetes mellitus, mental health, daytime 
sleeping, working status, and negative associations with diastolic blood pressure. How-
ever, in full mutual adjustment, only age and smoking remained independent predictors 
of HairF. These studies have produced important results, however, a systematic study 
with a large sample size and partial as well as mutual adjustment for predictors of HairF 
in a younger age group is still lacking. Furthermore, in different publications, the ef-
fects of sociodemographic and health and lifestyle variables on HairF show a noticeable 
discrepancy. Existing literature aiming at summarizing the effects of influencing factors 
have reported inconsistent and conflicting results for age, sex, alcohol and nicotine use, 
physical activity, and for hair (treatment) characteristics. Factors that could account 
for these incongruent findings are the relatively small sample sizes, therefore possibly 
rendering power problems. Furthermore, most studies varied in the extent to which 
they took other covariates into account. Disentangling these effects is of paramount 
importance to enable future studies to adjust their analyses for potential confounding 
factors. This seems especially important for research on stress and mental illness, as the 
effects of these conditions on the HPA-axis have been shown to be small [12], render-
ing them vulnerable to being overshadowed by stronger effects when these are not 
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controlled for. This could be one of the reasons that for example self-reported stress, has 
shown divergent relations with HairF, with positive, inverse, and no correlations [see 12, 
for review].
Until now, most studies on HairF have been conducted using immunoassays [13]. With 
the recent development and validation of HairF measurements with liquid chromatogra-
phy tandem-mass spectrometry (LC-MS/MS) [14, 15], the quantification of other steroids 
in scalp hair has become possible. As cortisol can be converted into inactive cortisone, 
the assessment of hair cortisone (HairE) in parallel to HairF may give even more insight 
into the cumulative amount of active and inactive corticosteroids in the body. Follow-
ing the argumentation of Stalder et al. [16], as recent research suggested that under 
specific circumstances, salivary cortisone may provide a better reflection of systemic 
cortisol levels than salivary F [17]. The authors showed that salivary cortisone closely 
reflected free serum cortisol after adrenal stimulation and hydrocortisone administra-
tion, and that it was unaffected by changes in corticosteroid-binding globulin (CBG). 
Furthermore, because HairE has been shown to be approximately 3-4-fold higher than 
HairF [16], it might also be more readily measureable than HairF. To further investigate 
the relevance of HairE, we also calculated the F/E-ratio, and an additive F+E measure as 
an indication of total glucocorticoid supply.
Results on both HairF and HairE have been reported in first publications [2, 16, 18, 
19]. In all studies, HairF and HairE strongly correlated. However, all reports on HairE have 
been exploratory, and as of yet no study has set out to systematically assess determi-
nants of HairE. The relevance of these determinants follows the same argumentation as 
for the determinants of HairF described above [19].
We therefore set out to examine the wide range of potential determinants of both 
HairF and HairE levels within one well-studied cohort. This seems necessary for future 
research as it aids in deciding which factors need to be assessed apart from the vari-
able of interest in order to control for their influence on HairF and HairE. The present 
study uses detailed information of 760 subjects participating in the Netherlands Study 
of Depression and Anxiety (NESDA) to examine which 1) sociodemographic, 2) health & 
lifestyle, and 3) hair (treatment) characteristics affect long-term HairF and HairE levels 
measured in scalp hair.
materials anD metHoDs
study sample
Data were derived from the Netherlands Study of Depression and Anxiety (NESDA), 
an ongoing longitudinal cohort study on the predictors, course and consequences of 
depressive and anxiety disorders. The NESDA sample consists of 2981 participants aged 
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18–65 years at inclusion, comprising persons with no depressive or anxiety disorder, 
persons who have had a disorder in the past, and persons with a current depressive and/
or anxiety disorder. A detailed description of the NESDA study can be found elsewhere 
[20]. The research protocol was approved by the Ethical Committee of the participating 
research centers, and all participants provided written informed consent. Hair data col-
lection was added to NESDA’s 6-year follow-up assessment, in which 2256 participants 
of the initial 2981 sample participated (75.68%). All determinants used for the present 
analysis were measured during this 6-year follow-up wave. For the present study, we only 
selected persons without recent (1-year recency) psychopathology in order to obtain an 
indication of the main determinants of HairF and HairE unbiased by potential HPA-axis 
altering effects by underlying psychopathology. A total of 1536 were considered ‘psychi-
atrically healthy’ as they had no recent depressive disorder, bipolar disorder, or anxiety 
disorder, as defined on the basis of the Composite International Diagnostic Interview 
(CIDI) [21]. Further inclusion criteria were willingness to provide a hair sample, sufficient 
hair growth at the posterior vertex position of the head, and a hair sample weight of at 
least 5 mg, rendering an initial sample of n = 1141 participants. Exclusion criteria for the 
present study were the use of antidepressants and (frequent use of ) benzodiazepines 
(n = 190), and use of corticosteroids (n = 126, of which n = 88 confirmed and n = 38 
unclear), resulting in a sample of 825 subjects.
Hairf and Haire measurement
During the visit at the research facility, hair strands of approximately 100 hairs were cut 
as close as possible from the scalp from a posterior vertex position. The most proximal 
three cm of hair were used for analysis. Based on a mean hair growth rate of one cm per 
month [22], the hair samples reflect the cumulative cortisol and cortisone secretion of 
the previous three months. Hair samples were weighted, finely cut with surgical scissors, 
and washed with 1.0mL of LC-MS grade isopropanol for two minutes. The extraction of 
cortisol and cortisone was achieved by overnight incubation with 1.4 mL LC-MS grade 
methanol and in presence of 100 μL internal standard (cortisol-d4) for 18 hours at 25 
⁰C while gently shaking. The analysis using LC-MS/MS including matrix interferences 
has extensively been described elsewhere [15]. The inter-day variation in the present 
study was <8.3% for cortisol and <4.8% for cortisone. Steroid peak integrations were 
reviewed and manually integrated by two independent persons when automated peak 
integration feature incorrectly or partially integrated peaks. The analyses were success-
fully performed in 760 participants, who comprised the final sample. In 65 individuals, 
HairF and HairE levels could not be determined due to interference in the sample by 
unknown compounds.
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sociodemographic variables, health and lifestyle factors, and hair (treatment) 
characteristics
The sociodemographic factors included sex, age, educational level (years of attained 
education), and ancestry (North-European or not North-European). Health and lifestyle 
factors included alcohol consumption, smoking behaviour, physical activity levels, as 
well as waist and hip circumference, presence of diabetes mellitus, hypertension, and 
other chronic disease information. Waist and hip circumference were each determined 
twice with a measuring tape, and the average of both measurements was used. Diabe-
tes mellitus and hypertension were ascertained using self-report. Other self-reported 
chronic diseases (lung disease, cancer, rheumatic, intestinal and liver disease) were 
grouped in an “other disease” indicator. For subgroup analyses in women, information 
on the use of oral contraceptives and pregnancy was obtained. Alcohol consumption 
was categorized into non-drinker, moderate drinker, and hazardous drinker according to 
the Alcohol Use Disorders Identification Test (AUDIT) [23], and also expressed as number 
of units of alcohol per week. Smoking status was categorized into current smoker or 
non-smoker, and the number of cigarettes per week was recorded. The average number 
of cigarettes per week was calculated on all subjects. Non-smokers are represented 
in all analyses with zero cigarettes per week. Physical activity was assessed with the 
International Physical Activity Questionnaire (IPAQ) and expressed per 1000 metabolic 
equivalent of task minutes (MET-min) a week. A self-developed questionnaire was used 
to assess hair characteristics. Participants were asked to indicate their natural hair color 
(blond, brown, red, black, or grey) and whether their hair was dyed and/or bleached 
and/or permed in the previous three months. The hair washing frequency (<3 times a 
week or ≥3 times per week) was assessed, as was the use of any products except for 
shampoo on the scalp on the day of sample collection. The day of sample collection was 
used for the calculation of the season that was represented in the most proximal three 
cm of hair.
statistical analysis
SPSS 20.0 for Windows (IBM, Chicago, Illinois) was used for statistical analysis. HairF 
and HairE values were logarithmically transformed to achieve normal distribution. 
For descriptive purposes, HairF and HairE are provided in pg/mg and are reported as 
median (Mdn) and interquartile range (IQR). Other data, unless otherwise indicated, 
are presented in original units with mean (M) and standard deviation (SD), or in sample 
size (n) and percentage (%). In a first step, associations between HairF, HairE, and 
socio-demographic, health and lifestyle factors, and hair treatment) characteristics were 
examined using simple linear regression analyses. In the next step, partially adjusted 
regression models with adjustment for sex and age were conducted. In a final step, fully 
adjusted regression analyses with all variables entered simultaneously were performed 
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to examine the independence of HairF and HairE predictors. Variables that were valid for 
women only (i.e. hormonal contraceptives and pregnancy) were not included in the fully 
adjusted model, however, the analyses were stratified and rerun for women with these 
variables included. The results of the linear regression are reported as standardized coef-
ficients (beta), and p-value. The significance level was set at p = 0.05.
Of the 760 participants, 616 provided a full dataset without any missing values. The 
missing information were as follows: 1.1% alcohol consumption, 0.1% smoking, 6.8% 
physical activity, 3.2% waist circumference, 3.0% hip circumference, 3.0% natural hair 
color, 3.2% hair treatment, 3.0% hair washing frequency, and 3.0% use of hair styling 
products. Multiple imputation was used to complete the dataset, assuming a missing at 
random approach and creating five imputed datasets. All characteristics were used as 
predictors to impute missing values, and the observed minimum and maximum values 
of from the original full dataset were used as constraints. The pooled estimates of the 
five imputed datasets are reported.
results
sample characteristics
The sample characteristics of the 760 participants (71.8 % female) are presented in 
Table 1. The median HairF of this sample was 3.18 (2.16 – 5.58) pg/mg hair, whereas the 
median HairE of this sample was 10.52 (7.41 – 15.22) pg/mg hair. 
table 1. Descriptive information of the study population
Characteristics All (n = 760) Women (n = 546) Men (n = 214)
Sociodemographics
Age (in years) 45.89 (13.80) 45.45 (13.33) 47.00 (14.91)
Educational level (in years) 13.35 (3.29) 13.42 (3.28) 13.18 (3.30)
North-European ancestry 736 (96.8 %) 526 (96.3 %) 210 (98.1 %)
Health and lifestyle indicators
Alcohol consumption (units/week) 5.84 (7.44) 4.69 (6.07) 8.80 (9.54)
No alcohol consumption (categories) 114 (15.0 %) 92 (16.9) 22 (10.3 %)
 moderate 539 (70.9 %) 401 (73.4 %) 137 (64.0 %)
 hazardous 107 (14.1 %) 53 (9.7 %) 54 (25.2 %)
Smoking (cigarettes/week) 16.04 (41.03) 14.94 (39.00) 18.87 (45.77)
Smoking (current) 117 (23.3 %) 122 (22.3 %) 55 (25.7 %)
No use of hormonal contraceptives* n/a 401 (73.4 %) n/a
 Oral contraceptives n/a 80 (14.7 %) n/a
 Other n/a 65 (11.9 %) n/a
Pregnancy* n/a 23 (4.2 %) n/a
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HairF and HairE showed a significant positive linear correlation with each other, r = .55, 
p <.001 (Figure 1).
table 1. Descriptive information of the study population (continued)
Characteristics All (n = 760) Women (n = 546) Men (n = 214)
Physical activity (1000 MET-min/week) 3.99 (3.37) 3.88 (3.20) 4.27 (3.78)
Waist circumference (in cm) 90.36 (13.41) 87.73 (12.34) 97.06 (13.72)
Hip circumference (in cm) 104.27 (10.22) 104.09 (10.75) 104.73 (8.72)
Diabetes mellitus 28 (3.7 %) 12 (2.2 %) 16 (7.5 %)
Hypertension 115 (15.1 %) 72 (13.2 %) 43 (10.1 %)
Other chronic disease 154 (20.3 %) 113 (20.7 %) 41 (19.2 %)
Hair (treatment) characteristics
Natural hair color black 38 (5.0 %) 22 (4.0 %) 17 (7.9 %)
Natural hair color brown 233 (30.7 %) 175 (32.1 %) 58 (27.1 %)
Natural hair color blond 331 (43.6 %) 254 (46.5 %) 78 (36.5 %)
Natural hair color red 26 (3.4 %) 22 (4.0 %) 4 (1.9 %)
Natural hair color grey 132 (17.4 %) 74 (13.6 %) 58 (27.1 %)
No hair treatment in past 3 months 496 (65.3 %) 286 (52.4 %) 210 (98.1 %)
 Hair dyed 69 (9.1 %) 65 (11.9 %) 4 (1.9 %)
 Hair bleached 223 (29.3 %) 221 (40.5 %) 2 (0.9 %)
 Hair permed 20 (2.6 %) 19 (3.5 %) 1 (0.5 %)
Hair washing frequency (≥ 3/week) 538 (70.8 %) 381 (69.8 %) 156 (73.1 %)
Use of hair styling products on day of  sampling 333 (43.8 %) 249 (45.6 %) 85 (39.7 %)
Season represented in hair sample
Winter 168 (22.1 %) 127 (23.3 %) 41 (19.2 %)
Spring 184 (24.2 %) 126 (23.1 %) 58 (27.1 %)
Summer 200 (26.3 %) 143 (26.2 %) 57 (26.2 %)
Fall 208 (27.4 %) 150 (27.5 %) 58 (27.1 %)
Data are presented as pooled mean (pooled standard deviation), and as pooled n (pooled percentage). Met-
min, minutes of metabolic energy turnover; *, in women only; n/a, not applicable; other chronic diseases, lung 
disease, cancer, rheumatic, intestinal and liver disease.
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figure 1. The association between HairE and HairF. 
Both are expressed as log-transformed values of the 
respective hormone in pg/mg hair.
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associations with Hairf concentrations
In partially adjusted regression analyses, men showed significantly higher HairF than 
women (3.57 (2.42 – 7.89) vs. 2.98 (2.07 – 5.19)), β = .104, p = 0.003 (Table 2). Older age 
was significantly associated with higher HairF (β = .184, p < 0.001). Higher waist circum-
ference was related to higher HairF (β = .089, p < 0.03). HairF were also higher in case 
of diabetes mellitus (β = .092, p = 0.01). Natural hair color showed an association with 
HairF, indicating that persons with black hair had increased HairF compared to persons 
with other hair colors (β = .084, p = .02). The hair washing frequency was also associated 
with altered HairF (β = -.118, p = 0.002), demonstrating that persons who wash their hair 
three or more times a week have lower HairF (2.97, 2.05 – 4.86) than persons who wash 
their hair twice a week or less (3.81, 2.54 – 8.64). An effect of season was detected, in that 
hair samples representing covering winter months show lower HairF than hair samples 
covering spring and summer (β = -.120, p = .007, and β = -.097, p = .03, respectively). In 
women, use of oral contraceptives was associated with higher HairF (β = .107, p = .01).
table 2. Regression analyses on HairF and HairE
Characteristics
Standardized 
simple linear 
regression 
coefficients p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(adjusted for 
sex and age)1 p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(mutual 
adjustment)2 p-value
Sex (female) -.114 .002 -.104 .003 -.070 .117 HairF
-.173 <.001 -.160 <.001 -.057 .186 HairE
Age (years) .189 <.001 .184 <.001 .108 .028 HairF
.264 <.001 .255 <.001 .155 .001 HairE
Educational level (years) -.035 .332 .005 .883 .029 .470 HairF
-.068 .060 -.012 .735 -.011 .786 HairE
North-European ancestry -.021 .562 -.031 .383 -.020 .594 HairF
-.017 .647 -.031 .369 -.020 .583 HairE
Alcohol consumption 
   (units/week)
.078 .032 .011 .774 .015 .708 HairF
.154 <.001 .061 .100 .059 .123 HairE
No alcohol consumption  
   (categories)
Ref Ref Not included
  moderate -.031 .520 -.039 .402 HairF
-.019 .724 -.069 .539 HairE
  hazardous .041 .384 .018 .698 HairF
.061 .226 .071 .619 HairE
Smoking (cigarettes/week) .026 .482 .022 .534 .021 .562 HairF
.066 .068 .061 .078 .054 .132 HairE
Smoking (current) .046 .207 .049 .166 Not included HairF
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table 2. Regression analyses on HairF and HairE (continued)
Characteristics
Standardized 
simple linear 
regression 
coefficients p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(adjusted for 
sex and age)1 p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(mutual 
adjustment)2 p-value
.075 .039 .079 .022 Not included HairE
No use of hormonal 
   contraceptives*
Ref Ref Not included
Oral contraceptives .017 .684 .107 .014 HairF
-.093 .027 .004 .923 HairE
Other -.047 .257 .013 .749 HairF
-.053 .210 .012 .777 HairE
Pregnancy* -.031 .449 .016 .692 Not included
-.040 .353 .021 .629
Physical activity (1000 .025 .488 .006 .876 .023 .549 HairF
MET-min/week) -.008 .833 -.036 .299 -.027 450 HairE
Waist circumference (cm) .166 <.001 .089 .026 .107 .107 HairF
.202 <.001 .082 .036 .116 .074 HairE
Hip circumference (cm) .085 .020 .062 .083 -.005 .927 HairF
.067 .066 .034 .323 -.038 .494 HairE
Diabetes mellitus .134 <.001 .092 .011 .095 .011 HairF
.137 <.001 .075 .034 .056 .120 HairE
Hypertension .086 .017 .009 .815 -.019 .648 HairF
.148 <.001 .044 .244 .012 .763 HairE
Other chronic disease .043 .235 -.002 .957 -.001 .980 HairF
.102 .005 .042 .237 .037 .309 HairE
Natural hair color blond Ref Ref Ref
Natural hair color brown .023 .561 .013 .744 -.002 .959 HairF
.090 .021 .076 .045 .056 .141 HairE
Natural hair color black .106 .004 .084 .023 .064 .110 HairF
.099 .010 .066 .081 .062 .125 HairE
Natural hair color red -.003 .937 -.001 .986 -.028 .525 HairF
.032 .404 .036 .334 .034 .406 HairE
Natural hair color grey .110 .005 .007 .874 .004 .927 HairF
.179 <.001 .033 .441 .012 .779 HairE
No hair treatment in past .003 .946 -.041 .317 .050 .675 HairF
3 months .134 <.001 .097 .013 -.010 .932 HairE
  Hair dyed -.017 .644 .014 .701 .006 .922 HairF
-.076 .042 -.032 .373 -.040 .532 HairE
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A fully adjusted regression was conducted with all variables entered (Table 2). This 
analysis revealed that with mutual adjustment, the effects of age, diabetes mellitus, 
hair washing frequency, and season remained statistically significant. Using only these 
significant variables in a regression analyses resulted in a model fit of .07 (adjusted r²). 
The analyses were stratified for sex, and in analyses on women, use of oral contracep-
tives and pregnancy were included in the model. In this model, full adjustment resulted 
in a model in which only age, diabetes mellitus, and use of oral contraceptives remained 
significant, with a resulting model fit of .06 (adjusted r²). Age remained the strongest 
predictor of HairF. Its relation with HairF is depicted in Figure 2, illustrating a rather linear 
association between age and HairF both in men and women.
table 2. Regression analyses on HairF and HairE (continued)
Characteristics
Standardized 
simple linear 
regression 
coefficients p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(adjusted for 
sex and age)1 p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(mutual 
adjustment)2 p-value
  Hair bleached .014 .704 .051 .193 .093 .398 HairF
-.125 .001 -.094 .014 -.082 .468 HairE
  Hair permed .014 .701 .018 .634 .033 .479 HairF
-.037 .364 -.032 .431 -.032 .507 HairE
Hair washing frequency 
   (≥ 3/week)
-.157 <.001 -.118 .002 -.135 .001 HairF
-.179 <.001 -.121 .002 -.116 .003 HairE
Use of hair styling products 
   on day of sampling
-.061 .093 -.006 .880 .004 .924 HairF
-.155 <.001 -.083 .022 -.053 .149 HairE
Season Winter Ref Ref Ref
  Season Spring .099 .031 .120 .007 .138 .002 HairF
.030 .516 .057 .191 .079 .074 HairE
  Season Summer .086 .061 .097 .032 .115 .012 HairF
.045 .333 .057 .191 .077 .079 HairE
  Season Fall .069 .113 .078 .086 .101 .028 HairF
-.025 .591 -.015 .740 .005 .916 HairE
Met-min, minutes of metabolic energy turnover; *, in women only; other chronic disease, lung disease, cancer, 
rheumatic, intestinal and liver disease.
1Age and sex themselves were only adjusted for each other.
2Multiple linear regression was performed including all variables listed in the table except for use of hormonal 
contraceptives and pregnancy (due to sex-specificity) and except for categories of alcohol consumption and 
smoking, as the continuous variable was already included.
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figure 2. Upper row: The correlation between age and HairF (log-transformed), stratifi ed for sex. Lower row: 
The correlation between age and HairE (log-transformed), stratifi ed for sex.
associations with Haire concentrations
As for HairF, men showed signifi cantly higher HairE than women (11.57 (8.49 – 18.28) 
vs. 10.15 (7.02 – 14.27)), β = .160, p < .001 (Table 2). Older age was also signifi cantly 
associated with higher HairE (β = .255, p < 0.001). Current smokers demonstrated higher 
HairE than non-smokers (β = .079, p = .02). Higher waist circumference and the presence 
of diabetes mellitus were associated with higher HairE (β = .082, p = .04, and β = .075, p 
= .03, respectively). The natural hair color showed an association with HairE, indicating 
that persons with brown hair had higher HairE compared to persons with blond hair (β 
= .076, p = .05). Bleaching of the hair as well as frequently washing of the hair and use of 
hair products was all associated with lower HairE (β = -.094, p = .01, β = -.121, p = .002, 
and β = -.083, p = .02, respectively).
A mutually adjusted regression was run with all variables. In this analysis, age and 
hair washing frequency remained signifi cant. The model fi t was .08 (adjusted r²). Age 
remained the strongest predictor of HairE, and both in men and women, age showed a 
signifi cant positive linear association with HairE (Figure 2).
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associations with Hairf/Haire ratio and sum of Hairf+Haire
In adjusted analyses, the ratio HairF/HairE showed associations with use of oral contra-
ceptives in women (β = .119, p = .01), as well as with season. The sum of HairF+HairE 
was significantly associated with age (β = .150, p = .002), presence of diabetes mellitus 
(β = .082, p = .03), hair washing frequency (β = -.132, p = .001), and season. No other 
associations reached significance with mutual adjustment (Table 3).
table 3. Regression analyses on the ratio HairF/HairE and the sum HairF+HairE
Characteristics
Standardized 
simple linear 
regression 
coefficients p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(adjusted for 
sex and age)1 p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(mutual 
adjustment)2 p-value
Sex (female) .010 .783 .011 .772 -.035 .450 Ratio
-.165 <.001 -.152 <.001 -.079 .073 Sum
Age (years) .011 .770 .011 .759 .004 .932 Ratio
.257 <.001 .250 <.001 .150 .002 Sum
Educational level (years) .013 .722 .015 .678 .043 .297 Ratio
-.068 .059 -.014 .696 .000 .992 Sum
North-European ancestry -.009 .813 -.008 .816 -.003 .927 Ratio
-.013 .727 -.027 .443 -.011 .756 Sum
Alcohol consumption 
   (units/week)
-.031 .397 -.035 .370 -.029 .468 Ratio
.124 .001 .032 .397 .032 .404 Sum
No alcohol consumption  
   (categories)
Ref Ref Not included
  moderate -.015 .759 -.014 .769 Not included Ratio
-.040 .416 -.053 .274 Not included Sum
  hazardous .000 1.000 .003 .950 Not included Ratio
.049 .311 .015 .755 Not included Sum
Smoking (cigarettes/week) -.024 .512 -.023 .521 -.020 .602 Ratio
.047 .192 .042 .223 .038 .293 Sum
Smoking (current) -.006 .878 -.005 .895 Not included Ratio
.068 .060 .073 .036 Not included Sum
No use of hormonal  
   contraceptives*
Ref Ref Not included
Oral contraceptives .090 .035 .119 .010 Not included Ratio
-.056 .185 .048 .277 Not included Sum
Other -.014 .740 .006 .899 Not included Ratio
-.045 .281 .023 .577 Not included Sum
Pregnancy* -.017 .682 -.010 .827 Not included Ratio
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table 3. Regression analyses on the ratio HairF/HairE and the sum HairF+HairE (continued)
Characteristics
Standardized 
simple linear 
regression 
coefficients p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(adjusted for 
sex and age)1 p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(mutual 
adjustment)2 p-value
-.016 .702 .045 .291 Not included Sum
Physical activity (1000 .041 .258 .041 .260 .054 .157 Ratio
MET-min/week) .016 .658 -.011 .746 .000 1.000 Sum
Waist circumference (cm) .031 .396 .038 .351 .032 .636 Ratio
.208 <.001 .095 .015 .114 .080 Sum
Hip circumference (cm) .047 .202 .046 .209 .026 .658 Ratio
.085 .019 .054 .123 -.021 .711 Sum
Diabetes mellitus .043 .239 .044 .236 .063 .098 Ratio
.153 <.001 .093 .008 .082 .025 Sum
Hypertension -0.19 .593 -.027 .498 -.033 .433 Ratio
.142 <.001 .040 .289 .009 .821 Sum
Other chronic disease -.033 .370 -.038 .311 -.032 .396 Ratio
.086 .018 .027 .457 .022 .539 Sum
Natural hair color blond Ref Ref Ref
   Natural hair color brown -.039 .318 -.040 .314 -.042 .297 Ratio
.059 .132 .045 .236 .029 .449 Sum
  Natural hair color black .046 .236 .046 .236 .028 .510 Ratio
.117 .002 .085 .019 .076 .055 Sum
  Natural hair color red -.030 .460 -.030 .451 -.059 .198 Ratio
.013 .734 .017 .653 -.002 .965 Sum
  Natural hair color grey -.016 .680 -.021 .645 -.005 .906 Ratio
.164 <.001 .022 .608 .007 .866 Sum
No hair treatment in past 
   3 months
-.113 .002 -.134 .001 .041 .683 Ratio
.081 .029 .035 .376 .056 .676 Sum
  Hair dyed .039 .296 .039 .300 .033 .550 Ratio
-.044 .239 -.001 .982 .000 .997 Sum
  Hair bleached .126 .001 .144 <.001 .175 .061 Ratio
-.067 .070 -.028 .472 .021 .857 Sum
  Hair permed .048 .214 .047 .224 .067 .118 Ratio
-.018 .638 -.013 .731 -.009 .855 Sum
Hair washing frequency -.039 .288 -.039 .314 -.064 .101 Ratio
(≥ 3/week) -.183 <.001 -.127 .001 -.132 .001 Sum
Use of hair styling products 
   on day of sampling
.051 .164 .058 .129 .044 .266 Ratio
-.123 .001 -.049 .172 -.031 .404 Sum
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Discussion
The current study examined HairF and HairE levels in a large sample and assessed the 
influence of different sociodemographic, health and lifestyle, and hair (treatment) 
characteristics on these hormones. Both HairF and HairE showed robust linear increases 
with age. Lower HairF and HairE levels were found in subjects who wash their hair more 
frequently. Elevated HairF levels were related to the presence of diabetes mellitus. 
Furthermore, hair samples representing the winter months showed lower HairF. This 
is the first study to show these effects in a large middle-aged sample with full adjust-
ment. This approach enabled the investigation of independent effects of all considered 
determinants and showed that for above mentioned results, the associations with HairF 
and HairE are indeed distinct.
The strongest influence on HairF and HairE was age of the participant. Age has often 
[9, 11, 16], but not consistently [1, 10], been associated with HairF in earlier research. 
However, studies that found curvilinear [9] or linear [11, 16] effects comprised a wider 
age range, and may therefore be more suitable to detect endocrine changes related to 
age. Thus, these studies indicate that age is a strong predictor of hair corticosteroids and 
needs to be included as possible covariate in studies that use participants with a range 
table 3. Regression analyses on the ratio HairF/HairE and the sum HairF+HairE (continued)
Characteristics
Standardized 
simple linear 
regression 
coefficients p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(adjusted for 
sex and age)1 p-value
Standardized 
multiple 
linear 
regression 
coefficients 
(mutual 
adjustment)2 p-value
Season Winter Ref Ref Ref
  Season Spring .102 .025 .106 .021 .110 .019 Ratio
.051 .263 .079 .074 .098 .027 Sum
  Season Summer .057 .101 .078 .093 .082 .077 Ratio
.059 .199 .072 .102 .090 .042 Sum
  Season Fall .110 .017 .112 .015 .122 .009 Ratio
.020 .664 .030 .492 .053 .239 Sum
Met-min, minutes of metabolic energy turnover; *, in women only; other chronic disease, lung disease, cancer, 
rheumatic, intestinal and liver disease.
1 Age and sex themselves were only adjusted for each other.
2 Multiple linear regression was performed including all variables listed in the table except for use of hormonal 
contraceptives and pregnancy (due to sex-specificity) and except for categories of alcohol consumption and 
smoking, as the continuous variable was already included.
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of age. Hair washing frequency also influenced HairF. Previous research has provided 
inconsistent results, with some studies reporting effects [24], whereas others could not 
detect any influence [1, 10]. Frequent washing of the hair might damage the hair struc-
ture and thereby lead to an increased wash-out of cortisol. This reasoning is consistent 
with the often replicated result that cortisol content decreases the more distal the hair 
segment is from the scalp [9, 25, 26]. The current study also found HairF to be associ-
ated with the presence of diabetes mellitus. This result is consistent with other research 
on this topic [5, 11], which was conducted in older adults. In middle-aged adults, this 
relationship has until now only been approximated. Stalder and colleagues provided 
evidence for a positive relationship of HairF with glycated haemoglobin, as an index of 
long-term glucose levels [16]. Taken together, these results suggest that higher HairF are 
associated with long-term increased glucose levels and presence of diabetes mellitus 
across different age spans. One unexpected finding was the effect of season on HairF. 
Recent studies approached aspects of this issue by investigating effects of temperature, 
humidity and sweating on HairF [27, 28]. An inverse correlation with temperature and 
positive correlation with relative humidity for HairF is reported. Our results of higher 
HairF in spring and summer contradict their findings regarding temperature but may 
support their result on humidity. Another study, examining determinants of maternal 
hair cortisol concentrations at delivery reflecting the last trimester of pregnancy, also 
reported a seasonal effect. Mothers showed significantly higher HairF in summer and 
autumn as opposed to winter [29]. These finding support our results on higher HairF in 
summer months. Grass et al showed that sweating did not seem to be of major influence 
on HairF. Thus, we cannot rule out that seasonal influences affect HPA- axis activity and 
thereby alter HairF.
In the present study, with partial adjustment, men showed higher HairF and HairE 
concentrations than women. Our results concur with three previous studies [5, 9, 11] 
but are at variance with others [1, 2]. A possible explanation for higher levels in men 
might be that men seem to have lower corticosteroid binding globulin (CBG) levels 
while total cortisol levels are comparable to women’s total cortisol [30]. This may result 
in higher free cortisol levels in men. It has been thought that the free fraction of cortisol 
is incorporated in hair [31], which might explain the observed sex differences. However, 
the gender effect was not independent of other covariates as it lost significance in 
full adjustment, which is in line with the study that used partial and full adjustment 
in older adults [11]. Higher waist circumference was associated with increased HairF in 
analyses with partial-adjustment. Significant results have been reported in most studies 
that investigated this association [1, 16]. The correlation between waist circumference, 
or better, visceral fat, and long-term cortisol is well supported by literature [see 32, for 
review]. A darker natural hair color was associated with higher HairF in analyses with 
partial adjustment. However, this effect was not independent of other covariates. A 
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non-significant trend for higher HairF in darker hair has been reported in one previous 
study [9]; however, in a direct comparison between light-blond and dark-brown hair, no 
differences were observed. This corresponds to our finding of no difference between 
blond and brown hair; however, no conclusion can be drawn from their study on the 
association between HairF and black hair as they did not investigate this specific as-
sociation. Furthermore, no other study has been able to replicate this result. This hair 
color effect was not caused by differences in socio-economic status (as approximated 
by educational level), body composition or Northern-European ancestry status in our 
study. This study is also the first to find a positive effect of oral contraceptives on HairF. 
These are surprising results, since HairF are generally considered to reflect the free frac-
tion of cortisol which should not be influenced by use of oral contraceptives [9]. Other 
studies examining the association between HairF and the use of oral contraceptives did 
not report significant results [9, 10, 33]. In this study, we could not unravel whether this 
effect was caused by a specific hormone combination.
The present study did not detect effects of alcohol and nicotine use on HairF levels. 
Smoking was not related to HairF in most studies [9, 28, 34], however, contradicting 
results have also been reported [11, 35]. No significant effect of alcohol use on HairE was 
found in this study. Previous studies were inconsistent regarding the effect of alcohol on 
HairF. Some studies found no effect [11, 16], whereas others reported increased HairF in 
excessive alcohol users [5, 35] and alcohol-dependant individuals [36].
Previous research has examined covariates of HairE [16, 19]; however, these factors 
not been systematically assessed until now. This is the first study to systematically assess 
the effect of different variables on HairE. HairE seems to be influenced by factors quite 
consistent with influences of HairF, namely age and hair washing frequency, and (al-
though not independent of other covariates) also gender, waist circumference, presence 
of diabetes mellitus, and natural hair color. In contrast to HairF, HairE were not affected 
by use of oral contraceptives or by season. They were, however, affected by smoking 
status, hair treatment, and use of hair styling products. Interestingly, current smokers 
had higher HairE, independent of their average number of cigarettes. This pattern has 
been reported before for HairF [35]. Hair treatment, i.e. bleaching of the hair, was associ-
ated with lower HairE. Reports on hair treatment on HairF have been inconsistent so far; 
however, in case of reported effects they usually tend to lower the hormone content [1, 
16, 37]. The use of hair styling products also influenced HairE. As the hair samples were 
washed before extraction and analysis, it seems unlikely that the actual product used on 
the day of sample collection caused this effect, however, repeated cosmetic treatment 
could affect and lower hormone concentrations, as has been suggested before [2].
HairE were 3.4-fold higher than HairF, a ratio that is comparable to the ratio reported 
by other studies [2, 16, 18, 19]. The ratio itself was generally not associated with the 
factors that influenced HairF and HairE. This corroborates previous results of Stalder et 
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al [16]. The sum of HairF and HairE as an indicator of a general glucocorticoid supply (i.e. 
active cortisol and inactivated cortisol that had been active once) showed associations 
with factors comparable to the associations of only HairF and/or HairE. Visual inspection 
of our data also showed that high outlying values were particularly present in HairF but 
less so in HairE levels (data not shown); a tendency also observed in Stalder et al..
Several limitations have to be acknowledged for the present study. The nature of the 
current study is cross-sectional, which prevents the interpretation of causal inferences. 
Due to the exploratory nature of this study, we did not correct for multiple testing.
In conclusion, the current study presents results of the first large scale study to sys-
tematically assess determinants of both HairF and HairE levels. Based on our results, age, 
sex, waist circumference, diabetes mellitus, hair washing frequency, natural hair color, 
and depending on the hormone in question, also use of oral contraceptives, season 
represented in the hair sample, smoking status, hair treatment, and use of hair styling 
products have been confirmed and identified as important influences and should be 
considered as potential confounding influences in future research.
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abstract
background
Depressive and anxiety disorders have been linked to a disturbed hypothalamus-
pituitary-adrenal (HPA)-axis, shown by altered short-term cortisol concentrations. Hair 
cortisol levels (HairF) and hair cortisone levels (HairE) have been shown to reflect inte-
grated long-term cortisol and cortisone levels, and are promising endocrine markers of 
chronic (psychological and physical) stress. We aimed to use hair corticosteroid analysis 
to assess corticosteroid exposure of a three-month period in persons with a depressive 
and/or anxiety disorder and to compare their levels with those of healthy controls and 
remitted persons.
methods
Data from 1166 participants of the Netherlands Study of Depression and Anxiety 
(NESDA) were used. A total of 266 participants had a recent (1-month) diagnosis of a 
depressive and/or anxiety disorder, 655 had remitted disorders, and 245 had no lifetime 
diagnosis (healthy controls). HairF and HairE were measured in the proximal three cm of 
scalp hair, using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
results
The presence of a comorbid depressive and anxiety disorder was significantly associated 
with increased HairF levels (p = .031), as was the severity of depressive symptoms (p = 
.029) and, with trend significance, the severity of anxiety symptoms p = .069). Remitted 
disorders were not associated with altered HairF or HairE levels.
conclusions
This study demonstrates that persons with current severe symptoms of depression and/
or anxiety, but not those with remitted symptoms, show higher levels of cortisol in scalp 
hair, which is indicative of a chronic overactivation of the HPA-axis.
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introDuction
Dysfunction of the hypothalamus-pituitary-adrenal (HPA)-axis may result in increased 
or decreased levels of its end-products, cortisol, commonly referred to as “the stress 
hormone”. A disproportionate change in cortisol levels is one of the main hypothesized 
pathophysiological mechanisms underlying stress-related disorders. Indeed, depressive 
and anxiety disorders have been linked to altered cortisol concentrations using point 
measures taken from urine, blood or saliva [1-5]. However, findings have been incon-
sistent regarding relative hyper- or hypocortisolism in different (subtypes of ) disorders. 
This problem coincides with one shortcoming of these methods, i.e. that they only reflect 
cortisol levels over a relative short time period, i.e. minutes to several days, thereby not 
reflecting chronic exposure to cortisol excretion, which likely is more relevant in terms 
of health effects. Related, a question that remains to be answered is whether altered 
cortisol levels represent a trait or state effect in depression [6] and anxiety. One pos-
sibility to shed more light on these issues is the use of a relatively new method to assess 
long-term cortisol concentrations, i.e. the analysis of cortisol in hair.
Hair cortisol concentrations (HairF) are assumed to reflect integrated long-term cor-
tisol levels, and have been proposed as a promising endocrine marker of chronic stress. 
Higher HairF in patients with depression compared to healthy controls have been re-
ported [7, 8], however, other studies showed no difference [9, 10]. Depressive symptoms 
were in some [11, 12] but not other [13, 14] studies associated with HairF. These studies 
used depressive symptoms rather than the diagnosis of a major depressive disorder 
(MDD) in diverse populations with various comorbidities. Research on HairF and anxiety 
disorders has also produced first results; posttraumatic stress disorder (PTSD) has been 
associated with increased HairF in the months after the trauma, followed by decreased 
HairF in the longer run [15-17]. HairF are lower in generalized anxiety disorder (GAD) 
[18], unchanged in social phobia [19], and were not associated with anxiety symptoms 
or severity of anxiety in patients with various other primary diagnoses [8, 20, 21].
To summarize, first studies have been published, but there still is a considerable lack of 
consistent information on the relationship with depressive and anxiety disorder charac-
teristics such as age of onset, duration of disorder, severity, and use of antidepressants. 
Furthermore, most studies involved small samples (many less than n = 50), which may 
partially explain discrepant results across studies. The development of new techniques 
to measure HairF have led to the possibility to measure other steroid hormones in scalp 
hair as well. One of these other hormones is cortisone, the inactive form of cortisol. 
The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) converts cortisone 
into active cortisol, whereas its counterpart 11β-hydroxysteroid dehydrogenase type 2 
(11βHSD-2) converts active cortisol to inactive cortisone. The assessment of hair corti-
sone (HairE) in parallel to HairF has been postulated to provide even more insight into 
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the cumulative amount of active and inactive corticosteroids in the body, and that HairE 
levels may provide a useful and robust marker of long-term HPA-axis activity [22]. Apart 
from the absolute levels of HairF and HairE, the cortisol-to-cortisone ratio is also of inter-
est, as it reflects the 11βHSD-activity [23]. The importance of this ratio in stress-related 
research has been emphasized by studies using urinary measures showing an altered 
ratio under stress [24] and demonstrating an enhanced ratio in depressed patients [25, 
26], suggestive of an increased conversion to active cortisol by 11βHSD-1.
Measurement of hair cortisone concentrations (HairE) have been shown by our group 
and by others to be easily measurable and to correlate with HairF [22, 23, 27, 28]. Until 
now, no study has investigated the associations between HairF, HairE, the ratio HairF/
HairE, and (characteristics of ) depressive and anxiety disorders while accounting for 
diverse covariates and using a large sample. Insight into the amounts of long-term 
cortisol and cortisone, as well as their ratio, may give new insights into the underlying 
pathophysiology of the HPA-axis and its role in depressive and anxiety disorders.
In the present study, we used data from the Netherlands Study of Depression and 
Anxiety (NESDA) to examine whether there are differences in HairF, HairE and their ratio 
(HairF/HairE) between healthy control subjects and subjects with a depressive disorder 
or an anxiety disorder. As the NESDA project comprises a large sample size, the unique 
set-up allows us to run statistical analyses on patients with current, remitted, and no 
disorders which provide insight into state versus trait associations and to examine the 
impact of specific characteristics, such as symptom severity and medication use, on the 
association between psychopathology and hair corticosteroid levels.
materials anD metHoDs
study Design
Data were used from the Netherlands Study of Depression and Anxiety (NESDA), an 
ongoing longitudinal cohort study on the predictors, course and consequences of de-
pressive and anxiety disorders. The NESDA sample consisted of 2,981 participants aged 
18–65 years at inclusion, comprising persons with no depressive or anxiety disorder, 
persons who have had a disorder in the past, and persons with a current depressive and/
or anxiety disorder. A detailed description of the NESDA study rationale, design, and 
sampling procedure can be found elsewhere [29]. The research protocol was approved 
by the Ethical Committee of the participating centres, and all participants provided 
written informed consent. Hair data collection was added to NESDA’s 6-year follow-up 
assessment, in which 2256 participants of the initial 2981 sample participated (75.68%). 
Therefore, the 6-year follow-up wave is considered baseline for the present analysis, and 
all determinants considered were measured at that wave. For the present study, from 
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the 2256 participants, we selected all participants that had sufficient hair on the poste-
rior vertex position of the head, the willingness to participate, and a hair sample weight 
of at least 5 mg (n = 1677). The participants filled in a self-developed questionnaire on 
their hair (treatment) characteristics. Psychiatric diagnoses were defined on the basis of 
the Composite International Diagnostic Interview (CIDI, versions 2.1) [30], which classi-
fies diagnoses according to the DSM-IV criteria. Exclusion criteria were the diagnosis of 
bipolar disorder within the past year (n = 22), use of lithium (n = 11), and current use of 
systemic or local corticosteroids in the past three months (n = 320), resulting in a sample 
of 1264 subjects.
Hairf and Haire measurement
During the visit at the research facility, hair strands of approximately 100 hairs were cut 
as close as possible from the scalp from a posterior vertex position. The most proximal 
three cm of hair were used for analysis. Based on a mean hair growth rate of one cm per 
month [31], hair samples reflect the cumulative cortisol and cortisone secretion of the 
previous three months. Hair samples were weighted, finely cut with surgical scissors, 
and washed with 1.0 mL of LC-MS grade isopropanol for two minutes. The extraction 
and subsequent analysis of cortisol and cortisone by liquid chromatography-tandem 
mass spectrometry has extensively been described elsewhere [32]. The inter-day varia-
tion in the present study was <8.3% for cortisol and <4.8% for cortisone [27]. Steroid 
peak integrations were reviewed and manually integrated by two independent persons 
when automated peak integration feature incorrectly or partially integrated peaks. In 98 
individuals, HairF or HairE levels could not be determined due to interference in the hair 
sample. The analyses were successfully performed in 1166 participants, rendering our 
final study sample.
Psychiatric characteristics
The DSM-IV Composite International Diagnostic Interview (CIDI) was used to assess di-
agnoses of depressive disorders (dysthymia, MDD) and anxiety disorders (social phobia, 
panic disorder, agoraphobia, panic disorder with agoraphobia, and GAD).
To investigate whether HairF and HairE levels were different between participants 
with a current diagnosis, participants with a remitted diagnosis, and healthy controls, 
we first created three groups of subjects. The first group consisted of participants with 
a current (1 month) depressive and/or anxiety disorder diagnosis (n = 266). The second 
group consisted of participants with no current (1 month), but a remitted diagnosis of 
depressive and/or anxiety disorder (n = 655). The third group comprised psychologically 
healthy subjects with no lifetime history of either depressive or anxiety disorders and 
served as control group (n = 245).
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The total score of the 30-item self-report version of the Inventory for Depressive 
Symptomatology (IDS) was used to measure the severity of depressive symptoms (range: 
0 - 84). The total score of the Beck Anxiety Inventory (BAI) was used to assess the severity 
of anxiety symptoms (range: 0 - 63). Additionally, the Fear Questionnaire (FQ) was used 
as an indicator of phobic symptoms (range: 0 - 120) and the total score of the childhood 
trauma questionnaire (CTQ) was used as a measure of childhood traumatization (range: 
0 - 100).
To account for the use of antidepressants, we distinguished tricyclic antidepressants 
(TCA, ACT-code N06AA), selective serotonin reuptake inhibitors (SSRI, ATC-code N06AB), 
and other antidepressants (ATC-code N06AF/N06AX). Whether respondents used 
antidepressants was based on drug container inspection of all drugs used in the past 
month at baseline and classified according to the World Health Organization Anatomi-
cal Therapeutic Chemical (ATC) classification. Duration of symptoms within the previous 
two years was assessed with a lifechart.
covariates
We previously described the effects of age, diagnosis of diabetes mellitus, hair washing 
frequency (0-3 times/week, > 3 times/week), and season (winter, spring, summer, fall) 
reflected in hair sample on HairF and HairE levels [27]. These will therefore be used as 
covariates in this study. Additionally, we included sex and hair treatment as covariates, 
as these factors were associated with HairF and/or HairE in other studies [33, 34]. Other 
covariates such as waist circumference, smoking, and alcohol intake were not found to 
be related to HairF and HairE levels in our previous study [27] therefore not considered 
in our analyses.
statistical analyses
For descriptive analyses, HairF and HairE are provided in pg/mg and are reported as 
median (Mdn) and interquartile range (IQR). For inferential analyses, HairF and HairE 
values were subjected to a logarithmic transformation to achieve normal distribution. 
Other data, unless otherwise indicated, is presented in original units with mean (M) and 
standard deviation (SD), or in sample size (n) and percentage (%). Baseline character-
istics of the three groups were compared using χ² and analysis of variance statistics. 
Differences between HairF and HairE levels of groups of participants were conducted 
with univariate analyses of covariance (ANCOVA) and with linear regression analyses. 
Results are derived from partially-adjusted (adjusted for sex and age) and as fully-
adjusted (adjusted for all covariates) analyses. The significance level was set at p <0.05. 
All analyses were conducted using SPSS 20.0 for Windows (IBM, Chicago, Illinois). For 
significant findings, effect sizes were calculated with Cohen’s d [35] between healthy 
controls and the group in question.
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Of the 1166 participants, n = 1075 provided a full dataset without any missing values 
on covariates. Multiple imputation was used to complete the dataset, assuming a miss-
ing at random approach and creating five imputed datasets. All characteristics were 
used as predictors to impute missing values, and the observed minimum and maximum 
values of the original full dataset were used as constraints. The pooled estimates of the 
five imputed datasets are reported.
results
sample characteristics
Characteristics across groups are presented in Table 1. A total of 245 subjects had no 
current or lifetime diagnoses (healthy controls), 655 participants had remitted depres-
sive and/or anxiety disorders, and 266 participants presented with a current (past one 
month) diagnosis of depressive disorder (n = 78), anxiety disorder (n = 122), or comorbid 
both depressive and anxiety disorder (n = 66).
As expected, participants with a current diagnosis had higher scores on the psychi-
atric questionnaires and higher use of antidepressants than had remitted participants, 
who in turn scored higher on psychiatric questionnaires and use of antidepressants than 
healthy controls.
Hairf and Haire
The median HairF of the sample was 3.26 (2.20 – 5.47) pg/mg hair, whereas the median 
HairE of this sample was 10.68 (7.58 – 15.36) pg/mg hair. HairF and HairE showed a 
significant positive linear correlation with each other, r = .58, p <.001.
long-term corticosteroids in relation to remitted and current diagnoses
Comparing HairF, HairE and the ratio HairF/HairE between the three groups (healthy 
controls, remitted diagnoses, current diagnoses) showed no difference in any of these 
parameters between the groups (F (2, 1153) = 1.217, p = .296 for HairF, F (2, 1153) = 
1.366, p = .255 for HairE, and F (2, 1153) = .355, p = .715 for HairF/HairE, respectively). The 
presence of a remitted disorder, analyzed as one group and as subgroups of remitted 
depressive disorder, remitted anxiety disorder and remitted comorbid depressive and 
anxiety disorder, was not significantly or trend associated with HairF, HairE, or HairF/
HairE (p > .10). Regarding current diagnoses, a current depressive disorder (n = 78) and 
a current anxiety disorder (n = 122) were not associated with altered HairF, HairE, or 
HairF/HairE (all p > .10). A current comorbid depressive and anxiety diagnosis (n = 66) 
was associated with elevated HairF (β = .067, p = .031, d = .33), see Figure 1, and trend-
associated with HairF/HairE (β = .055, p = .086, d = .34) but not with HairE (p > .10).
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The partially and fully adjusted models for HairF, HairE, and HairF/HairE in relation to 
disorder status are shown in Table 2.
In subgroup analyses (not in the Table), we explored current subtypes of depressive 
disorders (major depressive disorder, n = 43; dysthymia, n = 17; both major depres-
sive disorder and dysthymia, n = 18) and of anxiety disorders (social phobia, n = 29; 
table 1. Descriptive information of the study population
Characteristics Healthy controls
(n = 245)
Remitted diagnosis 
(n = 655)
1-month diagnosis 
(n =266)
p-value
Sociodemographics
Sex (female) 153 (62.4 %) 513 (78.3 %) 198 (74.4 %) <.001
Age (in years) 45.77 (15.05) 46.81 (12.95) 48.17 (12.78) .122
Health and lifestyle indicators
Diabetes mellitus 5 (2.0 %) 25 (4.1 %) 11 (4.1 %) .306
Hair (treatment) characteristics
Hair treatment in past 3 months 74 (30.2 %) 253 (38.6 %) 105 (39.5 %) .041
Dyed 12 (4.9 %) 62 (9.5 %) 17 (6.4 %)
Bleached 63 (25.7 %) 206 (31. 5 %) 90 (33.8 %)
Permed 2 (.1 %) 8 (1.2 %) 6 (2.3 %)
Hair washing frequency (> 3/week) 176 (71.8 %) 460 (70.2 %) 184 (69.2 %) .802
Season represented in hair .076
Winter 43 (17.6%) 173 (26.5%) 75 (28.2%)
Spring 59 (24.1%) 154 (23.5%) 65 (24.4%)
Summer 65 (26.5%) 164 (25.5%) 61 (22.9%)
Fall 78 (31.8%) 164 (25.5%) 65 (24.4%)
Psychiatric aspects
IDS 5.53 (5.53) 13.02 (8.53) 26.32 (12.98) <.001
BAI 2.99 (4.05) 6.95 (6.11) 15.57 (1.07) <.001
FQ 7.71 (8.77) 15.28 (13.77) 30.03 (18.76) <.001
CTQ 33.59 (10.20) 39.94 (12.56) 45.07 (14.89) <.001
Age of onset n/a 22.41 (12.98) 16.98 (11.28) <.001
Duration of depressive symptoms in 
   prior 2 years (months)
n/a 3.24 (6.88) 13.12 (10.49) <.001
Duration of anxiety symptoms in  
   prior 2 years (months)
n/a 5.59 (9.43) 16.91 (9.83) <.001
Use of antidepressants <.001
TCA 0 16 (2.4 %) 16 (6.0 %)
SSRI 1 (0.4 %) 88 (13.44 %) 48 (18.0 %)
Other antidepressants 0 27 (4.1 %) 35 (13.2 %)
Data are presented as pooled mean (pooled standard deviation), and as pooled n (percentage). IDS, Inventory 
of Depressive Symptomatology: BAI, Beck Anxiety Inventory; FQ, Fear Questionnaire; CTQ, Childhood Trauma 
Questionnaire; n/a, not applicable; TCA, Tricyclic Antidepressant; SSRI, Selective Serotonin Reuptake Inhibitor.
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panic disorder with agoraphobia, n = 19; panic disorder without agoraphobia, n = 10; 
agoraphobia, n = 28; generalized anxiety disorder, n = 15; and more than one anxiety 
disorder, n = 21). The presence of current social phobia and the presence of more than 
one current anxiety disorder simultaneously were associated with increased HairE (β = 
.074, p = .01, d = .53, and β = .058, p = .041, d = .24, respectively). No other significant or 
trend associations emerged (all p > .10).
long-term corticosteroids and severity measures
The severity of depressive symptoms (indicated by the IDS total score) was associated 
with HairF in the whole sample of participants (β = .63, p = .029), whereas the severity 
of anxiety (indicated by the BAI total score) was only trend-associated with HairF (β = 
.52, p = .069) (Figure 2). HairE showed no association with any of the severity scores 
(all p > .10). The ratio HairF/HairE was trend-significantly associated with the severity 
of depression (IDS), anxiety (BAI), and phobic symptoms (FQ) (β = .52 – .57, all p < .10).
long-term corticosteroids in relation to disorder characteristics
In participants with a current diagnosis of a depressive and/or anxiety disorder (n = 266), 
age of onset and duration of psychopathology was not associated with HairF, HairE, and 
the ratio HairF/HairE (all p > .10) (not in the Table).
Examining the relation of antidepressant medication revealed that the use of SSRIs was 
associated with increased HairF (β = .074, p = .010, d = .28) and trend-significantly associ-
ated with the ratio HairF/HairE (β = .054, p = .066, d = .27). No other associations between 
HairF, HairE, the ratio HairF/HairE and use of antidepressants reached significance (all p > 
.10). The use of SSRIs and the severity of depression were independently associated with 
elevated HairF (use of SSRIs: β = .070, p = .015; severity depression: β = .062, p = .038) 
when analyzed within one model. The use of SSRIs and the severity of anxiety also retained 
their independent (trend-) association with HairF (use of SSRIs : β = .072, p = .012; severity 
anxiety: β = .049, p = .098) when analysed within one model (not in the Table).
    
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figure 1. HairF values for healthy con-
trols, participants with a remitted diagno-
ses, a current depressive disorder, a current 
anxiety disorder, and a current comorbid 
disorder. HairF levels are expressed as geo-
metric mean with 95% CI. *, p < .05 in the 
fully-adjusted analyses.
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Discussion
The current study examined HairF and HairE levels as well as the ratio of HairF/HairE in 
a large sample with and without depression and anxiety. One aim of our study was to 
gain insight into the amounts of long-term cortisol and cortisone, as well as their ratio, in 
depressive and anxiety disorders. The 3.3-fold increase of HairE over HairF corresponds 
to previously reported research [10, 22, 23, 28]. We found that the current severity of 
symptoms was associated with higher long-term HairF levels rather than the presence 
of a specifi c current or remitted diagnosis per se. One explanation for this result could 
be the associated disease burden and daily impairments, and therefore increased stress 
that may come with a more severe disorder. This hypothesis would be supported by re-
search showing that increased stress has often been associated with increased HairF [12, 
36, 37]. This might also be refl ected by the association between HairF and the presence 
of a current comorbid depressive and anxiety disorder, in which a comorbid disorder 
might be interpreted as a more severe disorder than one single disorder. Indeed, the 
comorbid group had signifi cantly higher scores on the depressive and anxiety severity 
scales than the other participants (data not shown). A more technical explanation could 
be that the severity data had higher variation and thus more statistical power compared 
to analyses on the diagnostic groups.
We also explored whether subtypes of depressive and anxiety disorders were dif-
ferently associated with HairF, HairE, or HairF/HairE. However, these results have to be 
interpreted cautiously due to the small sample sizes. We found indications that the 
diagnosis of social phobia may be associated with increased HairE. The association be-
tween social phobia and HairF was subject to one other study and the authors found no 
diff erences in HairF between healthy controls and patients with social phobia [19]. This 
is in line with our results. The association between social phobia and HairE has not been 
figure 2. Log-transformed HairF values and their association with the severity indexes for depression and anxi-
ety. IDS, Inventory of Depressive Symptomatology: BAI, Beck Anxiety Inventory. Values are derived from fully-
adjusted models.
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described yet. We did not find associations of HairF, HairE, or HairF/HairE with any other 
anxiety disorder. Until now, one study that looked into HairF and GAD found decreased 
HairF in patients and one study on bipolar patients found lower HairF for patients with 
a comorbid panic disorder [38]. The presence of (only a) current depressive disorder did 
not show a relationship with HairF, HairE, or the ratio HairF/HairE. For MDD, conflicting 
results regarding the association between diagnosis and HairF have been reported [7-9, 
13]. To our knowledge, dysthymia has not been assessed in other studies until now.
Another aim was to use the information on the level of HairF, HairE, and the ratio HairF/
HairE to gain new insights into the underlying pathophysiology of the HPA-axis and its 
role in depressive and anxiety disorders.  This association seems to be less straightfor-
ward than initially assumed. The significant results were found in participants with a 
current diagnosis, whereas remitted patients did not show altered long-term cortico-
steroid levels. This is an interesting result, as it poses a possible answer to the question 
whether a dysregulated HPA-axis in mentally ill patients is a state or trait phenomenon. 
A stronger association with active cortisol rather than inactivated cortisol, as found in 
our study, may indicate that the alterations in HairF associated with psychopathological 
characteristics seem to be a state (reflected by HairF) rather than a trait (reflected by 
HairE). This would imply that during the episode of a disorder, the HPA axis is dysregu-
lated, but that the cortisol levels return to normal once the patient remits. This could be 
supported by the results that remitted patients did show long-term corticosteroid levels 
comparable to healthy controls. Interestingly, a study that investigated differences in 
HairF between healthy controls, patients with a recurrent depressive disorder and 
patients with a first-episode disorder found that only patients with a first episode had 
increased HairF, whereas patients with a recurrent depressive episode had comparable 
HairF as healthy controls [8]. The authors hypothesize that the duration or the number 
of recurring episodes of the depressive episode might alter the sensitivity of HPA axis of 
the patients with a recurrent depressive episode. This gives rise to the question whether 
the underlying pathophysiology is different for persons with a first/single episode com-
pared to persons with recurrent episodes. In our study, the duration of mental disorders 
showed no association with long-term corticosteroid levels. Future research will have to 
further shed light into these associations.
To our knowledge, this is the first study to assess relationships between the ratio HairF/
HairE and psychopathological characteristics. The ratio did not reach significance in as-
sociations; however, several trend-associations emerged. These trends were achieved in 
analyses showing significant associations with HairF but not HairE, which could mean 
that the trends are driven by the associations with HairF, making it likely that the ratio 
and the 11βHSD-activity do not provide additional information in hair research.
Another interesting finding is that the use of SSRIs is associated with higher HairF. The 
use of antidepressants has been shown to influence the HPA-axis in many ways, from 
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regulation of glucocorticoid receptor (GR) expression to post-translational modifications, 
which may result in differences in GR nuclear translocation and GR-dependent gene 
transcription [39, 40]. Two other studies reported associations between HairF and psy-
chotropic drugs [34, 41], whereas a third study did not find differences in HairF between 
users and non-users [42]. Apart from the working mechanisms of SSRIs on the HPA axis, 
another explanation could be that patients with more severe depressive symptoms may 
tend to use medication as opposed to patients with minor symptoms. However, the use of 
SSRIs and the severity of depression were independently associated with elevated HairF, 
rendering this hypothesis unlikely. Other explanations have yet to be found.
For significant effects, effect sizes were calculated, with effects ranging from .24 - .53 
and thereby reflecting small to moderate effects. This is in line with previously calculated 
effect sizes in long-term corticosteroid research [36], in which for long-term cortisol 
and mental illness, most effect sizes were small to medium. Our effect sizes are also 
comparable to those of a study assessing salivary cortisol levels, in which persons with 
a comorbid anxiety and depressive disorder had higher morning cortisol levels than 
healthy controls, with effect sizes ranging from .25 - .30) [2].
This study has several strengths and limitations that need to be acknowledged. The 
current study is the first study that included participants from a large, longitudinal co-
hort study on depression and anxiety. This allowed us to additionally study associations 
between long-term glucocorticoids and pure diagnostic subgroups free from other 
comorbid psychological disorders while still retaining sample sizes comparable to other 
studies. Furthermore, extensive information on covariates and psychological charac-
teristics were available. However, the cross-sectional nature of the study did not allow 
us to draw causal conclusions about the direction of associations between long-term 
glucocorticoids and depressive as well as anxiety symptoms. Another limitation is that 
although our study comprised a large sample size, the size of the diagnostic (sub)groups 
was rather small for some subgroups. Another factor that needs to be mentioned is that 
the time frame represented by the hair (i.e. three months) did not correspond to the time 
frame of the diagnosis used here (i.e. one month). This unequal time frame was caused 
by practical reasons, in that we had too little hair samples per person to allow for hair 
measurements of one cm. However, therefore we cannot exclude the possibility that we 
underestimate the effects of depressive and anxiety disorders on HairF and HairE, as also 
a healthy/diagnosis-free period may be covered by the hair sample.
To conclude, this study demonstrates that persons with current severe symptoms of 
depression or anxiety, but not those with remitted symptoms, show higher long-term 
levels of cortisol, as measured in scalp hair, which is indicative of chronic overactivation 
of the HPA-axis.
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abstract
background
Life events induce stress, which is considered to negatively impact the course of disease 
in patients with bipolar disorder (BD), its effects being predominantly mediated by 
cortisol. Cortisol in scalp hair has been identified as a biomarker for assessing long-term 
cortisol levels, and allows clarifying the relation between life events, hair cortisol con-
centrations (HCC), and clinical course over time.
methods
In 71 BD patients, we analyzed the proximal 3 cm of hair, reflecting 3 months of cortisol 
production, and investigated the association between HCC, the number of life events, 
the amount of social support, and mood in the 3 months prior to the hair assessment 
and between HCC and mood in the subsequent 3 months.
results
Although the total number of life events was not associated with HCC (p > 0.05), the 
number of negative life events was associated with increased HCC (r² = 0.04, p = 0.02). 
Social support showed an inverse association with HCC in patients reporting negative 
life events (r² = 0.07, p = 0.03). HCC and mood were neither associated in the 3 months 
prior to hair sampling nor in the subsequent 3 months.
conclusions
This study indicates that patients who experienced recent negative life events have 
increased hair cortisol levels, which seem to be attenuated by social support.
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introDuction
Evidence for stress as cause or amplifier of a wide range of somatic and mental disorders 
has been firmly established [1]. Individuals with a mental illness such as bipolar disorder 
(BD) are more likely to report the experience of a stressful life event and may also be 
more affected by the consequences of stress than healthy persons [2]. BD is a chronic 
mental illness that causes people to have one or more episodes of high (manic) and low 
(depressed) mood. The occurrence of life events as well as the hypothalamic-pituitary-
adrenal (HPA) axis has been reported to play a potential role in the induction of a new 
affective episode [3-4]. A life event is defined as a ‘dateable occurrence representing 
discrete changes in the subject’s social or personal environment that is external and 
verifiable rather than internal or psychological’ [5-6]. The availability or lack of social sup-
port is one of those environmental factors that have been widely recognized as a factor 
that may promote psychological well-being and physical health [7-8]. Social support 
has been defined as the actuality and the perception that one is cared for and valued, 
has assistance available from other people, and that one is part of a supportive social 
network. It can involve emotional support as well as instrumental support, information 
and companionship [9-11]. Social support can buffer the impact of stressful experiences 
and it can function as a coping mechanism [12].
BD has been associated with a dysregulation of the endocrine stress system, the HPA 
axis [3]. Conflicting data have been published on cortisol levels, the end product of the 
HPA axis. Normal as well as elevated basal salivary and serum cortisol levels have been 
reported [13-16]. These inconsistent findings could partly be caused by methodological 
differences between the studies but also by differential exposure to stressful life events.
The possibility to measure cortisol in scalp hair has the advantage of being non-
invasive and, unlike measurements in blood, saliva or urine, is insensitive to daily varia-
tion, short-term transient stress, and oral contraceptives [17], and to reflect the cortisol 
concentration of several weeks or months [18].
In our previous study on long-term cortisol in bipolar patients, no difference in hair 
cortisol concentrations (HCC) between mood episodes was found, however, increased 
HCC were observed in patients with a late age of onset (>30 years) [19]. Recently, evi-
dence was provided that the occurrence of stressful life events increases HCC in healthy 
young adults as well as in crack cocaine users [20-21].
Until now, it is not known whether patients with BD show increased HCC after a ma-
jor life event, and whether increased HCC after a life event are associated with mood 
symptoms. Initial results in a longitudinal study on our cohort showed an effect of life 
events on mood symptoms and functional impairment, especially in patients with BD I 
as compared to BD II [22].
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We aimed to explore the effects of life events and social support on hair cortisol levels 
in bipolar patients and to investigate whether HCC are associated with mood in the 
subsequent three months.
materials anD metHoDs
study Design
This is a cross-sectional and 3-month prospective study among outpatients with 
a diagnosis of BD. The current project is part of “The Bipolar Stress Study”, which is a 
cross-sectional and 24 month longitudinal study that aims on identifying risk factors 
that have an impact on the clinical course of BD and treatment of patients with BD. In the 
present study, we focused on the association between life events and HCC in patients 
with BD, and explore whether HCC in patients with life events are predictive of mood in 
the subsequent three months The study was approved by the local medical ethics com-
mittee and carried out in accordance with the declaration of Helsinki. After complete 
description of the study, all patients gave their informed consent.
Participants
Patients with BD from the same cohort whose hair cortisol characteristics have previously 
been published in our article concerning cross-sectional data [19] were included in this 
study. All patients were participants of The Bipolar Stress Study and were treated in the 
local outpatient Department of Mood Disorders in The Hague, the Netherlands. During 
their regular visits every three months at the outpatient clinic, information on mood and 
life events was assessed. The hair sample was obtained at the seventh measurement 
(after 21 months of participation); the second last assessment in this study. Detailed 
description of the assessment methods of the patients has been described elsewhere 
[19, 23]. Patients were eligible for inclusion if they had not been using glucocorticoids 
in the 6 months prior to hair sample collection and if they had sufficient hair growth at 
the posterior vertex. The first 100 patients that fulfilled these requirements were asked 
to participate and to provide a hair sample.
Patients were interviewed by trained psychologists to collect socio-demographic data 
and disease characteristics. Diagnoses of BD and psychiatric co-morbidities were based 
on DSM-IV criteria and were assessed with a standardized diagnostic interview [24] us-
ing the Dutch version of the MINI International Neuropsychiatric Interview Plus (version 
5.00-R; MINI-PLUS; [25]). Patients were classified in subtypes according to the DSM-IV-TR: 
bipolar I disorder, bipolar II disorder, cyclothymia, and bipolar disorder NOS, which vary 
in severity and frequency of mood episodes. BD I is characterized by one or more manic 
episodes, whereas BD II is defined by no manic episodes, but one or more hypomanic 
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episodes and one or more major depressive episode. The Questionnaire for Bipolar Ill-
ness, Dutch translation [26-27] was used to identify subtypes of BD, its course over time 
and detailed information about age of onset of first symptoms regarding hypomanic, 
manic and depressive episodes.
Hair sample collection, preparation, and cortisol measurement
From all patients, approximately 100—150 hairs were cut from the posterior vertex as 
close to the scalp as possible. Hair sample preparation has been described in detail else-
where [18]. In short, the hair was taped to a paper and stored until preparation. The 3 cm 
hair segments most proximal to the scalp were weighted in separate glass vials and then 
minced with small surgical scissors. One mL of methanol was added to extract cortisol 
from the hair samples and incubated for 16 h at 52°C while gently shaking. Afterwards, 
the methanol was transferred to a clean glass vial and was evaporated under a constant 
nitrogen stream until completely dry. The samples were then dissolved in 250 microliter 
phosphate buffered saline (pH 8.0) and vortexed until thoroughly mixed. Cortisol levels 
in the hair extracts were measured using a commercial ELISA kit for salivary cortisol 
(DRG Instruments GmbH, Marburg, Germany). Cross reactivity of other steroids with 
the kit’s antibodies was reported as follows: Corticosterone (29.00%), Cortisone (3.00%), 
11-Deoxycortisol (<1.00%), 17-OH Progesterone (<0.50%), other hormones (<0.10%). 
Intra-assay variation was below 5% and the inter-assay variation below 8% as reported 
by the supplier. The low-end detection limit for this assay is 1.5 nmol/L. HCC are reported 
as median and interquartile range (IQR).
life events
The occurrence of life events in the previous three months was assessed with Paykel’s 
self-report questionnaire consisting of 61 life events [28]. Patients indicated which events 
on the list occurred within the preceding three months. The 61 single life event items 
were a priori grouped into three main categories: negative life events, positive life 
events, and ambiguous life events. Events were categorized by independent raters, since 
patients’ rating of an event may be influenced by their current mood state. A total of 39 
different negative life events consisted of life events such as increasing arguments with 
the spouse, relationship break-up, business failure, serious illness of a family member, 
failure of an important exam, demotion at work, and unemployment for one month. A 
total of eleven positive life events consisted of life events such as promotion at work, en-
gagement, marriage, and a desired pregnancy. Eleven life events were rated as neutral 
or ambiguous events (change of work field, change of work hours, moving).
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social support
The presence and degree of social support was assessed with the Social Support List 
(Sociale Steun Lijst (SSL; [9]). This list quantifies two aspects of social support: ‘frequency 
of social support’ measures the frequency of social support that the patient receives; and 
‘perceived lack of social support’ is the perceived difference in social support between 
that which is desired and what is received by the patient. Patients rated items from the 
three subscales using a 4-point scale to indicate the frequency in which they received 
social support (“frequency”). For the “perceived” score, patients rated the perceived 
discrepancy between the desired and received level of social support on a 4-point scale, 
ranging from too little to too much. The scores were summed for each variable, with a 
higher score indicating a higher amount of social support.
mood
Illness severity was assessed in two ways. Symptom severity as well as the functional 
impact of the mood disturbances was measured. The observer based Young Mania Rat-
ing Scale (YMRS, [29]) was used to assess the number and severity of mania symptoms. 
The Quick Inventory of Depressive Symptoms (QIDS, [30]) was administered to assess 
the number and severity of depression symptoms. Both the YMRS and the QIDS were 
administered during the visit at the outpatient clinic. The functional impact of mood 
disturbances was measured with the monthly retrospective life chart method (LCM-r) by 
the National Institute of Mental Health (NIMH) [31]. This instrument was used to assess 
medication use and monthly functional impairment resulting from mania or depression 
symptoms in the subsequent three months after collecting the hair sample and was ad-
ministered by the research psychologist during every visit at the outpatient clinic. Based 
on the life chart data, the mean severity of functional impairment was calculated by 
averaging the monthly severity scores for depression and mania of every three-month 
period between the visits. A similar method has been used previously [32].
statistical analysis
SPSS 20.0 for Windows was used for statistical analysis. Hair cortisol levels, the number of 
life events, social support, age, and BMI were continuous variables, and gender, dyeing 
of hair, bleaching of hair, age of onset before/after the age of 30, comorbidities, and 
medication use were used as dichotomous variables. Pearson Chi-Square tests were 
used to compare frequency distributions. After log transformation, hair cortisol levels 
were normally distributed. Linear regression analyses were performed to analyze the as-
sociation between the number of life events and HCC, between social support measures 
and HCC, and between HCC and mood. Backward stepwise regression was used to iden-
tify the best predictors of the following variables: gender, age, BMI, natural hair color, 
frequency of hair wash, use of hair products, use of lithium, use of antiepileptics, use 
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of antidepressants, use of antipsychotics, use of benzodiazepines, mood phase, bipolar 
disorder subtype, psychiatric comorbid disorders (except for panic disorder), comorbid 
panic disorder, age of onset, the presence of metabolic syndrome, and the presence 
of an endocrine disease. The final model consisted of the age of onset, presence of 
comorbid disorders, hair treatments, and use of benzodiazepines to account for their 
influences, and the variable in question, such as number of life events. The results of the 
linear regression are reported as standardized coefficients (beta), t-value of the life event 
variable, and r² change (increase in explained variation that the life event variable adds 
to the model). The association between life events and mood was analyzed using non-
parametric (Spearman) correlation. The temporal relations are illustrated in Figure 1.
figure 1. Schematic overview of the assessment moments and the analyzed relationships between the differ-
ent measurements. We investigated the influence of life events, social support, stability (life chart) and mood 
(QIDS, YMRS) on hair cortisol levels that were assessed at the 3-month assessment, and whether hair cortisol 
levels from the 3-month assessment had an influence on mood and stability as reported at the 6-month assess-
ment.
results
Hair cortisol measurements were available in 100 patients. For 96 of these patients, life 
event data were available. Of these 96 patients, 71 patients had complete information on 
the final set of covariates and constituted our final study sample. Ten patients reported 
a treated endocrine disease (n = 2 diabetes, n = 7 hypothyroidism, n = 1 diabetes and 
hypothyroidism), and a total of 17 patients presented with metabolic syndrome. Group 
characteristics are shown in Table1. The median HCC was 30.28 with an interquartile 
range from 22.73 to 48.96. Hair cortisol levels of patients with either metabolic syndrome 
or an endocrine disease were not different from the hair cortisol concentrations of the 
other patients (F(1,66) = 0.87, p = 0.35 and F(1,69) = 0.03, p = 0.86) respectively, and 
controlling for these variables did not alter the results.
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table 1. Group characteristics (n = 71)
Age (years) – median (IQR) 52 (43 – 62)
Number of women – n (%) 41 (57.7 %)
BMI (kg/m2) – median (IQR) 25.5 (23.5 – 27.75)
HCC (pg/mg) – median (IQR) 30.28 (22.73 – 48.96)
Hair treatment
Hair dyed 30 (42.3 %)
Hair bleached 8 (11.3 %)
Frequency of hair wash
< 2 times/week 39 (54.9 %)
≥ 3 times/week 32 (45.1 %)
Age of onset BD
< 30 years of age – n (%) 45 (63.4 %)
> 30 years of age – n (%) 26 (36.6 %)
Psychiatric comorbidities
Anxiety disorder without panic disorder – n (%) 19 (26.8 %)
Somatoform disorder – n (%) 3 (4.2 %)
Pain disorder – n (%) 2 (2.8 %)
Panic disorder – n (%) 13 (18.3 %)
Medication
Lithium – n (%) 59 (83.1 %)
Antiepileptics – n (%) 14 (19.7 %)
Antidepressants – n (%) 25 (35.2 %)
Antipsychotics – n (%) 24 (33.8 %)
Benzodiazepines – n (%) 18 (25.4 %)
Diagnosis
Bipolar disorder type 1 54 (76.1 %)
Bipolar disorder type 2 and NOS 17 (23.9 %)
IQR, interquartile range; BMI, body mass index; HCC, hair cortisol concentrations; BD, bipolar disorder; NOS, not 
otherwise specified.
life events and hair cortisol
Descriptive information of the life events is provided in Table 2. The total number of life 
events was not associated with HCC (Table 3). The number of negative life events was 
associated with increased HCC (β = 0.22, t(64) = 2.07, r² = 0.04, p = 0.04). Selecting the 
patients that only experienced negative life events (excluding all patients that reported 
any positive or ambiguous life events in addition to negative events), the results became 
even more significant (β = 0.31, t(64) = 2.54, r² = 0.08, p = 0.02), as illustrated in Figure 2. 
For positive life events and ambiguous life events, the analyses could not be performed 
separately due to small sample sizes.
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table 2. Reported life events by BD patients (n = 71)
Occurrence of at least 1 life event – n (%) 49 (69.0 %)
At least 1 negative event – n (%) 45 (63.4 %); only negative events – 32 (45.1 %)
At least 1 positive event – n (%) 12 (16.9 %); only positive events – 3 (4.2 %)
At least 1 ambiguous event – n (%) 7 (9.9 %); only ambiguous events – 1 (1.4 %)
Number of all events – M (SD) 1.70 (1.84)
Number of negative events – M (SD) 1.34 (1.56)
Number of positive events – M (SD) 0.24 (0.60)
Number of ambiguous events – M (SD) 0.13 (0.41)
Descriptive information on the occurrence of 61 life events. M, mean; SD, standard deviation.
table 3. The effect of life events on HCC for the whole group and stratified for subgroups
All BD patients (n = 71)
All life events β = 0.18, t(64) = 1.65, r² = 0.03, p = 0.10
Negative life events β = 0.22, t(64) = 2.07, r² = 0.04, p = 0.04
Only negative life events β = 0.31, t(64) = 2.54, r² = 0.08, p = 0.02
BD I (n = 54)
All life events β = 0.25, t(47) = 1.91, r² = 0.05, p = 0.06
Negative life events β = 0.28, t(47) = 2.18, r² = 0.06, p = 0.03
Only negative life events β = 0.31, t(47) = 2.18, r² = 0.07, p = 0.04
BD II/NOS (n = 17)
All life events β = -0.09, t(10) = -0.37, r² = 0.007, p = 0.72
Negative life events β = -0.09, t(10) = -0.32, r² = 0.005, p = 0.76
Only negative life events β = 0.36, t(10) = 1.11, r² = 0.06, p = 0.35
Age of onset < 30 (n = 45)
All life events β = 0.19, t(39) = 1.58, r² = 0.03, p = 0.12
Negative life events β = 0.23, t(39) = 2.04, r² = 0.05, p = 0.05
Only negative life events β = 0.28, t(39) = 2.28, r² = 0.07, p = 0.03
Age of onset > 30 (n = 26)
All life events β = 0.11, t(20) = 0.47, r² = 0.008, p = 0.64
Negative life events β = 0.20, t(20) = 0.85, r² = 0.03, p = 0.41
Only negative life events β = 0.39, t(20) = 1.47, r² = 0.11, p = 0.17
HCC, Hair cortisol concentrations; BD, bipolar disorder; all life events, the total number of life events; negative 
life events, the number of negative life events in presence of positive and/or ambiguous life events; only nega-
tive life events, the number of negative life events in presence of no positive and/or ambiguous life events. The 
table shows the results of linear regression analyses. All p-values were adjusted for dyeing and bleaching of the 
hair, use of benzodiazepines, comorbidities except for panic disorder, and comorbid panic disorder. Except for 
the analysis stratified for age of onset, all values were also adjusted for age of onset before or after 30 years. R² 
indicates the change in r² of the model by adding the variable in question to the model.
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figure 2. First row: The number of negative life events is associated with an increase in hair cortisol concentra-
tions in patients with only negative life events, whereas in presence of positive or neutral life events, this associa-
tion was not signifi cant. This graph shows the inverse log-transformed cortisol values. Second row: The score of 
the frequency measurement of the Social Support List is associated with a decrease in hair cortisol concentra-
tions in the presence of negative life events, whereas no association was found between social support and hair 
cortisol concentrations in patients with also positive or neutral life events.
Based on the recent fi nding that life events relate to mood in BD I but not in BD II patients 
[22], analyses were stratifi ed for subtype of BD. We found a trend for an eff ect of the 
total number of life events on hair cortisol for patients with BD I (β = 0.25, t(47) = 1.91, 
r² = 0.05, p = 0.06) whereas this was not signifi cant for patients with BD II/NOS. More 
specifi cally, an increase in HCC was only seen in patients with BD I for the number of only 
negative events (β = 0.31, t(47) = 2.18, r² = 0.07, p = 0.04) but not in patients with BD II.
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As our group showed before that age of onset before or after 30 years of age is associ-
ated with different HCC [19], analyses were also stratified for age of onset before or after 
30. The total number of life events was not associated with HCC in either the early age 
of onset or the late age of onset patients. The number of negative life events was associ-
ated with increased HCC in patients with an early age of onset (β = 0.23, t(39) = 2.04, r² = 
0.05, p = 0.05; only negative events: β = 0.28, t(39) = 2.28, r² = 0.07, p = 0.03), but not in 
patients with a late age of onset. Age of onset was not associated with BD subtype, and 
the frequency distribution was not different for the groups (χ (1, N=71) = 0.02, p = 0.90).
Hair cortisol and mood
Patients reported a mean score of 0.54 (SD = 1.94) on the YMRS (range of potential scores: 
0 - 60) and a mean score of 6.90 (SD = 5.18) on the QIDS (range of potential scores: 0 - 27). 
The mean functional impairment as assessed with the LCM-r was 0.52 (SD = 0.67) for 
the depressive symptoms and 0.17 (SD = 0.39) for the manic symptoms. For both LCM-r 
measurements, the range of potential scores is 0 to 4). Hair cortisol was neither associ-
ated with mood symptoms in the three months prior to the hair collection and therefore 
corresponding to the time frame captured by the hair sample nor predictive of mood 
in the three months after taking the hair sample (all p > 0.05). The disorder state in the 
corresponding three months has earlier been shown to not be associated with HCC [19].
life events and mood
The number of all life events correlated significantly with the QIDS score in the corre-
sponding three months, ρ = 0.26, p = 0.03. The number of negative life events in presence 
of other life events also showed this association; ρ = 0.29, p = 0.02. Reducing the sample 
to the patients with only negative life events made the association even stronger, ρ = 
0.33, p = 0.02. The relation between life events (all, negative, only negative), the YRMS 
score and the functional impairment for depressive symptoms and manic symptoms did 
not reach significance (all p > 0.05).
Hair cortisol, life events, and social support
The frequency of social support and the perceived social support showed a mean score 
of 66.58 (SD = 13.81) and -34.68 (SD = 12.14), respectively. The frequency of social sup-
port was inversely associated with HCC (β = -0.21, t(64) = -2.04, r² = 0.04, p = 0.05), as was 
the perceived social support (β = -0.22, t(64) = -2.06, r² = 0.04, p = 0.04). Further analyses 
revealed that the decreasing effect of the frequency of social support on hair cortisol 
concentrations was only present in patients who experienced negative life events (β 
= -0.28, t(38) = -2.21, r² = 0.07, p = 0.03), as illustrated in Figure 2, and not in patients 
who did not experience life events (Table 4). Perceived social support did not reach 
significance when stratifying for the occurrence of negative life events.
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table 4. The effect of social support on HCC in presence and absence of life events
All BD patients (n = 71)
Frequency of social support β = -0.21, t(64) = -2.04, r² = 0.04, p = 0.05
in no life events β = 0.46, t(15) = 0.46, r² = 0.006, p = 0.65
in life events β =-0.27, t(42) = -2.21, r² = 0.07, p = 0.03
in negative life events β = -0.28, t(38) = -2.21, r² = 0.07, p = 0.03
Perceived social support β = -0.22, t(64) = -2.06, r² = 0.04, p = 0.04
in no life events β = -0.11, t(14) = -0.55, r² = 0.30, p = 0.60
in life events β = -0.18, t(41) = -1.45, r² = 0.03, p = 0.15
in negative life events β = -0.18, t(37) = -1.39, r² = 0.03, p = 0.17
BD I
Frequency of social support β = -0.19, t(47) = -1.48, r² = 0.03, p = 0.15
in no life events β = 0.14, t(9) = 0.87, r² = 0.02, p = 0.40
in life events β = -0.29, t(31) = -1.98, r² = 0.07, p = 0.06
in negative life events β = -0.30, t(29) = -1.97, r² = 0.08, p = 0.06
in only negative life events β = -0.40, t(20) = -2.29, r² = 0.13, p = 0.03
BD II
Frequency of social support β = -0.34, t(10) = -1.46, r² = 0.09, p = 0.18
in no life events -
in life events β = -0.57, t(4) = -1.69, r² = 0.18, p = 0.19
in negative life events β = -0.03, t(2) = -0.05, r² < 0.001, p = 0.97
in only negative life events -
Age of onset < 30
Frequency of social support β = -0.09, t(39) = -0.72, r² = 0.007, p = 0.48
in no life events β = 0.22, t(15) = 1.51, r² = 0.05, p = 0.17
in life events β = -0.18, t(25) = -1.23, r² = 0.03, p = 0.23
in negative life events β = -0.18, t(24) = -1.23, r² = 0.03, p = 0.23
in only negative life events β = -0.28, t(16) = -1.85, r² = 0.07, p = 0.08
Age of onset > 30
Frequency of social support β = -0.64, t(20) = -3.96, r² = 0.33, p = 0.001
in no life events β = -1.18, t(4) = -1.44, r² = 0.27, p = 0.25
in life events β =-0.56, t(12) = -2.80, r² = 0.28, p = 0.02
in negative life events β = -0.62, t(9) = -2.85, r² = 0.33, p = 0.02
in only negative life events β = -1.18, t(4) = -3.02, r² = 0.45, p = 0.04
HCC, Hair cortisol concentrations; BD, bipolar disorder; in negative life events, in presence of negative life events 
irrespective of concurrent positive and/or ambiguous life evens; only negative life events, in presence of nega-
tive life events while in absence of positive and/or ambiguous life events. The table shows the results of linear 
regression analyses. All p-values were adjusted for dyeing and bleaching of the hair, use of benzodiazepines, 
comorbidities except for panic disorder, and comorbid panic disorder. Except for the analysis stratified for age of 
onset, all values were also adjusted for age of onset before or after 30 years. R² indicates the change in r² of the 
model by adding the variable in question to the model.
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As with life events, stratification for type of bipolar disorder showed that the frequency 
of social support in presence of negative life events was trend-associated with decreased 
HCC in patients with BD I (β = -0.30, t(29) = -1.97, r² = 0.08, p = 0.06, only negative events: 
β = -0.40, t(20) = -2.29, r² = 0.13,p = 0.03) but not in patients with BD II/NOS or in patients 
with no negative life events. Stratification for age of onset showed that the frequency of 
social support in presence of negative life events showed no effect on HCC in patients 
with an early age of onset, but a trend in patients with only negative events: β = -0.28, 
t(16) = -1.85, r² = 0.07, p = 0.08) and decreased HCC in patients with a late age of onset 
and with negative life events (β = -0.62, t(9) = -2.85, r² = 0.33, p = 0.02, only negative 
events: β = -1.18, t(4) = -3.02, r² = 0.45, p = 0.04).
Discussion
The focus of our research project “The Bipolar Stress Study” is to identify the influence of 
biological and psychological stress on characteristics and course of bipolar disorder. In 
the current study we focused on the association between life events and HCC in patients 
with BD, and to explore whether HCC in patients with life events are predictive of mood 
in the subsequent three months. For this purpose, we benefited from earlier findings 
regarding the same cohort [19, 22] as we could account for the previously reported rela-
tions such as age of onset and subtype of bipolar disorder, and extended these findings.
In this study, we found an association between the number of negative life events and 
increased HCC, in particular in patients with the BD I subtype or in those who had an age 
of onset before 30 years. The observed increased HCC after life events are consistent with 
current literature on the influence of life events on hair cortisol levels [20-21]. However, 
we showed that it is not the total number of life events but in particular the number of 
negative life events, which significantly increases HCC in the corresponding months. 
Negative life events might aggravate rumination that may exacerbate the already adverse 
experience [33], thereby potentiating the effect of life events. Interestingly, it has previ-
ously been reported that bipolar patients show normal initial cortisol responses to stress-
ful life events, but that they have more difficulty in terminating the stress response and 
returning to a stable baseline mood. Whereas healthy participants reported that it took 
them on average 2.3 days to return to pre-event mood and behavioral levels, cyclothymic 
and dysthymic patients stated that their average recovery time was 3.9 days and 7.7 days, 
respectively [34]. It is essential that an individual is able to terminate the cortisol response 
appropriately to prevent hypercortisolemic effects [35]. A failure to do so would reflect in 
higher mean cortisol levels over a prolonged period of time, which would contribute to 
higher HCC levels. Regarding social support, our first analyses indicated that the frequency 
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of social support and perceived social support were associated with decreases in HCC. 
Further analyses revealed that the attenuating effect of the frequency of social support 
on HCC was only present in patients with BD I that experienced (negative) life events and 
not in patients without any life events, suggesting that social support could partially at-
tenuate the increasing HCC after negative life events. One might speculate that mitigating 
against increased long-term cortisol levels might protect from new mood episodes, as 
the “social zeitgeber theory” has proposed that life events might induce a new mood epi-
sode through disruptions in social and biological rhythms [36]. Through this mechanism, 
increased social support may stabilize the social and thereby also the biological rhythm.
Stratifying the analyses led to interesting findings, i.e. that the number of negative life 
events leads to HCC increases in BD I patients and in patients with an early age of onset. 
Stronger effects of life events on HCC in patients with BD I and an early age of onset could 
be due to various reasons. One reason might be a power problem that reflects the smaller 
number of participants in BD II and with a late age of onset rather than an underlying differ-
ence between the subtypes. This seems probable, as the standardized coefficients of BD II 
and a late age of onset are greater than the standardized coefficients of BD I and early age of 
onset, but fail to reach significance. However, other possibilities need to be acknowledged. 
A stronger effect of life events on mood symptoms and functional impairment on patients 
with BD I patients as compared to BD II patients has already been found in a longitudinal 
study on this cohort [22]. One possibility might be the different course trajectory of the 
subtypes. BD II is associated with a more chronic course and fluctuations in mood [37]. This 
is also consistent with the kindling theory, suggesting that stress triggers the initial episodes 
and recurrences, but that successive episodes are progressively induced independently of 
stressors [38]. With more episodes and a more chronic course, the association between stress 
and a new mood episode may already be too weak to be detected. For age of onset, an early 
onset BD has been suggested to be associated with a genetic vulnerability [39], whereas late 
onset BD is thought to be initially triggered by a major life event preceding the first episode 
[40]. A late onset is therefore more likely associated with a chronic HPA axis disturbance, 
which is in line with the earlier reported higher HCC in patients with a late age of onset 
compared to patients with a younger age of onset in this cohort [19]. Therefore, another 
major life event might not influence HCC as much as it would in patients with early age of 
onset and hypothetically more normal HPA axis functioning.
The question arises, how these results have to be interpreted, i.e. whether this increase 
reflects a healthy reaction of the HPA axis to a stressor, or whether it is a risk factor for 
a new mood episode. The same holds true for the potential absent HCC increase in BD 
II patients and patients with a late age of onset, and whether this reflects the failure to 
start a stress reaction to a life event, or whether it is a protective property that these 
patients have. An answer to this question would need a more frequent monitoring of 
the patients to assess exactly when a life event has happened, and a smaller time frame 
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covered by the hair sample, for example 1 cm instead of 3 cm. This would yield insight 
in whether an increase in HCC happens in all patients and that some patient groups 
are faster in ending the prolonged stress response than others, or whether the increase 
is a feature associated with different patient characteristics. In our study, this frequent 
monitoring was not possible due to logistic reasons.
In the current study, we found no association between hair cortisol concentrations 
and mood. However, for investigating the influence of HCC on mood and vice versa, the 
presence of distinct mood symptoms is required. Our well-treated sample only showed 
minor mood fluctuations and reported few clinical symptoms, thereby questioning the 
validity of our negative findings.
Several strengths and limitations of the present study need to be mentioned. The 
patients that participated in this research projects were seen regularly and frequently, 
i.e. every 3 months, and the occurrence of life events and presence of mood disorder 
symptoms were inquired upon every visit. For research on life events this is of high 
value, as in long periods between visits, patients may either forget to report life events, 
or may aggravate the meaning of events in order to explain for example a new mood 
episode, a process called “effort after meaning” [4]. However, we have to acknowledge 
the already mentioned small sample size of patients with either only positive or only 
ambiguous events, and the lack of a control group, i.e. HCC of healthy controls who also 
provided information on life events and mood. Furthermore, our sample presented with 
sparse mood symptoms which could be related to the high number of patients that 
used psychotropic medication. This treatment might be another limitation for this study 
as the effects of psychotropic medication on HCC have not been extensively examined 
until now; however, it seems an almost inevitable factor when dealing with this patient 
group. A related point is that patients with serious mood problems at the moment 
of assessment might not come to the outpatient department [41]. Our timeframe of 
observation amounted to six months, one period of three months that comprised the 
hair sample and the information on mood and life events of the corresponding three 
months, and the period of the subsequent three months, that comprised information 
on mood. Seeing that manic patients report on average 0.4 - 0.7 mood episodes per 
year [42], our design was likely too short to appropriately capture major mood changes.
To summarize, in the present study we showed that the number of negative life events 
is associated with increased hair cortisol concentrations in bipolar patients. These results 
indicate that even in the presence of a disorder that is associated with a dysregulation 
of the HPA-axis, exposure to negative life events might induce further HPA-axis distur-
bances. This relationship seems to be modified by social support, pointing towards the 
flexibility of the HPA-axis in both directions. Furthermore, these are first indications that 
there might be subtypes of bipolar patients that react differently to life events in terms 
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of cortisol secretion, which might on the long term warrant different approaches to cop-
ing with stress or treatment of these patients.
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abstract
background
In obese subjects a relatively high cortisol output in urine has been observed compared 
to non-obese individuals. However, cortisol levels in blood, saliva and urine in associa-
tion with obesity have been inconsistent across studies, possibly due to the high vari-
ability of systemic cortisol levels. Cortisol levels measured in scalp hair provide a marker 
for long-term cortisol exposure, and have been associated with cardiovascular disease in 
an elderly population and to disease course in Cushing’s disease. We aimed to compare 
hair cortisol levels between obese patients and non-obese controls.
methods
We measured hair cortisol levels of 47 obese patients (median BMI 38.8, range 31.1 - 65.8), 
41 overweight and 87 normal-weight subjects using an enzyme-linked immunosorbent 
assay (ELISA).
results
Obese patients had higher hair cortisol levels than overweight and normal weight sub-
jects (respectively 30.8 vs. 8.5 and 8.4 pg/mg hair, p < 0.001). No significant difference in 
hair cortisol levels was found between normal weight and overweight subjects.
conclusions
Our results suggest a higher long-term cortisol exposure in obese patients, which may 
contribute to cardiovascular disease risk. Future research will determine whether long-
term cortisol levels provide a novel treatment target in the management of cardiovas-
cular disease risk in obesity.
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Chapter 5
introDuction
Cortisol, the main glucocorticoid hormone in humans, is produced by the adrenal cortex 
under the influence of pituitary adrenocorticotropic hormone. An extreme excess of 
cortisol, as seen in Cushing’s syndrome, is often marked by obesity and features of the 
metabolic syndrome (MetS), including dyslipidemia, hypertension, hyperglycemia and 
insulin resistance [1-2]. This observation has given rise to the hypothesis that a modest 
increase in cortisol exposure may contribute to obesity and MetS in the general popula-
tion.
In line with this, obesity has been associated with increased cortisol output, as 
determined by urinary free cortisol. However, these results were inconsistent across 
studies, and this increased cortisol production does not seem to be reflected by serum 
and salivary cortisol [3]. These inconsistencies can be partially explained by the high 
variability in systemic cortisol levels, caused by pulsatile secretion, a diurnal rhythm and 
day-to-day fluctuations [4]. A relatively novel method to measure cortisol exposure is 
through scalp hair analysis. Several laboratories have successfully validated hair cortisol 
concentrations (HCC) as a marker of long-term cortisol exposure for periods of up to 
several months, thereby avoiding the limitations of time-point measurements [5-7]. 
With the use of HCC, increased long-term cortisol levels have recently been linked to 
disease course in Cushing’s disease, presence of MetS and cardiovascular disease [8-11].
Previously, a positive correlation has been reported between HCC and body mass 
index (BMI) and waist circumference [5, 9, 12]. Furthermore, we recently reported in-
creased HCC in obese children [13]. However, in an elderly cohort and a group of healthy 
adults we found no association between HCC and BMI [5, 10]. Until now, no study has 
been published which reported long-term cortisol levels in a patient population be-
ing evaluated for obesity. Therefore, we devised this study to examine whether obese 
individuals who visited our obesity center have higher hair cortisol concentrations than 
non-obese controls.
metHoDs anD ProceDures
Participants
Obese patients were recruited from an outpatient academic obesity center at the 
Erasmus MC, Rotterdam, The Netherlands. Inclusion criteria were age above 18 years, 
BMI above 30 kg/m2, ability to take part in physical exercise and at least one minor 
complication related to obesity, such as dyslipidemia, impaired glucose tolerance 
or hypertension. Patients were excluded when a secondary cause of the obesity was 
found, such as Cushing’s syndrome, hypothyroidism or syndromal obesity, or if they took 
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glucocorticoid-containing medication. Between October 2011 and September 2013, we 
approached all patients who fulfilled the inclusion criteria (n = 60). In total, 141 healthy 
normal weight (BMI 18.5 - 24.9) and non-obese overweight (BMI 25.0 - 29.9) subjects 
from our previous validation study served as controls [5]. This study was approved by 
the local medical ethics committee. Written informed consent was obtained from all 
participants. All study procedures were conducted in accordance with the declaration 
of Helsinki.
Hair sample collection and analysis
From all subjects, a lock of approximately 100 hairs was collected from the posterior 
vertex prior to treatment for obesity, cut as close to the scalp as possible. Preparation 
and analysis of hair samples was performed as described previously [5]. In brief, ap-
proximately 15 mg of the proximal 3 cm of hair was weighed and finely cut. Extraction 
took place in 1 ml of methanol at 52 °C for 16 hours. After extraction, methanol was 
transferred into glass tubes, and evaporated under constant nitrogen stream. Next, 
250 μL of phosphate buffered saline (PBS, pH 8.0) were added. Samples were vortexed 
prior to analysis, which was performed using a commercially available enzyme-linked 
immunosorbent assay (ELISA) kit for cortisol in saliva (DRG Instruments GmbH, Marburg, 
Germany).
laboratory diagnostics
In obese patients, blood was drawn after an overnight fast. HbA1c, glucose, triglycerides 
and total, LDL and HDL cholesterol were measured using routine laboratory procedures. 
Patients were coded as having MetS according to ATPIII criteria [2].
statistical analysis
IBM SPSS version 21 and GraphPad Prism version 5.01 were used for analysis. Differ-
ences in characteristics were tested using Chi-square and Kruskall-Wallis tests. HCC 
values were logarithmically transformed to attain normal distribution. HCC differences 
between groups of subjects were analyzed using analyses of (co)variance. Correlations 
between HCC and metabolic parameters were tested using Spearman’s rho. Statistical 
significance was defined as a P-value < 0.05.
results
Sixty obese patients were approached. Of these, 53 had sufficient scalp hair to obtain a 
sample. One patient was excluded, because she was diagnosed with an obesity-related 
syndrome. We successfully measured HCC in 47 out of 52 obese patients, and in 128 
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out of 141 non-obese controls. Baseline characteristics of all subjects are summarized 
in Table 1. Compared to controls, obese patients were on average older and comprised 
more women. The majority of obese patients (n = 39, 75%) fulfi lled ATPIII criteria for 
diagnosis of MetS, while all of the 13 remaining patients had at least one component 
of MetS.
table 1. Baseline, hair characteristics, and hair cortisol levels for normal weight, overweight and obese 
subjects
Normal weight 
N=87
Overweight 
N=41
Obese 
N=47
P value of 
diff erence
Baseline characteristics
Male 37 (43%) 25 (61%) 11 (23%) 0.002
Age 33 (20 – 61) 34 (19 – 63) 47 (18-68) 0.024
BMI (kg/m2) 22.5 (19.3 – 24.8) 27.2 (25.0 – 29.7) 38.8 (31.1 – 65.8) <0.001
Hair characteristics
Hair washings >3 week 65 (76%) 30 (73%) 31 (66%) 0.491
Use of hair products a 41 (48%) 20 (49%) 19 (40%) 0.666
Hair coloring b 17 (20%) 6 (15%) 14 (30%) 0.170
Hair bleaching b 6 (7%) 0 (0%) 5 (11%) 0.116
Hair cortisol levels
Hair cortisol (pg/mg hair) 8.4 (6.5 – 10.9) 8.5 (5.9 – 12.4) 30.8 (21.8 – 43.5) <0.001
Values of baseline and hair characteristics represent median (range) or number (percentage). Hair cortisol values 
represent mean (95% CI). aHair products concern hairspray, mousse, gel and wax used on the day of sample col-
lection. bConcerns coloring or bleaching in the 3 months before hair sample collection.
figure 1. Hair cortisol levels (pg/mg hair, logarithmic scale) in normal weight and overweight controls, and in 
obese patients. Horizontal lines represent the group median. *P<0.001
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Obese patients had significantly higher HCC than normal-weight and overweight con-
trols (F(2, 172) = 19.788, P < 0.001, see Figure 1). However, HCC did not significantly 
differ between normal weight and overweight controls (post hoc comparison, P = 0.96; 
Figure 1, Table 1). Additional stepwise adjustment for age, sex, hair treatment and use 
of hair products did not significantly change our results. Within obese patients, HCC did 
not correlate significantly with BMI, waist circumference, HbA1c, LDL cholesterol, HDL 
cholesterol, triglycerides and glucose (data not shown).
Discussion
In this case-control study, we found that obese patients had higher cortisol levels in 
scalp hair compared to non-obese controls. Our results are in agreement with results 
from Stalder et al. and our own results in a population of shift work employees, as both 
studies reported a positive correlation between HCC and BMI [9, 12]. In our previous 
studies in healthy adults and in a group of elderly subjects, we did not find this correla-
tion, however we observed a correlation with waist/hip ratio in healthy adults [5, 10].
Notably, obese individuals had higher HCC than overweight and normal weight indi-
viduals, but HCC was similar between normal weight and overweight subjects. Possibly, 
the association between increased weight and long-term cortisol only reveals itself in a 
more extreme phenotype of adiposity. BMI does not discriminate between muscle and 
fat mass. Although it stands to reason that our obese group (with a median BMI of 38.8) 
has a higher fat mass than non-obese controls, the same may not be true for overweight 
versus normal-weight individuals. This may also explain why we did not find a correla-
tion between BMI and HCC in our previous study, which comprised individuals mainly of 
the normal to overweight BMI group [5].
It would be of interest to study the correlation with features of MetS, however, meta-
bolic data were only available for obese patients, and we found no significant correla-
tion between HCC and cardiometabolic risk factors in this group. Previously, Stalder et 
al., reported significant associations between HCC and all separate components of MetS 
[9]. However, obese patients in our study represent a relatively metabolically unhealthy 
population, with a 75% prevalence of MetS. Presumably, a wider range of risk profiles is 
needed to reveal associations.
Due to the cross-sectional design of this study, our results do not provide evidence 
for a causal relationship between high cortisol exposure and obesity. Further research 
is warranted to investigate whether relatively high cortisol exposure precedes weight 
gain and other cardiometabolic risk factors. We recently reported an increased HCC in 
obese children, indicating that long-term cortisol exposure may influence weight early 
in life [13]. An explanation for the increase in long-term cortisol in obese patients may be 
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that obesity has been associated with psychosocial stress and mental health disorders 
[14-15]. This may increase long-term cortisol levels [16]. In this context, it is of interest 
that shift workers who have an altered diurnal rhythm have increased HCC [12]. Alter-
natively, one might speculate that liver steatosis associated with obesity affects cortisol 
breakdown, inducing a vicious circle with elevated long-term systemic cortisol levels, 
which may in turn promote adiposity [17].
In follow up studies of these patients we will investigate whether therapies for 
weight loss are associated with a decrease in long-term cortisol levels. The associations 
between HCC and cardiovascular disease and MetS that recently have been reported 
provide a first indication that strategies that lower long-term cortisol levels may reduce 
cardiovascular risk [9-11].
In conclusion, we found that obese patients who visit an outpatient obesity clinic have 
significantly higher cortisol levels in scalp hair than normal-weight and overweight sub-
jects. Future research will show whether long-term cortisol provides a novel treatment 
target in the reduction of cardiovascular disease risk in obese patients.
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abstract
background
Intrinsic imperfections and lack of reliable biomarkers preclude optimal individual dos-
ing of hydrocortisone replacement in adrenal insufficiency (AI). However, the clinical 
relevance of optimal dosing is exemplified by frequently occurring side effects of over-
replacement and the dangers of under-replacement. Cortisol in scalp hair has been 
identified as a retrospective biomarker for long-term cortisol exposure. We compared 
hair cortisol concentrations (CORThair) of patients with primary or secondary AI on re-
placement therapy with those of patient controls with a pituitary disease without AI (PC) 
and of healthy controls (HC).
methods
In this cross-sectional study, hair samples and anthropometric data were collected in 
132 AI patients (52 males), 42 PC (11 males), and 195 HC (90 males). The proximal 3 cm 
of hair were used. CORThair were measured using ELISA.
results
CORThair were higher in AI patients than in HC and PC (p < 0.001), and hydrocortisone 
dose correlated with CORThair (p = 0.04). Male AI patients demonstrated higher CORThair 
than female patients (p < 0.001). AI patients had higher body mass index (BMI) than HC 
(p < 0.001), and BMI correlated with CORThair in the whole sample (p < 0.001).
conclusions
Physiological hydrocortisone replacement is associated with increased CORThair. The as-
sociation between CORThair and BMI could suggest a mild overtreatment that may lead 
to adverse anthropomorphic side effects, especially in males. CORThair measurements 
may be a promising additional tool to monitor cumulative hydrocortisone replacement 
in AI.
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introDuction
Adrenal insufficiency (AI) in which the adrenal corticosteroid synthesis, i.e. cortisol 
production, is insufficient can be primary in case of pathology of the adrenal glands, or 
secondary in case of hypopituitarism. Patients with AI need replacement therapy with 
exogenous glucocorticoids, preferably hydrocortisone, which is synthetically produced 
cortisol [1]. In persons with intact adrenal function around 5 to 10 mg of cortisol per 
m² of body surface area per day is produced [2], with increased requirements during 
stress. The corresponding chronic oral replacement dosage is 15–25 mg per day, usually 
divided in three dosages in an attempt to mimic the circadian rhythm of natural cortisol 
secretion, with a peak in the morning and a gradual decrease during the day and evening 
[1, 3]. It is recommended that hydrocortisone replacement should be individualized, 
taking into account blood pressure, metabolic derangements and sense of well-being 
[4]. Various maintenance dosing strategies have been published [5]. However, it is likely 
that there will be large individual variation in substitution requirements in view of differ-
ences in cortisol sensitivity due to polymorphisms of the glucocorticoid receptor gene 
[6]. Currently available cortisol measurements in plasma, urine or saliva do not reflect 
cortisol action at tissue level. In accordance, plasma and salivary cortisol concentrations 
vary considerably between patients receiving hydrocortisone replacement, limiting the 
possibility to titrate individual hydrocortisone doses upon single plasma, or salivary 
measurements [7]. A method to retrospectively assess cortisol for longer periods of time 
is the analysis of cortisol in scalp hair [8]. As hair grows approximately one cm per month 
[9], a hair sample of for example three cm represents the long-term cortisol concentra-
tion of three months. Hydrocortisone is identical to human cortisol and has been shown 
to be measureable in scalp hair [8, 10]. Hair cortisol levels (CORThair) have repeatedly been 
associated with body mass index (BMI) and increased risk of metabolic syndrome and 
cardiovascular disease in populations with endogenous cortisol metabolism [11-15]. 
Until now, there is very limited data on the clinical utility of CORThair measurements in 
patients with hydrocortisone replacement as is the case in AI. A recent study by Gow et 
al. demonstrated that hydrocortisone dose was significantly positively associated with 
CORThair in patients with primary AI [10]. Furthermore, they demonstrated a significant 
difference in CORThair in male subjects between patients and controls, but no statistically 
significant difference in females. In addition, they did not observe a difference between 
male and female patients’ CORThair. Thus, this study provided data indicative of a po-
tential gender dependent effect in CORThair in patients on hydrocortisone replacement. 
However, it should be acknowledged that this study included only 13 male patients 
vs. 80 female patients, which limits the generalizability of the results. Therefore, we 
aimed to compare CORThair in a large cohort of patients with primary and secondary AI 
on hydrocortisone replacement therapy (AI patients) with CORThair of control patients 
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with a pituitary disease but no hydrocortisone replacement therapy (PC) and healthy 
controls (HC). Furthermore, we aimed to explore possible determinants of CORThair in 
hydrocortisone treated AI patients, i.e. self-reported hydrocortisone intake, sex, age, and 
weight. We hypothesized that AI patients would have higher CORThair than PC and HC, 
and that AI patients show side effects associated with high cortisol levels. Moreover, 
we hypothesized that CORThair are associated with doses of hydrocortisone replacement 
and BMI.
metHoDs anD ProceDures
study design
This study was designed as a cross-sectional assessment of patients seen at the out-
patient clinic of the department of Endocrinology of the Leiden University Medical 
Center. This study was conducted between July 2012 and January 2014. Hair samples 
were collected and patients were asked to fill out two short self-developed question-
naires: one questionnaire about their hair treatment, and one questionnaire about their 
hydrocortisone intake (i.e. self-reported daily dose, time of intake, frequency of increas-
ing/decreasing hydrocortisone dose) and/or the potential usage of other exogenous 
glucocorticoids. Clinical data of patients were obtained from their medical records.
Participants
Patients
We included two groups of patients: group I) patients with primary or secondary adrenal 
insufficiency using hydrocortisone (AI patients), and group II) patient controls (PC) with 
a pituitary disease not using hydrocortisone. A total of 184 patients were willing to par-
ticipate. Patients could not participate in case of insufficient hair growth at the posterior 
vertex of the scalp. Ten patients were excluded from the analysis because of interpreta-
tive difficulty of their chronic steroid replacement scheme; three had high levels prob-
ably due to a hydrocortisone stress scheme for Addison’s crisis in the three months prior 
to hair collection, three patients were excluded because of CORThair >3 SD with no clear 
explanation, and four patients were excluded due to debatable AI diagnosis and incon-
sistent hydrocortisone use. The final sample comprised a total of 174 patients (i.e. 132 AI 
patients and 42 PC). Primary AI had been diagnosed by very low early morning cortisol 
concentrations (<120 nmol/l) or insufficient stimulation following ACTH test (below 550 
nmol/l) usually in the presence of positive adrenal auto-antibodies or an alternative 
explanation. Secondary adrenal insufficiency was preferably diagnosed using an insulin 
tolerance test (ITT), or if contra-indicated, a CRH test using the same cut-off as for ACTH 
stimulation. Pituitary hormone replacement was prescribed dependent on the results of 
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the annual evaluation of pituitary functions. In case of AI, hydrocortisone was prescribed 
(usually 20 mg/d divided into 3 dosages, with adjustments if clinically judged necessary 
by the treating physician) together with advices to increase the hydrocortisone dose 
in case of exposure to severe somatic and/or psychological stressors. In case of other 
hormone deficiencies, patients were substituted accordingly.
Healthy controls
To compare CORThair between patients and healthy individuals, we used a group of 195 
healthy controls (HC) previously described elsewhere [8]. The study was approved by the 
local ethics committee. All patients and controls gave written informed consent.
Hair cortisol assessment
A lock of approximately 150 hairs was cut as close to the scalp as possible from the 
posterior vertex. For analysis, the most proximal three cm of hair were used, correspond-
ing to the most recent three months. Hair sample preparation and analysis has been 
described previously [8]. In short, a minimum of 10 mg of hair was weighed and cut into 
small pieces in a glass vial. Extraction of cortisol took place in 1 mL of methanol for 16h at 
52⁰C while gently shaking. After extraction, the methanol was transferred to another vial 
and evaporated under a constant stream of nitrogen. The samples were dissolved in 250 
μL of phosphate buffered saline (PBS, pH 8.0) for analysis. A commercially available ELISA 
Kit for salivary cortisol (DRG GmbH, Marburg, Germany) was used to measure cortisol 
levels. A correction factor was applied to the results to account for the potential influ-
ence of different hair weights. Cross reactivity of other steroids with the kit’s antibodies 
was reported as follows: Corticosterone (29.00%), Cortisone (3.00%), 11-Deoxycortisol 
(<1.00%), 17-OH Progesterone (<0.50%), other hormones (<0.10%). Intra-assay variation 
was below 5% and the inter-assay variation below 8% as reported by the supplier. The 
recovery of the assay was described previously [8].
statistical analysis
SPSS 20.0 for Windows was used for statistical analysis. Differences in demographic in-
formation between groups were tested with One-Way-ANOVAs and Pearson Chi Square 
tests. After logarithmic transformation, CORThair were normally distributed. Analyses on 
CORThair and differences between groups were performed by means of univariate gen-
eral linear models. If groups differed on age, sex, BMI, or hair treatment (see Table 1 and 
Table 2), analyses on group differences were adjusted accordingly. For analyses of the 
etiologies of hydrocortisone use, post-hoc tests were applied. Pearson and spearman 
correlations were used for correlation analyses, depending on normality of the distribu-
tion. CORThair are provided in pg/mg and are reported as median (Mdn) and interquartile 
range (IQR).
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role of the funding source
This study was sponsored by the Leiden University Medical Center and the Erasmus 
Medical Center, the Netherlands. The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or writing of the report. The corre-
sponding author had full access to all the data in the study and had final responsibility 
for the decision to submit for publication.
results
Participant characteristics (table 1)
132 AI patients, 42 PC, and 195 HC were included in the analysis. The frequency of us-
ing glucocorticoid containing medication (other than hydrocortisone or maintenance 
dose) was 14.9% and did not differ between AI patients and PC (p = 0.26). Of these, 
12.6% used one, and 2.3% used two kinds of glucocorticoid containing medication. The 
most frequent used products were ointments (n = 8) and inhalation aerosols (n = 8). Five 
patients used nasal spray, and one patient had received an injection into a joint. Patients 
that used externally applied glucocorticoid containing medication did not show differ-
ent CORThair than non-applying patients and were therefore not excluded (p = 0.75). The 
mean disease duration was not significantly different between AI patients (18.33 ± 13.54 
table 1. Baseline characteristics of patients, patient controls and HC
AI patients
(n = 132)
PC 
(n = 42)
HC 
(n = 195)
P-value1 P-value2 P-value3
Age 54.84 (14.99) 49.07 (12.94) 36.17 (12.23) 0.05 0.001 0.001
Sex (male) 52 (39.4%) 11 (26.2%) 90 (46.2%) 0.12 0.23 0.02
BMI 27.80 (5.12) 28.70 (7.45) 24.34 (3.85) 0.95 0.001 0.001
Use of exogenous glucocorticoids # 15 (11.5%) 2 (4.9%) NA 0.21 NA NA
Hypertension 56 (43.8%) 24 (60.0%) NA 0.07 NA NA
Diabetes mellitus 21 (9.2%) 4 (9.8%) 5 (2.6 %) 0.92 0.008 0.029
Hair dyed 42 (36.2%) 16 (42.1%) 37 (19.0%) 0.52 0.001 0.002
Hair bleached 13 (9.9%) 9 (22.0%) 13 (6.7%) 0.04 0.29 0.002
Hair permed 2 (1.5%) 3 (7.3%) 2 (1.0%) 0.05 0.69 0.01
Use hairproduct 66 (50.0%) 22 (53.7%) 90 (46.4%) 0.68 0.52 0.40
Frequency hair wash   > 3 times/week 46 (35.1%) 17 (41.5%) 143 (74.1%) 0.46 0.001 0.001
Data are presented as mean (standard deviation), and as n (valid percentage). AI, adrenal insufficiency; PC, pa-
tient control group; HC, healthy control group; BMI, Body Mass Index; NA, not applicable; #, use of other external 
glucocorticoids (besides hydrocortisone).
P-value1: comparison between AI patients and PC, P-value2: comparison between AI patients and HC, P-value3: 
comparison between PC and HC.
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years) and PC (15.06 ± 10.30 years), p = 0.16). Presence of hypertension (defined as either 
blood pressure above 140/90 or use of antihypertensive medication) and presence of 
diabetes mellitus (defined as use of oral medication and/or insulin injection) was not dif-
ferent between AI patients and PC, and in AI patients, frequencies of hypertension and 
diabetes mellitus were comparable between genders. Both AI and PC showed higher 
frequencies of diabetes mellitus than HC (both p < 0.005). Hypertension data were not 
available for HC.
corthair in ai patients, Pc, and Hc (figure 1a-b)
Analyses showed a significant difference in CORThair between the three groups, F(2, 
343) = 35.39, p < 0.001, adjusted for age, gender, and dyeing of the hair. Post-hoc tests 
indicated that AI patients had higher CORThair (33.89, 14.82 – 89.29) than PC (13.66, 6.22 – 
26.58), p = 0.001, and HC (10.07, 3.52 – 17.83), p < 0.001, and that PC had higher CORThair 
than HC, p = 0.04. In AI patients, 35.6% (61.5% males, 18.8% females) presented with 
CORThair above our lab-internal cut-off for normal, as did 7.1% (9.1% males, 6.5% females) 
of PC and 3.1% (5.6% males, 1.0% females) of HC. Our lab-internal upper limit of normal 
is 52 pg/mg. For determination, we restricted our group of healthy controls to the ones 
with a BMI between 18.5 and 30.0, and used the 97.5 percentile as cut-off value.
In AI patients, men had significantly higher CORThair (75.25, 28.91 – 159.81) than women 
(19.59, 11.49 – 38.49), F(1, 112) = 8.17, p = 0.00 5), adjusted for age and dyeing of the hair. 
No gender differences were observed in CORThair in PC. In HC, females showed higher 
CORThair than males, F(1, 191) = 5.45, p = 0.02. Stratified analysis for gender revealed that 
male AI patients had higher CORThair than male PC and HC (p = 0.02 and p < 0.001, re-
spectively), whereas for female AI patients, CORThair was trend-significantly higher than 
in female PC (p = .07) and significantly higher than in female HC (p < 0.001). Males in the 
figure 1. Median and IQR of CORThair. AI, adrenal insufficiency; PC, patient control group; HC, healthy control 
group. Untransformed data are shown. 1a) CORThair of AI patients, PC, and HC. 1b) CORThair for AI patients, PC, 
and HC, stratified for sex. *** = p < 0.001; ** = p < 0.01; * = p < 0.05,  = p < 0.1. Black lines represent differences 
between the participant groups, whereas grey lines represent sex differences within each participant group.
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PC group did not show different CORThair from males in the HC group, and females in the 
PC group had not different CORThair compared to females in the HC group (all p > 0.1). 
Within AI patients, no difference in CORThair was found for the various etiologies of AI.
correlation between hydrocortisone dose and hair cortisol levels (figure 2)
Self-reported daily hydrocortisone maintenance dose correlated with CORThair (ρ = 0.18, 
p = 0.04). Stratification for gender showed that this correlation was primarily driven by 
the female AI patients (ρ = 0.24, p = 0.04), whereas the correlation was not significant in 
male AI patients. Neither incidental higher and/or lower hydrocortisone dosages nor the 
morning (peak) dose of hydrocortisone (ρ = 0.15, p = 0.09) were related to CORThair. The 
self-reported daily hydrocortisone dose in mg/kg or mg/m2 was not related to CORThair 
and stratification for sex did not render different results.
figure 2. The relationship between daily hydrocortisone dose (mg/day) and CORThair (pg/mg), ρ = 0.18, p = 
0.04, as indicated with the black solid line, which is the regression line of the group analysis. Analyses stratified 
for sex show that this effect was driven by the female AI patients (grey; ρ = 0.24, p = 0.04), whereas no effect was 
observed for the male AI patients (black; ρ = -0.04, p = 0.79). CORThair are shown on a log scale.
correlations between anthropometrics and hair cortisol levels (figure 3)
As indicated in Table 2, BMI differed significantly between AI patients, PC and HC (F2, 
327) = 23.90, p < 0.001. Post-hoc tests revealed that the BMI of AI and PC patients was 
significantly higher compared to HC (p < 0.001), but there was no significant difference 
between AI and PC. For the whole group of participants, BMI showed a significant cor-
relation with CORThair (ρ = 0.24, p < 0.001). Stratification for sex and participant group 
revealed a significant correlation between BMI and CORThair for male AI patients (ρ = 
0.34, p = 0.02), but not for female AI patients nor for male or female PC or HC. Waist-to-
hip ratio (WHR) information was only available in a subset of 50 AI patients, 12 PC, and 
45 HC. WHR was not different between the groups. In the whole sample of participants, 
WHR and CORT correlated significantly (r = 0.20, p = 0.04). WHR and waist circumference 
were related to self-reported dose in mg/kg (r = -0.3, p = 0.04, and r = -0.58, p < 0.001, 
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respectively) and to self-reported dose in mg/BSA (r = -0.36, p = 0.01, and r = -0.64, p < 
0.001, respectively), but were not related to the total self-reported daily hydrocortisone 
maintenance dose (r = 0.11, p = 0.46, and r = 0.19, p = 0.17, respectively).
figure 3. The relationship between BMI and CORThair. 3a) The association between BMI and CORThair for all par-
ticipants was significant (ρ = 0.24, p < 0.001, black solid line); stratification for sex did not change the results (ρ 
= 0.35, p < 0.001 for male participants (black); ρ = 0.18, p = 0.02 for female participants (grey). 3b) In only the 
adrenal insufficiency (AI) patients, the association between BMI and CORThair was not significant; ρ = 0.11, p = 
0.23 (black solid line). Stratification for sex rendered a significant correlation for male AI patients (ρ = 0.34, p = 
0.02, black) but no association for female AI patients (ρ = 0.04, p = 0.73, grey). 3c) In the control persons, the as-
sociation did reach significance (ρ = 0.14, p = 0.04, black solid line). Stratified analyses showed that this effect 
was driven by the male controls (ρ = 0.24, p = 0.02, black) but was not significant for female controls (ρ = 0.10, 
p = 0.31, grey).
table 2. Baseline characteristics of male and female AI patients.
Males (n = 52) Females (n = 80) P-value
Age 55.94 (16.01) 54.13 (14.35) 0.50
BMI 27.57 (3.85) 27.95 (5.80) 0.68
Duration of follow-up (years) 17.87 (12.69) 18.62 (14.11) 0.76
Daily hydrocortisone dose (mg) 21.58 (4.98) 20.39 (4.21) 0.15
Daily hydrocortisone dose mg/kg 0.25 (0.07) 0.27 (0.07) 0.12
Daily hydrocortisone dose mg/BSA 10.35(2.54) 10.84 (2.27) 0.26
Use of external glucocorticoids # 5 (10.0%) 10 (12.5%) 0.66
Hypertension 23 (46.9%) 33 (41.8%) 0.57
Diabetes Mellitus 4 (8.0%) 8 (10.0%) 0.70
Hair dyed 0 42 (58.3%) 0.001
Hair bleached 0 13 (16.5%) 0.002
Hair permed 1 (1.9%) 1 (1.3%) 0.76
Use hairproduct 19 (36.5%) 47 (58.8%) 0.01
Frequency hair wash 0.03
   < 2 times/week 28 (53.8%) 57 (72.2%)
   > 3 times/week 24 (46.2%) 22 (27.8%)
Data are presented as mean (standard deviation), and as n (valid percentage). #: use of other external glucocor-
ticoids (besides hydrocortisone); BMI, Body Mass Index; BSA, body surface area.
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Discussion
The present study showed that patients using hydrocortisone replacement for AI demon-
strate higher CORThair than pituitary patients and healthy controls with an intact HPA-axis. 
Furthermore, a gender-effect was identified, with male patients with AI demonstrating 
higher CORThair than females, without differences in self-reported hydrocortisone intake. 
Intriguingly, this gender effect seems to be specific for hydrocortisone use, since it is 
not present in controls with an intact HPA-axis. In female patients, higher self-reported 
hydrocortisone intake was associated with higher CORThair, whereas this association was 
not found in male patients who demonstrated on average higher CORThair even in the 
lower dose range.
In male, but not female AI patients, higher CORThair were associated with higher BMI. 
This relation suggests that high CORThair may reflect chronic overexposure to hydrocorti-
sone, at least in male patients. However, further study is required to understand the role 
of gender in the determination of cortisol levels in hair and to confirm whether CORThair 
are indeed representative for corticosteroid exposure in the rest of the organs. Further-
more, it is still unclear how exactly cortisol, and hence hydrocortisone, is incorporated 
into scalp hair [16]. Therefore, the question remains whether it is the cumulative amount 
of cortisol or the cortisol peak that is most influential on CORThair. In our study, total dose 
appears to be associated with CORThair, and not a single/maximum dose. In contrast, the 
three patients who received a hydrocortisone bolus for an Addison crisis had extremely 
high values and were excluded from the study (data not shown), suggesting a role for 
a supraphysiological peak in determination of CORThair. In contrast to the positive cor-
relation between the absolute hydrocortisone dose and CORThair, we found no relation 
between body weight-adjusted dose and CORThair,. This is an interesting finding, since 
previous research has reported that clearance of hydrocortisone in serum is faster in 
obese patients, and that adjusting the dose for body weight may be beneficial for the 
patient [5, 17]. However, the current study may imply that tissue exposure following 
ingestion of hydrocortisone (at a physiological level) is independent of distribution 
volume, i.e. weight, at least for these patient groups as measured by CORThair, and thus 
questions the need to increase the hydrocortisone dose in obese patients. This is in 
accordance with recent guidelines pointing to no adjustment for weight (except for 
children) [3]. Male patients reached higher CORThair with considerably lower hydrocor-
tisone dosages than female patients. This “higher sensitivity” to hydrocortisone is in 
accordance with the positive association between CORThair and BMI in male patients. A 
possible explanation for this higher sensitivity in male patients might be that men seem 
to have lower corticosteroid binding globulin (CBG) levels while total cortisol levels are 
comparable to women’s total cortisol [18]. This may result in higher free cortisol levels 
in men upon hydrocortisone intake. As free cortisol is thought to be the cortisol fraction 
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which is incorporated in hair [19], this might explain the sex difference found in our 
study and in the study of Gow and colleagues [10].
However, the clearly increased CORThair suggest that in general patients with AI are 
chronically over-replaced, despite prescribed hydrocortisone replacement dosages aim-
ing at mimicking a “physiological” level. A higher daily hydrocortisone dose has been 
previously linked to a more adverse cardiometabolic risk profile, characterized by higher 
BMI [20]. Steroid excess-related morbidity is well known from AI cohorts treated with 
higher doses, resulting in the awareness to replace hydrocortisone with the lowest dose 
possible, generally regarded to as a daily hydrocortisone dose of 20 mg [21-22]. It is 
intriguing that AI patients treated with the currently advised low hydrocortisone dose 
have clearly increased CORThair and additionally present with steroid-related side effects, 
such as increased BMI.
It appears unlikely that an increased perceived stress of being a patient influences 
CORThair in this study. Some AI patients are known to occasionally increase their hydro-
cortisone doses in situations of increased psychological stress [23], which might result 
in higher CORThair. In population studies, CORThair has been associated with perceived 
stress [24-26], but if this was the case in the present study, the increased stress of being 
a patient should then also be present in our PC group. However, CORThair between PC 
and HC were comparable.
Several strengths and limitations of the present cross-sectional study need to be 
mentioned. In total, we included a considerable number of patients, which enabled 
us to examine CORThair of patient groups with pituitary diseases due to different eti-
ologies. Furthermore, we included a patient control group with a pituitary disease and 
normal adrenal function. All concurrent pituitary insufficiencies were treated, but we 
do acknowledge that, such as hydrocortisone replacement therapy, intrinsic imperfec-
tions of hormone replacement are also an important issue for gonadal steroids, thyroid 
hormone, and growth hormone replacement.
Besides the demonstrated association between CORThair and anthropometrics, a con-
siderable amount of studies demonstrated the association between high CORThair and 
psychological symptoms [25]. Furthermore, in a recent study it was demonstrated that a 
higher hydrocortisone intake in patients with primary adrenal insufficiency was associ-
ated with more impairments in quality of life, psychological morbidity, and maladaptive 
personality traits [27]. For future research, it would be interesting to assess patients’ 
perceived well-being in relation to CORThair.
In conclusion, patients on hydrocortisone replacement therapy have elevated COR-
Thair, a finding which is predominantly present in male patients. Despite a low dose of on 
average 21 mg/day only 64.4% of patients had CORThair in the normal range. This study 
provides important data on the fact that contemporary steroid replacement still results 
in clear supraphysiological (hair) cortisol levels, especially in males. However, it needs to 
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be confirmed that CORThair reflects cortisol (over)exposure in other organs of the body in 
exogenously treated patients, or that the incorporation of CORThair is different from the 
reference population with normal HPA-axis. Next, it needs to be established which are 
safe, gender-specific CORThair for patients to allow for the monitoring of hydrocortisone 
dose while avoiding the dangers of under- and over-replacement.
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abstract
background
In patients with adrenal insufficiency (AI) a higher hydrocortisone intake has been asso-
ciated with more impairment in Quality of Life (QoL). Irrespective of age, sex and severity 
of AI the dosage of hydrocortisone is titrated around 20 mg/D in all patients with AI 
based on physical and mental signs and symptoms. However, until now it is unknown 
whether these QoL impairments are related to increased systemic cortisol exposure. 
Measurement of hair cortisol levels (CORThair) can be used to assess chronic systemic 
cortisol exposure. This study aimed to explore whether QoL in patients with AI is associ-
ated with CORThair and daily hydrocortisone intake.
methods
We performed a cross-sectional study in 120 patients with AI on stable hydrocortisone 
replacement, in whom hair samples and QoL data were collected. CORThair were mea-
sured with ELISA, and QoL was assessed with validated questionnaires (SF-36, EQ-5D, 
HADS, MFI-20).
results
Patients reported impairments in 14 of 15 QoL subscales (p < .001). More impairments in 
physical aspects of QoL correlated with higher CORThair and higher daily hydrocortisone 
intake (p < .05), an effect that was more pronounced in female patients. Regression 
analyses including both CORThair and hydrocortisone intake revealed a significant nega-
tive contribution of higher hydrocortisone intake on physical aspects of QoL (p < .046), 
whereas no significant contribution was found for CORThair.
conclusions
The present study showed that patients with AI report several impairments in QoL which 
are associated with hydrocortisone intake, and to a lesser extent reflected by chronic 
systemic cortisol exposure as measured by hair cortisol. This suggests that QoL impair-
ments in patients with AI are not per se the effect of prolonged exposure to elevated 
systemic cortisol levels.
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introDuction
Adrenal insufficiency (AI) is treated with glucocorticoid replacement therapy, usually 20 
to 30 mg of hydrocortisone daily, divided in three dosages (10-15 mg in the morning, 
5-10 mg in the afternoon, 4-5 mg in the evening), in order to mimic the natural circadian 
secretion of cortisol [1]. However, even when patients with primary AI are in a stable 
medical condition, they report impaired quality of life (QoL) [2-6]. In addition, in patients 
with secondary AI due to pituitary disease, hypopituitarism was found to be an important 
predictor of QoL impairments [7-9]. It has been suggested that these QoL impairments 
are associated with intrinsic imperfections in glucocorticoid replacement therapy, 
and therefore, it is advised that hydrocortisone replacement should be individualized 
[10]. For instance, there is large individual variation in sensitivity to cortisol, which is 
partly explained by polymorphisms of the glucocorticoid receptor gene [11]. However, 
determining an optimal hydrocortisone replacement dose is complicated by the lack of 
reliable chronic parameters, and as a result many patients may be chronically under- or 
overtreated with potential paramount consequences for well-being and health.
Until now, it is not well established whether QoL is affected by the degree of cortisol 
exposure (i.e., adequacy of hydrocortisone replacement) in patients with AI. In a single 
study, authors investigated plasma cortisol day curves and well-being in a small sample 
of seven patients with AI and demonstrated that subphysiological cortisol levels cor-
related with lower well-being [12]. Other studies examined the relation between the 
dosage and intake scheme of glucocorticoid replacement therapy and QoL, and dem-
onstrated that in patients with AI, QoL was inversely correlated with the hydrocortisone 
dose [6, 13]. Importantly, associations between hydrocortisone intake and QoL do not 
provide any information about causality, since it might be that high cortisol levels cause 
QoL impairments, but it might also be that patients with worse QoL need more hydro-
cortisone.
Addressing this relationship is further complicated by the difficulty of adequately 
measuring cortisol levels throughout the day, since cortisol levels vary depending on 
different treatment regimens (i.e., varying hydrocortisone doses, as well as differences in 
timing, absorption, and metabolism of hydrocortisone), and currently available cortisol 
measurements (i.e., plasma, urinary, salivary) are limited to short-term assessments.
A promising method to assess cortisol for prolonged periods of time is the analysis of 
cortisol levels in scalp hair (CORThair) [14-15]. We (and others) recently assessed the use 
of this measure in AI patients treated with exogenous hydrocortisone. Patients with AI 
have increased levels and hydrocortisone intake has been found to correlate with COR-
Thair [16-17]. A significant gender effect has been reported in CORThair in patients with 
AI treated with glucocorticoid replacement therapy, with male patients demonstrating 
higher CORThair than females while using the same dose of hydrocortisone [16-17].
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In the present study, we aimed to explore whether CORThair is correlated with QoL. 
We first compared QoL in patients with stable treatment for AI with QoL in healthy 
controls. Second, we examined potential correlations between QoL, CORThair, and daily 
hydrocortisone intake as another parameter to assess cortisol exposure.
metHoDs anD ProceDures
Participants
Scalp hair samples were collected of 132 patients with primary or secondary AI on 
hydrocortisone replacement from the Endocrinology out-patient clinic of the Leiden 
University Medical Center (cohort previously described in [17]). Of this group, nine 
patients did not fill out QoL questionnaires and three patients filled out less than 75% 
of the questionnaires and were therefore excluded from the analysis. Thus, 120 patients 
with longstanding AI on a stable dose were included in the present study. Primary AI had 
been diagnosed by very low early morning cortisol concentrations (<120 nmol/l) or in-
sufficient stimulation following ACTH test (below 550 nmol/l) usually in the presence of 
positive adrenal auto-antibodies or an alternative explanation. Secondary adrenal insuf-
ficiency was preferably diagnosed using an insulin tolerance test, or if contra-indicated, 
a CRH test using the same cut-off as for ACTH stimulation. Pituitary hormone replace-
ment was prescribed dependent on the results of the annual evaluation of pituitary 
functions. In case of AI, hydrocortisone was prescribed (usually 20 mg per day divided 
into three dosages, adjusted at the discretion of the treating physicians) together with 
the advice to increase the hydrocortisone dose in case of exposure to severe somatic 
and psychological stressors. Comparison QoL data of 437 healthy controls were derived 
from a previous study from our department [18].
The local ethics committee approved this study. All patients gave written informed 
consent.
Qol assessment
QoL was assessed with the following four validated questionnaires:
The Short-Form 36 (SF-36) assesses functional status and general well-being and consists 
of 36 items covering nine health concepts: 1) physical functioning, 2) social functioning, 
3) role limitation (physical), 4) role limitation (emotional), 5) mental health, 6) vitality, 7) 
pain, 8) general health perception, and 9) general perception of change in health. Scores 
are expressed on a 0–100 scale, and higher scores indicate better QoL [19].
The EuroQoL-5D (EQ-5D) assesses the current health status reflected in five health 
dimensions; 1) mobility, 2) self-care, 3) usual activities, 4) pain/discomfort, and 5) anxi-
ety/depression. Scores are expressed on a 1-3 scale per dimension, with higher scores 
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indicating worse QoL. Also a visual analogue scale is included ranging from 0 to 100 for 
recording an individual’s rating for their current health-related well-being, with higher 
scores indicating a better health status [20].
The Hospital Anxiety and Depression Scale (HADS) assesses both anxiety and depres-
sive symptoms and consists of 14 items on a 4-point scale. Higher scores indicate more 
severe anxiety and depressive symptoms [21-22].
The Multidimensional Fatigue Inventory (MFI-20) consists of 20 statements assessing 
fatigue on a five-point scale covering five dimensions; 1) general fatigue, 2) physical 
fatigue, 3) reduced activity, 4) reduced motivation, and 5) mental fatigue. Scores vary 
from 0-20; with higher scores indicating greater fatigue [23].
Qol of healthy controls
QoL data of healthy controls were previously collected at our department [18]. The 
EuroQoL-5D and two subscales of the Short-Form 36 (i.e., mental health, vitality) were 
not assessed in this group of healthy controls. QoL data of 437 healthy controls (136 
males) with a mean age of 50.9 ± 13.6 years were available and the total group was used 
for comparison.
Hair collection, preparation, and analysis
A lock of approximately 150 hairs from the posterior vertex was cut as close to the scalp 
as possible. The hair samples were taped to paper and stored in the dark at room tem-
perature until further analysis. One cm represents the average cortisol concentrations 
of one month [15], since it is assumed that hair grows one cm per month, with a range 
of 0.6 – 1.4 cm/month [16]. Hair samples are specifically taken from the vertex region of 
the scalp because its most uniform growth pattern and phase [17-18], and importantly, 
has been specifically been validated for cortisol with the lowest mean coefficient of 
intra-individual variation [19]. For analyses, the most proximal 3 cm of hair was used, cor-
responding to the most recent 3 months. A minimum of 10 mg of hair was weighed and 
cut into small pieces. For extraction, 1 mL of methanol was added and the samples were 
incubated for 16h at 52⁰C. After extraction, the methanol was transferred to another 
vial and evaporated under a constant stream of nitrogen. The samples were dissolved 
in 250 μL of phosphate buffered saline (PBS, pH 8.0). A commercially available ELISA Kit 
for salivary cortisol (DRG GmbH, Marburg, Germany) was used to measure cortisol levels. 
The procedure has been described in detail elsewhere [14]. Our laboratory internal up-
per limit of normal is 52 pg/mg.
statistical analyses
Data were analyzed using PASW Statistics version 20.0 (SPSS Inc., Chicago, IL). CORThair 
were reported as median and interquartile ranges (IQR). Other data were presented as 
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Mean ± SD, unless mentioned otherwise. After logarithmic transformation, CORThair were 
normally distributed. The primary analysis comprised the comparison of QoL of patients 
with AI to healthy controls by using independent sample t-tests when data were nor-
mally distributed and Mann-Whitney U tests when data were not normally distributed. 
In order to evaluate whether the previously found gender effect in CORThair is reflected 
in QoL, this analysis was also performed after stratification for gender.
The secondary analysis comprised the assessment of the potential association be-
tween QoL, CORThair, and daily hydrocortisone intake. Partial correlations were calculated 
between QoL and CORThair and daily hydrocortisone intake, adjusted for age and gender. 
Subsequently, groups were stratified for gender and partial correlations were calculated 
between QoL and CORThair and daily hydrocortisone intake, adjusted for age. Regression 
analyses including linear and quadratic terms were used to examine possible u-shaped 
associations. Furthermore, regression analyses including both CORThair and daily hy-
drocortisone intake were used to differentiate between the contributions of these two 
factors. Because of the exploratory nature of these analyses, adjustment of the level of 
significance for multiple testing was not performed, and the level of significance was set 
at p < .05.
results
Patient characteristics
A total of 120 patients with longstanding AI (46 males) with a mean age of 55.0 ± 14.7 
years were included in the analyses. The duration of follow-up was on average 18.5 ± 
13.3 years, with a median of 15.8 years (IQR: 8.1-28.9). Patients used a mean daily dose of 
21.1 ± 4.5 mg. In the whole group of patients, 34% presented with CORThair above our lab-
internal cut-off for normal (52 pg/mg). Of the males, 59% demonstrated CORThair higher 
than the lab-internal cut-off, in contrast to 19% of the females (p < .001). As previously 
reported [17], also in the present study male patients demonstrated higher CORThair than 
female patients (75.3 (26.2 - 150.1) vs. 19.7 (11.6 - 38.5), p < .001). Furthermore, female 
patients dyed or bleached their hair more and used hair products more frequently than 
male patients (all p < .03) (Table 1).
Daily hydrocortisone intake and CORThair showed a significant, but modest correla-
tion (r = 0.185, p = .047). To evaluate whether there were differences in CORThair between 
different etiologies of AI, five groups were formed: 1) AI due to previous treatment for 
Cushing’s disease (n = 18), 2) other functioning pituitary adenomas (n = 14, including 
acromegaly (n = 5), prolactinoma (n = 8), and FSH producing adenoma (n = 1)), 3) non-
functioning pituitary adenoma+craniopharyngioma (n = 48, nonfunctioning pituitary 
adenoma (n = 35) and craniopharyngioma (n = 13)), 4) primary AI (n = 18), and 5) other 
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causes of hypopituitarism (n=22, including congenital hypopituitarism (n = 6), hypopitu-
itarism after radiotherapy/surgery/traumatic brain injury (n = 7), and other causes such 
as pituitary inflammation or Sheehan’s syndrome (n = 9)). CORThair was lowest in patients 
with CD, but group differences did not reach statistical significance (p = .126) (Figure 
1). The self-reported hydrocortisone dose was significantly different between groups (p 
= .003), with patients with primary AI using a higher dose (24.7 ± 4.5 mg) compared to 
patients with CD (20.0 ± 4.8), NFA+CP (20.9 ± 3.8) or other causes of hypopituitarism 
(19.2 ± 5.4).
Qol
Compared to healthy controls, patients with AI reported worse QoL on all subscales 
(except general health perception, SF-36) (p < .05) (Table 2). After stratifying for gender, 
male patients reported worse QoL on 12 of the 15 subscales (p < .05) and female pa-
tients reported worse QoL on 14 of the 15 subscales (p < .001) in comparison to controls 
(Table 2). Comparing QoL between the different etiology groups revealed significantly 
more depressive symptoms (HADS) in patients with CD (7.3 ± 4.0) relative to patients 
with NFA+CP (4.3 ± 3.5) (p = .022) (Figure 2). Furthermore, patients with CD reported 
more physical fatigue (14.7 ± 2.0), more reduced activity (12.9 ± 1.2) (MFI-20), and worse 
table 1. Clinical characteristics of AI patients (males vs. females)
Patients with AI
(n = 120)
Males with AI
(n = 46)
Females with AI 
(n = 74)
p value
Age (years) 55.0 ± 14.7 57.2 ± 14.8 53.6 ± 14.6 .167b
BMI (kg/m2) 28.0 ± 5.1 27.5 ± 3.5 28.3 ± 5.9 .799b
Duration of follow-up (years) 18.5 ± 13.3 18.2 ± 12.6 18.7 ± 13.8 .995b
Use of external glucocorticoids # 15 (13%) 5 (11%) 10 (14%) .702c
Hair cortisol levels 23.7 (14.0 – 84.7) 75.3 (26.2 – 150.1) 19.7 (11.6 - 38.5) <.001a
Hair cortisol above our lab-internal cut- 
   off (52 pg/mg)
41 (34%) 27 (59%) 14 (19%) <.001c
Daily hydrocortisone dose (mg) 21.1 ± 4.5 21.5 ± 5.1 20.8 ± 4.2 .334b
Daily hydrocortisone dose (mg/kg) 0.26 ± 0.07 0.2 ± 0.07 0.3 ± 0.07 .065b
Daily hydrocortisone dose (mg/BSA) 10.7 ± 2.4 10.3 ± 2.5 11.0 ± 2.3 .077b
Hair dyed 44 (37%) 0 (0%) 44 (60%) <.001c
Hair bleached 18 (15%) 0 (0%) 18 (24%) <.001c
Hair permed 3 (3%) 1 (2%) 2 (3%) .848c
Use of hair product 60 (50%) 17 (37%) 43 (58%) .024c
Frequency hair wash > 3 times/week 42 (35%) 21 (46%) 21 (28%) .061c
Data are presented as mean (standard deviation), and as n (valid percentage). a Independent samples t-test, b 
Mann-Whitney U-test, c Chi-square test. AI, adrenal insufficiency; BMI, body mass index; BSA, body surface area; 
#: use of other external glucocorticoids (in addition to their regular hydrocortisone substitution). p value: AI 
males vs. AI females.
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mental health (58.9 ± 20.2) (SF-36) compared to patients with PAI (11.7 ± 4.7; 10.7 ± 4.2; 
77.7 ± 18.2) (p = .004, p = .009, p = .044, respectively). Considering that only patients 
with CD differed from the other groups, QoL analyses were corrected for etiology of CD.
relations between corthair and Qol
As shown in Table 3, correlations between CORThair and QoL, adjusted for age, gender, 
and etiology CD revealed that in the whole group, higher CORThair correlated at trend 
level with more limitations in daily activities (EQ-5D) (r = 0.180, p = .059). After stratifica-
tion for gender, it was observed that in male patients higher CORThair was associated 
with more physical fatigue (r = .355, p = .018). In female patients higher CORThair was 
associated with more limitations in daily activities (r = 0.239, p = .046) and more pain (r 
= 0.269, p = .024) (EQ-5D).
In the whole group, QoL of patients with CORThair above the lab-internal cut-off for 
normal was not different from patients with CORThair in the normal range (p > .05). How-
ever, female patients with CORThair levels above the lab-internal cut-off (n = 14 (19%)) 
reported lower physical functioning (52.9 ± 28.7, p = .025) and more pain on the SF-36 
(52.8 ± 29.7, p = .033), as well as on the EQ-5D (2.2 ± 0.8, p = .049) relative to females with 
CORThair within the normal range. No differences in QoL were found between male pa-
tients with CORThair above the lab-internal cut-off (n = 27 (59%)), and male patients with 
CORThair within the normal range (p > .05). Regression analyses including age, gender, 
and etiology CD, as well as CORThair as a quadratic term did not render significant results.
figure 1. Comparison of CORThair between patient groups. Mean hair cortisol levels (CORThair) +/- standard error 
to the mean, stratified per patient category as follows: 1. CD: Cushing’s disease (n = 18); 2. FA: other functioning 
pituitary adenomas (n = 14, including acromegaly (n = 5), prolactinoma (n = 8), FSH producing adenoma (n = 
1)); 3. NFA+CP: non-functioning pituitary adenomas (n = 48, including craniopharyngeoma (n = 13) and NFA 
(n = 35)); 4. PAI: primary adrenal insufficiency (n = 18); 5. Other: other causes of hypopituitarism (n = 22, includ-
ing congenital hypopituitarism (n = 6), hypopituitarism after radiotherapy/surgery/traumatic brain injury (n=7), 
other causes such as pituitary inflammation or Sheehan’s syndrome (n = 9)). The figure shows a difference in 
CORThair between patients with AI due to previous treatment for CD and the other groups, but this difference was 
not found to be statistically significant (p = .126).
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relationships between daily hydrocortisone intake and Qol
Correlations between hydrocortisone intake and QoL, adjusted for age, gender, and 
etiology CD, revealed that in the whole group, higher hydrocortisone intake was associ-
ated with more impairments in physical functioning (r = -0.208, p = .027), less vitality (r 
= -0.251, p = .007), a greater decrease in perceived health (change in health) (r = -0.317, 
p = .001) (SF-36), more limitations in daily activities (r = 0.206, p = .032), and a worse 
perceived health status (r = -0.297, p = .002) (EQ-5D). After stratifi cation for gender, it 
was observed that higher hydrocortisone intake was associated with a worse perceived 
health status in male patients (r = -0.319, p = .048). In female patients, higher hydro-
cortisone intake was associated with less vitality (r = -0.334, p = .005), a greater change 
in health (r = -0.349, p = .003) (SF-36), more limitations in daily activities (r = 0.264, p 
= .028), and a worse perceived health status (r = -0.307, p = .012) (EQ-5D). Regression 
analyses including age, gender, and etiology CD, as well as daily hydrocortisone dose 
as a quadratic term revealed a signifi cant quadratic contribution of hydrocortisone 
dose to depressive symptoms (HADS) (β = 1.150, p = .019), mental fatigue (MFI-20) (β 
= -1.079, p = .033), physical functioning (β = -0.946, p = .046), social functioning (β = 
-1.232, p = .012), change in health (SF-36) (β = -1.031, p = .039), pain (β = 1.413, p = .004) 
and perceived health status (EQ-5D) (β = -1.022, p = .036), indicating that relatively low, 
as well as relatively high hydrocortisone intake was associated with more depressive 
symptoms, more limitations in physical functioning and social functioning, more pain, 
and lower perceived health, but less mental fatigue.
figure 2. Comparison of depressive symptoms (HADS) between patient groups. Depressive and Anxiety symp-
toms as measured by the Hospital Anxiety and Depression Scale (HADS), stratifi ed by the following patient cat-
egories: 1. CD: Cushing’s disease (n = 18); 2. FA: functioning pituitary adenomas (n = 14, including acromegaly 
(n = 5), prolactinoma (n = 8), FSH producing adenoma (n = 1)); 3. NFA+CP: non-functioning pituitary adenomas 
(n = 48, including craniopharyngeoma (n = 13) and NFA (n = 35)); 4. PAI: primary adrenal insuffi  ciency (n = 18) 
5. Other: other causes of hypopituitarism (n = 22, including congenital hypopituitarism (n = 6), hypopituitarism 
after radiotherapy/surgery/traumatic brain injury (n=7), other causes such as pituitary infl ammation or Shee-
han’s syndrome (n = 9)).
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regression analysis including corthair and hydrocortisone intake
Regression analysis including both CORThair and daily hydrocortisone dose, as well as 
age, gender, and etiology CD, revealed a significant contribution of daily hydrocortisone 
dose to physical functioning (β = -0.182, p = .046) change in health (SF-36) (β = -0.254, 
p = .008), limitations in physical activities (β = 0.204, p = .034) perceived health status 
(EQ-5D) (β = -0.277, p = .004). No significant contribution of CORThair was found in this 
by using this regression model. Post-hoc analyses on these significant results using 
the same regression analyses, but without CORThair, resulted in slightly increased beta’s 
(increases ranging from .008 to .022), indicating that part of the variation of CORThair was 
explained by hydrocortisone intake, which is not surprising considering the association 
between daily hydrocortisone intake and CORThair (r = 0.185, p = .047).
Discussion
The present exploratory study confirmed that patients with AI report more impairments 
in QoL compared to healthy controls [2-4, 6], which is dependent on the cause of AI 
and demonstrated that daily hydrocortisone intake was inversely correlated with QoL 
(physical aspects). This is in accordance with some [6, 13, 28], but not all studies [2-3, 
29]. Interestingly, this association was not found with systemic cortisol exposure, since 
only a few aspects of QoL were associated with CORThair, suggesting that QoL impair-
ments are not per se due to chronic overtreatment with hydrocortisone. Nevertheless, 
CORThair did explain a part of the variation of the observed associations between daily 
hydrocortisone intake and QoL, indicating that the actual cumulative cortisol exposure 
should also be taken into account.
table 3. Correlations between QoL, CORThair and hydrocortisone dose
Patients with AIa Males with AIb Females with AIb
CORThair HC dose CORThair HC dose CORThair HC dose
SF-36 Physical functioning -.097 -.208* -.019 -.200 -.122 -.164
Vitality -.068 -.251** .067 -.085 -.164 -.334***
Change in health .015 -.317*** .011 -.258 .031 -.349***
MFI-20 Physical fatigue .120 .136 .335* .203 -.028 .066
EQ-5D Activity .180 .206* .016 .153 .239* .264*
Pain .131 .134 -.054 .013 .269* .215
VAS -.071 -.297*** .171 -.319* -.164 -.307*
a partial correlations correcting for age and gender; b partial correlations correcting for age. *p < .05; **p < .01; 
***p < .005. AI: adrenal insufficiency. CORThair (pg/mg); hydrocortisone dose (mg). Only significant correlations 
are shown.
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Previous QoL studies in patients with AI identified several influencing factors, such 
as autoimmune co-morbidity [300], delay of diagnosis [30], higher age at manifesta-
tion, and female gender [30]. Furthermore, it is suggested that intrinsic imperfections 
in replacement therapy also play a role [10]. The present study is the first to examine 
the relation between actual chronic cortisol tissue exposure and QoL in patients with 
AI as measured by CORThair. Based on this first explorative study it seems that associa-
tions between hydrocortisone intake and QoL are not (directly) influenced by cortisol 
exposure. This suggests that QoL impairments in patients with AI are not per se related 
to higher cortisol exposure, but it might be more obvious that the relation between 
hydrocortisone intake and QoL is (at least partly) explained by that patients who take 
more hydrocortisone basically need more hydrocortisone. Furthermore, assessing the 
potential effect of occasionally taking higher hydrocortisone doses did not reveal a 
significant effect (data not shown).
Cortisol acts in the central nervous system by binding to mineralocorticoid- and 
glucocorticoid receptors. The current notion is that the effects of cortisol binding to 
mineralocorticoid and glucocorticoid receptors follow an inverted u-shaped dose 
response curve, with both pathological low and high cortisol levels negatively affect-
ing the mediating function of these receptors [31]. This mechanism might underlie the 
observed impairments in QoL in female patients with CORThair above the lab-internal 
cut-off. Since there is no explicit lower limit of CORThair, there is no evidence that under-
replacement negatively affects QoL. Interestingly, this inverted u-shaped dose response 
curve was identified in the quadratic associations found between hydrocortisone intake 
and physical, mental and social aspects of QoL.
Despite the heterogeneous origin of AI in this cross-sectional analysis, we found that 
CORThair correlated with two physical aspects of QoL (physical activities and pain) in 
female patients, and one physical aspect in male patients (physical fatigue). In addition, 
female patients with CORThair above the lab-internal cut-off reported more impairment 
in QoL relative to females with CORThair below the lab-internal cut-off. This difference 
was not found for male patients. The found gender difference in CORThair in the pres-
ent sample with males demonstrating higher CORThair than females, was previously 
described [21] and may be due to, among other factors, sex-specific differences in levels 
of circulating cortisol binding globulin. Therefore, analyses of the present study were 
stratified for gender. Furthermore, in male patients higher CORThair was associated with 
higher BMI [21], suggesting a metabolic effect of overexposure. Recently, Quinkler et 
al. demonstrated in patients with AI using conventional hydrocortisone replacement 
that switching to once-daily hydrocortisone dual release tablets did not ameliorate 
QoL, although BMI and HbA1c improved [32]. Together with the results of the present 
study, this would suggest that more adequate cortisol exposure predominantly affect 
somatic outcome, and to a lesser extent patient-perceived well-being, in particular in 
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males. Furthermore, it was observed that patients with CD showed lower CORThair rela-
tive to the other groups (although not significant). We postulate that this observation is 
also related to the gender effect since ninety-four percent of the patients with CD were 
females, and comparing CORThair between female patients with CD and other female pa-
tients revealed no significant results (data not shown). Furthermore, it can be speculated 
that low CORThair found in patients with CD might be explained by irreversible changes 
in cortisol metabolism (e.g. more efficient breakdown of cortisol) related to the previous 
exposure to elevated cortisol levels.
In addition, the observation that patients AI due to previous treatment for CD reported 
more QoL impairments compared to the other diagnostic groups, while also having the 
lowest CORThair (not significant), could potentially be explained by the fact that these 
patients have been exposed to excessive cortisol levels in the past. Previous literature 
reported that potential damage caused by this excessive exposure to cortisol might only 
be party reversible [7, 9]. Therefore, it might be that QoL impairments in the CD group 
are to a larger extent explained by the previous hypercortisolism, than due to current 
cortisol levels as measured by CORThair.
As previous studies show, the assessment of CORThair is a useful tool in the diagnosis of 
Cushing’s syndrome or AI [20, 33] or as indicator of somatic disease and distress [34-36]. 
Furthermore, the assessment of CORThair in the present study enabled us to discriminate 
between cause and consequences, since impairments in QoL were associated with a 
higher hydrocortisone intake, but were not reflected by higher CORThair. Several small 
studies on the relation between CORThair and depressive symptoms, anxiety or general 
well-being in subjects without AI have been published, however at present no other 
study primarily focused to this extent on QoL in relation to CORThair in AI [34, 37-39]. 
Younge and colleagues assessed CORThair, as well as QoL and psychological parameters 
(i.e., SF-36, HADS) in patients with structural heart disease. They demonstrated that 
higher CORThair was correlated with lower self-reported physical functioning, which re-
mained significant after adjustment for age, gender and BMI. No significant correlations 
were found on other aspects [40]. Similarly, in the present study, physical aspects of QoL 
were associated with QoL, while no correlations were found with other aspects of QoL.
In the present study, CORThair and some physical aspects of QoL were associated with 
each other in a heterogeneous group of patients with AI. It is important to acknowledge 
that we studied correlations within a group of patients with AI with impairments in QoL 
[2-6]. This group is potentially yielding a relatively small variation of QoL, thereby imped-
ing finding associations between CORThair and QoL. Other aspects that should be taken 
into account while interpreting the results are the multidimensional character of QoL 
[41], and the possibility that the used generic and domain-specific QoL questionnaires 
might have been not sensitive enough. Although a disease-specific QoL questionnaire 
for primary adrenal insufficiency (i.e., AddiQoL [42-43]) could have been more sensitive 
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and suitable, it was not used because it has not yet been translated and validated into 
the Dutch language. In addition, it should be acknowledged that although the present 
sample was heterogeneous regarding etiology of AI and that both patients with primary 
and secondary AI were included, it provides a representative sample of everyday clinical 
practice. Finally, no conclusions can be drawn about causality due to the cross-sectional 
design of this study. Future studies using a longitudinal design could provide more 
information about the time course of QoL impairments, as well as the contribution of 
CORThair.
In conclusion, this is the first report that further explored the relation between QoL, 
hydrocortisone intake and actual cortisol exposure in AI patients by measuring hair cor-
tisol, a marker of long-term systemic cortisol exposure. Patients with AI demonstrated 
several impairments in QoL which were sex-specifically associated with hydrocortisone 
intake, but were to a lesser extent reflected by chronic cortisol exposure as measured by 
hair cortisol, suggesting that QoL impairments in patients with AI are not explained by 
the effect of prolonged exposure to elevated systemic cortisol levels.
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8 rationale
This thesis contains five studies on the relationship between long-term cortisol (and 
cortisone) as measured in scalp hair – as indicator of the chronic activity of the hypothal-
amus-pituitary-adrenal (HPA) axis – and various factors of stress-related diseases and 
disorders. The research described can be divided into two main areas, i.e. long-term cor-
tisol and cortisone in psychology and psychiatry, and long-term cortisol and cortisone 
in somatic medicine.
In this general discussion, implications of the main findings will be reviewed, method-
ological considerations will be discussed, and suggestions for future research directions 
will be provided.
8.1 implications of main findings
8.1.1  Sociodemographic, Health and Lifestyle, Hair (Treatment) Characteristics, and Long-
Term Corticosteroid Levels
Already in the first publication that used hair as a measurement of long-term corticoste-
roids in 2004 [1], the question arose which factors - other than the variable of interest - 
could influence long-term corticosteroid levels. In subsequent publications, researchers 
investigated associations between their variable of interest and diverse hypothetical co-
variates and confounders. Disentangling the effects of covariates seemed of paramount 
importance to enable studies to adjust their analyses for potential confounders. This was 
the focus of our study described in chapter 2. For this study, we used data from 760 re-
spondents participating in the research cohort of the Netherlands Study of Depression 
and Anxiety (NESDA), an ongoing longitudinal cohort study on the predictors, course 
and consequences of depressive and anxiety disorders. The analysis indicated that both 
long-term cortisol and long-term cortisone levels showed robust linear increases with 
age. Age has often been associated with long-term cortisol [2-4] in earlier research. 
However, studies that found curvilinear [4] or linear [2, 3] effects comprised a wider age 
range, and may therefore be more suitable to detect endocrine changes related to age. 
Thus, our study and others indicate that age is a strong predictor of hair corticosteroids 
and needs to be included as possible covariate in studies that use participants with a 
range of age. Reasons why higher age coincides with higher cortisol levels are manifold. 
A higher production could be due to more ‘triggers’ of the HPA axis due to psychological 
stress [5], to more inflammation [6] and/or more metabolic and cardiovascular diseases 
[7]; factors that are biologically associated with higher cortisol levels.
Lower long-term cortisol and long-term cortisone levels were found in subjects who 
wash their hair more frequently. This effect has also been reported earlier in other re-
search [8]. Frequent washing of the hair might damage the hair structure and thereby 
lead to an increased wash-out of cortisol. This reasoning is consistent with the often 
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replicated result that cortisol content decreases the more distal the hair segment is from 
the scalp [4, 9, 10]. Other studies have reported no effect of hair washing frequency on 
long-term cortisol levels [10, 11]. It is undetermined yet how clinically relevant this factor 
is as relationships between biological parameters and long-term cortisol levels are also 
apparent when not accounting for the hair washing frequency; however, accounting for 
this effect in group comparisons is advised.
We further found that elevated long-term cortisol levels were related to the presence 
of diabetes mellitus. This result is consistent with other research on this topic [2, 3, 12]. 
The association was to be expected and is biologically sound, as already in subclini-
cal Cushing’s Syndrome, characterized by elevated cortisol levels, a high prevalence of 
diabetes mellitus is noted [13, 14]. Taken together, these results suggest that higher 
long-term cortisol levels are associated with long-term increased glucose levels and 
presence of diabetes mellitus across different age spans.
Furthermore, in our study, hair samples representing the winter months showed lower 
long-term cortisol. A seasonal effect on long-term cortisol has also been reported by an-
other group, in which participants had higher long-term cortisol in summer and autumn 
as opposed to winter [15]. As mentioned in the Introduction (Chapter 1), seasonal effects 
on the HPA axis have been reported before [16], however, the mechanisms behind that 
mechanisms are not well understood [17]. Apart from that regulatory mechanism, an-
other explanation for the seasonal effect observed in our study may be that participants 
tend to sweat more in warmer months and there may be an effect of cortisol in sweat on 
the hair in the proximity of the scalp. However, results of a study in which the influence 
of sweating on long-term cortisol levels was examined show no effect of sweating [18], 
therefore rendering this explanation unlikely. Other explanations have yet to be found.
Weaker effects were found for sex. Men showed higher long-term cortisol and long-
term cortisone levels than women, which is in line with previous studies [2, 4, 12] but 
at variance with others [1, 11]. However, the sex effect was not independent of other 
covariates. Higher waist circumference was associated with increased long-term cortisol 
levels, which concurs with most studies that investigated this association [3, 11]. The 
correlation between waist circumference, or better, visceral fat, and long-term cortisol is 
well supported by literature [see 19, for review]. A darker natural hair colour was associ-
ated with higher long-term cortisol. Other studies also observed this trend [4].
Our study was the first to report a positive effect of oral contraceptives on long-term 
cortisol. These are surprising results, since long-term cortisol levels are generally con-
sidered to reflect the free fraction of cortisol which should not be influenced by use 
of oral contraceptives [4]. Other studies examining the association between long-term 
cortisol levels and the use of oral contraceptives did not report significant results [4, 20, 
21]. As we had no information on the type of oral contraceptives (i.e., which hormone 
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combination), we could not further unravel whether this effect was caused by a specific 
hormone combination.
Long-term cortisone seems to be influenced by factors quite consistent with influenc-
es of long-term cortisol, namely age and hair washing frequency, and weaker with sex, 
waist circumference, presence of diabetes mellitus, and natural hair colour. In contrast 
to long-term cortisol, long-term cortisone levels were additionally affected by smoking 
status, hair treatment, and use of hair styling products. Current smokers had higher 
long-term cortisone, independent of their average number of cigarettes. Hair treatment, 
i.e. bleaching of the hair, was associated with lower long-term cortisone. Furthermore, 
the use of hair styling products also influenced HairE. As the hair samples were washed 
before extraction and analysis, it seems unlikely that the actual product used on the day 
of sample collection caused this effect; however, repeated cosmetic treatment could 
affect and lower hormone concentrations, as has been suggested before [1].
Based on our results, age, sex, waist circumference, diabetes mellitus, depending on 
the hormone in question also use of oral contraceptives, season and smoking status 
have been confirmed and identified as potential influencing factors, while hair washing 
frequency, natural hair colour, hair treatment, and use of hair styling products have been 
confirmed and identified as potential confounding factors and should be considered in 
future research when examining long-term corticosteroid levels.
8.1.2 Long-Term Corticosteroids in Mental Health Aspects
We then studied the associations between long-term corticosteroids and psychopatho-
logical characteristics. We found that participants with a current comorbid depressive 
and anxiety disorder presented with higher long-term cortisol, while long-term cortisol 
was not different in patients with a remitted disorder or with a current single diagnosis 
(chapter 3). For this study, we again used the NESDA cohort, including this time 1166 
participants. Additional analyses revealed that the severity of current symptoms was 
associated with higher long-term cortisol levels. Long-term cortisone was associated 
with the presence of social phobia, but not with other current or remitted diagnoses. 
The interesting fact that the significant results were found in participants with a current 
diagnosis, whereas remitted persons did not show altered long-term corticosteroid 
levels, poses a possible answer to the question whether a dysregulated HPA axis in 
mentally ill patients is a state or trait phenomenon. A stronger association with active 
cortisol rather than inactivated cortisol, as found in our study, may also support the 
concept that the alterations in long-term cortisol associated with psychopathological 
characteristics are a state (reflected by long-term cortisol) rather than a trait (reflected 
by long-term cortisone). This would imply that during the episode of a disorder, the 
HPA axis is dysregulated, but that the cortisol levels return to normal once the patient 
remits. This is also supported by the findings that remitted patients showed long-term 
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corticosteroid levels comparable to healthy controls. The state vs trait phenomenon has 
also been examined using salivary cortisol levels with somewhat different results. For 
example, the cortisol awakening curve (CAR) has been shown to be increased in patients 
with a current as well as a remitted major depressive disorder [22] and a current as well 
as remitted panic disorder with agoraphobia [23] as compared to control subjects, 
which does support the notion of a trait rather than a state marker [22], and which was 
hypothesized to reflect either a specific biological vulnerability or a biological scar [24]. 
As the assessments of salivary cortisol and long-term cortisol capture different aspects 
of HPA axis functioning, the integration of both methods will likely further the quest for 
an answer regarding state or trait factors of HPA axis dysregulation in psychopathology.
In a different group of patients with a mental illness, i.e. bipolar disorder, we showed 
an association between long-term cortisol and the number of negative life events 
(chapter 4). For this study, we included 71 patients from The Bipolar Stress Study, a 
cross-sectional and 24 month longitudinal study that aims on identifying risk factors 
that have an impact on the clinical course of bipolar disorder and treatment of patients 
with bipolar disorder. The effect of elevated long-term cortisol levels after life events 
is consistent with studies in other populations [25, 26]. Negative life events might ag-
gravate rumination that may exacerbate the already adverse experience [27], thereby 
potentiating the effect of life events. It has previously been reported that bipolar pa-
tients show normal initial cortisol responses to stressful life events, but that they have 
more difficulty in terminating the stress response. It is essential that an individual is able 
to terminate the cortisol response appropriately to prevent hypercortisolemic effects 
[28], as a failure to do so would reflect in higher mean cortisol levels over a prolonged 
period of time. This would contribute to higher long-term cortisol levels. Interestingly, 
social support showed an inverse association with long-term cortisol in patients report-
ing negative life events. This indicates that social support may attenuate the adverse 
effects of negative life events. As the “social zeitgeber theory” has proposed that life 
events might induce a new mood episode through disruptions in social and biological 
rhythms [29], increased social support during a difficult time may stabilize social rhythm, 
sleep pattern, and thereby also the biological rhythm.
8.1.2.1 Long-Term Corticosteroids in Mental Health Aspects: Conclusion
To conclude, the research in this thesis conducted on the association between long-term 
cortisol and psychiatric aspects show that long-term cortisol is higher in patients with 
severe symptoms of depression and anxiety, and in patients with major negative events. 
This is in line with the idea that chronic stress as measured in hair cortisol shows a more 
pronounced effect, whereas the altered HPA axis activity in mental illness is more subtle. 
The chronic dysregulation of the HPA axis might therefore begin in the transition of the 
stress reaction to the (unsuccessful) recovery. Alternatively, the dysregulation might 
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prevent an appropriate stress reaction. These and other hypotheses have to be explored 
in quest of the starting point of mental illness. Until this issue is resolved, the combina-
tion of long-term cortisol levels and short-term cortisol levels may provide the most 
thorough information on HPA axis activity and dynamics. Consensus between those 
kinds of measurements is neither desired nor required to add up to a more complete 
understanding of the role of cortisol concentrations in the stress system. If anything, 
integrating both methods to display both baseline activity and stress reactivity of the 
HPA axis seems the most promising approach to understand the neurobiological com-
ponents of development and remission of (mental) illnesses.
8.1.3 Long-Term Corticosteroids in Somatic Health Aspects
In addition to psychopathophysiology, we also studied associations between long-term 
cortisol and somatic factors. Herefore, we recruited 47 obese patients from the Obesity 
Center CGG of the Erasmus Medical Center, a multidisciplinary referral center for diag-
nostic testing and tailored treatment of obesity. We compared their data to that of 41 
overweight and 87 normal weight controls. One of the results is that obese participants 
had higher long-term cortisol levels than overweight and normal weight participants, 
while between overweight and normal weight participants, no difference n long-term 
cortisol was detected (chapter 5). Our results are in line with other studies that reported 
a positive correlation between HCC and BMI [3, 30]. Results on an association between 
long-term cortisol and increased (central) adiposity/obesity have also been reported 
before [11, 12]. Interestingly, long-term cortisol was similar between normal weight and 
overweight participants. BMI does not discriminate between muscle and fat mass, and 
although it is to assume that our obese group (with a median BMI of 38.8) has a higher 
fat mass than non-obese controls, this might not apply for overweight individuals. This 
may also explain null results of correlations between BMI and long-term cortisol in stud-
ies comprising participants with normal to overweight BMI [e.g. 11]. A reason as to why 
the obese individuals have higher long-term cortisol levels may be due to metabolic 
processes in the liver. The liver is the major site of cortisol clearance. Obesity (and corti-
sol excess) is known to be associated with non-alcoholic fatty liver disease (NAFLD) [31], 
which first manifests with liver steatosis and gradually progresses to steato-hepatitis. 
The activity of hepatic enzymes responsible for cortisol clearance and regeneration 
has been shown to be decreased and increased, respectively, in patients with steato-
hepatitis [32]. It therefore could be speculated that the hypercortisolism we observed 
in obese patients is due to liver steato-hepatitis yielding dysfunction of liver enzymes.
Two of our studies focussed on patients with adrenal insufficiency, conducted in 
patients from the outpatient clinic of the department of Endocrinology of the Leiden 
University Medical Center. In the first study, we compared long-term cortisol levels of 
132 patients with primary or secondary adrenal insufficiency on replacement therapy 
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with those of 42 patient controls (with a pituitary disease without adrenal insufficiency) 
and of 195 healthy controls, and demonstrated that long-term cortisol levels were 
higher in patients with primary or secondary adrenal insufficiency on replacement 
therapy than in patient controls and healthy controls (chapter 6). This result is in line 
with all other studies on this association [33-35]. On the one hand, this finding might 
imply a possible chronic overtreatment with hydrocortisone. On the other hand, the 
intake of hydrocortisone medication is associated with peaks of cortisol shortly after 
ingestion, and it may be that the peaks are integrated into the hair, thereby increased 
the long-term cortisol levels measured in hair. We also showed that the hydrocortisone 
dose correlated with long-term cortisol. This result is in line with one other study with a 
comparable patient group [33], supporting the assumption that long-term cortisol lev-
els reflect hydrocortisone intake. Additional analyses revealed that male patients with 
adrenal insufficiency had higher long-term cortisol levels than female patients, an effect 
that was not observed in the other study on this patient group [33]. Furthermore, we 
showed that patients with adrenal insufficiency had higher body mass index (BMI) than 
healthy controls. In male, but not in female patients with adrenal insufficiency, higher 
long-term cortisol levels were associated with higher BMI. The association between 
long-term cortisol and BMI could also suggest a mild overtreatment that may lead to 
adverse anthropomorphic side effects, especially in males. The results further indicate 
that long-term cortisol in combination with clinical symptoms of hydrocortisone over-
treatment may be used to first identify overtreatment with hydrocortisone and then to 
improve refinement of individualized hydrocortisone substitution therapy in patients 
with adrenal insufficiency. In this study, we also assessed whether the increased stress of 
being chronically ill might influence long-term cortisol levels and might result in need 
of dose adjustment (as some patients with adrenal insufficiency known to occasion-
ally increase their hydrocortisone doses in situations of increased psychological stress 
[36], which might result in higher long-term cortisol). In population studies, long-term 
cortisol has been associated with perceived stress [37-39], but if this was the case in the 
present study, the increased stress of being a patient should then also be present in our 
patient control group. However, long-term cortisol levels between patient controls and 
healthy controls were comparable. Besides the demonstrated association between long-
term cortisol and anthropometrics, a considerable amount of studies demonstrated 
the association between high long-term cortisol and psychological symptoms [38]. We 
therefore examined the association between long-term cortisol, hydrocortisone intake, 
and quality of life (QoL) in 120 patients with stable adrenal insufficiency (chapter 7). 
We confirmed that patients with adrenal insufficiency report more impairments in QoL 
compared to healthy controls [40-43], which is dependent on the cause of adrenal insuf-
ficiency. Patients reported impairments in 14 of 15 QoL subscales. We demonstrated 
that daily hydrocortisone intake was inversely correlated with physical aspects of QoL. 
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This is in accordance with some [43-45] but not all studies [40, 41, 46]. Interestingly, this 
association was to a lesser extent found with systemic cortisol exposure, since only a few 
aspects of QoL were associated with long-term cortisol. Nevertheless, long-term cortisol 
did explain a part of the variation of the observed associations between daily hydrocorti-
sone intake and QoL, indicating that the actual cumulative cortisol exposure should also 
be taken into account. The correlation of more impairment in physical aspects of QoL 
and higher daily hydrocortisone intake was more pronounced in female patients. These 
results show that patients with adrenal insufficiency report several impairments in QoL 
which are sex-specifically associated with hydrocortisone intake, and to a lesser extent 
reflected by chronic systemic cortisol exposure as measured by long-term cortisol. This 
suggests that QoL impairments in patients with adrenal insufficiency are not per se due 
to chronic overtreatment with hydrocortisone.
8.1.3.1 Long-Term Corticosteroids in Somatic Health Aspects: Conclusion
To conclude, the associations between long-term cortisol and somatic aspects show that 
also in weight and BMI, long-term cortisol is higher in the more severe forms than in the 
normal range. In patients with adrenal insufficiency, long-term cortisol correlates with 
the dose of hydrocortisone and in males also with higher BMI. Hair cortisol analysis may 
provide a new method for identifying chronic hydrocortisone overtreatment in patients 
with adrenal insufficiency, which may improve current glucocorticoid replacement qual-
ity and limit the health effects of previously unobserved overtreatment.
8.2 technical aspects and considerations
The use of scalp hair as a method to study long-term cortisol levels has received increas-
ing attention from several research groups around the world. Until 2012, when work 
on this thesis began, according to PubMed, 24 original articles had been published 
on “hair cortisol” in humans. Four years later, the number of articles had increased to 
over 100. However, with the growing interest and more research groups working in this 
area, the methods used in long-term corticosteroid analyses increased, as well. Overall, 
the methods used are very comparable, with some variations in procedures among 
laboratories. As mentioned in Chapter 1, enzyme-linked immunosorbent assay (ELISA), 
luminescence immunoassay (LIA), radioimmunoassay (RIA), or liquid chromatograph–
mass spectrometry (LC–MS/MS) have all been used for cortisol quantification [10, 11, 
47-50]. In the beginning, immunoassays were the most popular, as they are technically 
straightforward and easy to implement. However, immunoassays come with drawbacks 
such as cross-reactivity and the limitation to single component measurement per assay. 
More advanced methods, based on mass spectrometry, have been long available, but 
were costly and unsuited for high-throughput routine laboratory measurements. Dur-
ing the last years, however, mass spectrometry has overcome these limitations and has 
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become the preferred method for steroid analysis in high-quality clinical research due 
to its superior specificity and sensitivity.
With the growing interest in long-term cortisol analyses, comparability and standard-
ization of methods between laboratories seemed paramount, as there can be significant 
interassay variability among commercially available immunoassays, not to mention the 
extraction protocols in the laboratories themselves. This need was acknowledged by 
several laboratories, who subsequently worked together to examine interlaboratory 
differences. Four different laboratories divided hair samples of the same persons and 
animals and analyzed them using their different methods, comparing four immunoas-
say methods and two LC–MS/MS methods. The results showed that when all laboratories 
analyze a common batch of hair, each laboratory’s immunoassay long-term cortisol 
levels were highly positive correlated with the results of their LC–MS/MS methods 
(with r²-values ranging between .88 and .98) [51]. The absolute values of the long-term 
cortisol determined by each group differed for the immunoassays, however, the correla-
tions between the different assays were rather strong. In addition, long-term cortisol 
determined by the two LC–MS/MS methods produced virtually identical results (r2 = 
0.98). Therefore, the development of the LC–MS/MS method and the ongoing transition 
in different laboratories from immunoassays to LC–MS/MS allows for the better com-
parability between studies. Furthermore, the high sensitivity and the addition of other 
adrenal and sex steroids broaden the scope of clinical use of hair analysis to a variety of 
psychopathological and somatic diseases.
Despite the many developments regarding the method of long-term corticosteroid 
analysis in hair, there are still open questions and limitations. One uncertainty is the 
way in which cortisol is incorporated in the hair shaft, and where this happens. This 
is important as this will provide information about possible external factors that can 
influence the concentration of long-term corticosteroids. The hair shaft consists of three 
parts; the medulla, the cortex, and the cuticle. At present, it is assumed that incorpora-
tion happens via diffusion from the capillary system directly into the hair root. Other 
possible incorporation mechanisms are the incorporation via sebum or sweat, however, 
an in vivo examination revealed that long-term cortisol levels were not acutely altered 
by interventions that induced significant sweating, and that long-term cortisol levels 
were unrelated to sweat cortisol levels or to individuals’ sweating rate [52], rendering 
this possibility unlikely.
Another issue of importance in long-term cortisol research is the hair growth rate, 
especially when creating timelines. Generally, it is assumed that hair grows one centi-
metre per month, with a range of 0.6 – 1.4 cm/month [53, 54]. It has been shown that 
hair growth rate differs between ethnicities. Asian hair is reported to grow the fastest 
(~ .48 mm/day, therefore 1.44 cm/month), whereas African hair is reported to grow the 
slowest (~ .26 mm/day, therefore .78 cm/month), and Caucasian hair to lie in between 
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(~ 40 mm/day, therefore 1.2 cm/month) [55, 56]. As intraindividual long-term cortisol 
levels are relatively stable over months to years [57], a different growth rate should not 
influence the results when assessing one value (of e.g. three months, i.e. three cm) as 
general indicator of the long-term cortisol value. However, it does matter when creat-
ing hair timelines and should therefore be considered in the analysis. One limitation 
of long-term cortisol levels is obvious when it comes to persons who are bald or suffer 
from substantial hair loss at the scalp. These individuals cannot be included in studies 
on long-term cortisol. Hair loss can be associated with psychological stress [58, 59], with 
hormonal imbalances [60], and with psychiatric disorders such as anorexia nervosa [61] 
or trichotillomania. Only if hair loss is that substantial that no hair is available at the 
posterior vertex of the scalp, short-term cortisol level assessment remains the main 
method to investigate cortisol values.
Regarding the other cortisol assessments available, a short overview has already been 
given in the Introduction (Chapter 1).
Short-term measurements offer information on cortisol levels in a time range of sec-
onds up to one day. One technique is the point-measurement, in which cortisol levels at 
one or more specific time points are measured in saliva or serum. This provides informa-
tion on acutely circulating cortisol levels and requires minimal effort, however, they are 
highly fluctuating during the day. Short-term measurements also offer the possibility to 
assess cortisol day curves, in which several samples of saliva or serum are taken during 
the day. This method provides information about the circadian rhythm and mean cor-
tisol levels during the day. Disadvantages for the participant include intense sampling, 
in case of serum sampling also invasive sampling that requires admission. The CAR, part 
of the day curve, is assessed by collecting samples of serum or saliva in the first hour 
after awakening and informs about basal activity as well as the response to awakening. 
While it is not as intensive as a day curve assessment, it is highly dependent on the 
time of awakening. In case of saliva sampling, the compliance of patients is crucial, in 
case of serum sampling, again an admission is required. Urinary free cortisol requires the 
sampling of 24 hours of urine. It reflects the total cortisol production in one day and is 
non-invasive; however, it also depends on participants’ compliance and is cumbersome 
for the participant. A further rather new method is the assessment of cortisol from finger 
nails [62]. Fingernail cortisol levels were shown to moderately correlate with hair cortisol 
and salivary cortisol [63]. Fingernail cortisol offers the possibility to retrospectively as-
sess long-term cortisol (as does hair cortisol), however, not much is known about the nail 
growth rate and influencing factors (both for growth rate as for cortisol content). It has 
been hypothesized that four to five months are required for nails to fully extend from 
the mail matrix [63] and that nail growth rate increases with temperature and declines 
with age [64], however, nothing is known about effects of for example nail polish or 
nail-biting habits. One further difficulty arises regarding the creation of timelines. It has 
128
been stated that hormones are integrated into nails via passive diffusion from capillaries 
to the nail matrix and that they become incorporated into keratin during nail formation 
[65]. However, other studies show that nail growth only occurs to 80% in the matrix, 
whereas the remaining 20% are formed during the progressive growth in the nail bed 
[66]. Therefore, for now, it is not known whether timelines are an option in fingernail 
cortisol analysis.
Table 1 provides a summary of these different methods.
table 1. Methods to measure cortisol levels
Test Sample Information Advantages Disadvantages
Point-
measurement
Saliva or 
serum
Cortisol level at one 
specific time point
Minimal effort, gives 
detailed current 
information
Highly fluctuating 
during the day In serum: 
invasive
cortisol 
awakening rise
Saliva or 
serum
Cortisol levels’ basal 
activity and response to 
awakening
Provides detailed 
information In saliva: 
patients can collect it 
at home
Highly dependent on 
time of awakening 
In serum: invasive, 
admission required In 
saliva: compliance of 
patient required
cortisol day curve Saliva or 
serum
Mean cortisol levels 
during the day and 
circadian rhythm
Provides information of 
day rhythm and mean 
cortisol levels during 
the day
Intensive for patients 
In serum: invasive, 
admission required
urinary free 
corisol
Urine Total cortisol 
production in one day
Information on total 
production
Cumbersome for 
patient; compliance 
required
Hair cortisol Hair Mean cortisol in one or 
more months
Informs on mean 
cortisol levels for 
months to years Non-
invasive, easy to collect 
Potential to create 
historical timelines
Hair length ≥1 cm 
required, some issues 
not resolved
nail cortisol Finger nail Mean cortisol in several 
months
Informs on mean 
cortisol levels for 
months Non-invasive, 
easy to collect
New method, Historical 
timelines not possible 
many issues not 
resolved
Summary of short-term and long-term cortisol measurement methods.
A recent study investigated the comparability of methods regarding salivary cortisol, 
urine cortisol, and hair cortisol, and measured all three matrices for one month (3x daily 
salivary cortisol, 1x weekly urine cortisol, 1x hair cortisol) [67]. The authors found that 
long-term cortisol was associated with the daily integrated salivary cortisol levels but 
not with the integrated CAR, the integrated diurnal slope, or integrated urinary free 
cortisol. They concluded that long-term cortisol levels of one month measured in hair 
provide a reliable estimate of a long-term integrated free cortisol production that cor-
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responds with one-month integrated daily salivary cortisol production measured in the 
same period. This supports the notion that long-term cortisol, as measured in hair, is 
a valid method to assess cortisol if one is interested in long-term values that can be 
assessed retrospectively and with minimal disadvantages for the participant. However, 
long-tem cortisol does not provide information about HPA axis dynamics.
8.3 clinical implications and future Perspectives
The clinical applicability of long-term corticosteroid research seems to increase with 
the fine-tuning of the method. In general, analysis of cortisol in scalp hair has provided 
researchers with a readily applicable tool to measure cortisol exposure over extended 
periods of time. Studies by our group and by others have indicated that long-term cor-
ticosteroid analysis may provide a new tool to investigate the chronic HPA axis activity 
in clinical practice. One of the unique advantages is the creation of timelines in hair. 
The clinical applicability has been reviewed and discussed by our group [68]. For both 
psychopathological and somatic health factors, Wester and van Rossum concluded that 
long-term cortisol measurements can be used to evaluate disturbances of the HPA axis, 
to diagnose specific diseases (such as cyclic hypercortisolism) and to evaluate (hydro-
cortisone) treatment. They state that potentially, long-term cortisol analyses could form 
a future marker for a cardiovascular risk profile and may serve as a treatment evaluation 
target.
For now, the question regarding the potential of long-term cortisol analysis as a 
new biomarker is still not answered. At this moment, it seems that a distinction in the 
potential is to be made for mental health and somatic health. For mental health, long-
term cortisol analyses have shown only small effect sizes regarding healthy controls and 
patient groups [38]. Furthermore, as the alterations in cortisol values are only subtle, one 
cannot use the long-term cortisol values to discriminate between patients and controls. 
Therefore, at present time, it seems that long-term cortisol analysis is a valuable research 
tool for psychiatric and psychological studies; however, clinical applications are not pos-
sible at the moment. It may be different for somatic health. As previous research has 
shown, long-term cortisol analysis has high sensitivity and specificity in the diagnosis 
of both cyclic and non-cyclic CD [69], with percentages comparable to standard salivary 
and urinary cortisol. It therefore seems that clinical applicability is well justified for 
somatic health.
Regarding future applications, there are several directions that are worthy to be 
pursued. One direction is the application of timelines also in mental health. Here, 
one possibility is the assessment of long-term corticosteroid levels before and after 
an (stressful) event to investigate whether and how the levels change. In the case of 
long-term corticosteroid analysis, hair strands can be divided into different segments, 
allowing the participating individuals to serve as their own controls. First studies using 
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this method have been published. One study investigated children’s long-term cortisol 
levels before and after school entry [70] and found that levels were higher after school 
entry. Other studies examined the influence of traumatic events on long-term cortisol 
levels while using the individuals’ levels before the event as baseline level [71, 72].
The next important step in long-term cortisol research to further establish this claim 
is the investigation of interventions. These interventions can be divided into a) interven-
tions aiming at symptom reduction and in parallel studying hypothetical changes in 
long-term cortisol levels, or b) interventions aiming at lowering or increasing long-term 
cortisol levels and in parallel studying hypothetical changes in symptoms. First interven-
tion studies have been published. In a retrospective study, our research group showed 
that in patients with (cyclic) Cushing’s Disease, the treatment trajectory can be observed 
in hair [69]; thereby demonstrating applicability for this sort of research. Until now, three 
studies have been published on patients attending a stress management program, and 
on long-term cortisol levels at the start and the end of the training. In the first study, 
participants at a smoking cessation intervention showed decreased long-term cortisol 
levels after a mindfulness training and smoking abstinence [73]. In the second study, 
patients with structural heart disease participated at a mindfulness training, however, 
the effect of the mindfulness training on long-term cortisol levels was not significant 
[74]. In the third study, participants attended a stress management program and had 
lower long-term cortisol levels in the last session than in the first session [75]. Taken to-
gether, the first studies seem promising that long-term cortisol analysis might be a novel 
biomarker for the evaluation of interventions. Another area that is of interest for future 
research is the individual sensitivity to cortisol. It has been hypothesized that a person’s 
vulnerability to stress is essential in the development of psychopathology [76]. One fac-
tor that determines the individual vulnerability is the genetic sensitivity to cortisol. The 
genetic sensitivity is expressed by two steroid receptors; the fast-acting, high-sensitive 
mineralocorticoid receptor (MR) and the slow(er)-acting and less-sensitive glucocorti-
coid receptor (GR). Genetic polymorphisms of MR and GR account for variations in re-
ceptor expression and sensitivity [77]. Several single nucleotide polymorphisms (SNPs) 
have been detected to have specific effects on MR and GR function. For the MR (NR3C2) 
gene, these are −2G/C and I180V. Carriers of -2G/C respond with higher cortisol levels 
to psychosocial stress [78], show enhanced optimism and a lower risk for depression in 
females [79]. Carriers of I180V present with a higher prevalence of depression [80, 81]. 
For the GR (NR3C1) gene, research has mainly focused on four polymorphisms that have 
been associated with distinct differences in glucocorticoid sensitivity, as assessed with 
the dexamethasone suppression tests (DST), and/or changes in glucocorticoid recep-
tor transactivation or transrepression activity. Two of these polymorphisms have been 
associated with a profile consistent with a more resistant response to glucocorticoids 
(ER22/23EK [82-85], 9β [86, 87]), whereas the other two polymorphisms (N363S [88, 89], 
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BclI [90, 91]) seem indicative of a more sensitive profi le. So far, no studies have been 
published in which long-term cortisol levels and glucocorticoid receptor sensitivity have 
been combined. Integration of these two factors may provide exciting opportunities for 
clinical research, as high long-term cortisol levels against a background of a hypersensi-
tive glucocorticoid receptor may synergistically produce stronger adverse health eff ects 
compared to participants with a more resistant glucocorticoid receptor. Therefore, we 
propose that future research combining these two aspects adds to a more complete 
picture of an individual’s cortisol profi le.
8.4 concluding remarks
In this thesis, we have shown that elevated long-term cortisol levels play a role in several 
stress-related diseases and disorders. A graphic overview is illustrated in Figure 1.
figure 1. An overview of the signifi cant associations shown in this thesis.
More research is required to gain further insight into the underlying factors. The 
combination of endocrine, genetic and psychological paradigms is a prerequisite to 
an integrated approach that aims to understand etiology and mechanisms of HPA axis 
dysregulation. Long-term cortisol research has repeatedly been used for this aim, with 
promising results. In the long run, this integrated approach will eventually help to pre-
dict the response to one or another pharmacological or psychotherapeutic treatment, 
and thus, to design personalized tailored interventions.
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Chapter 9
summary
Cortisol, the main glucocorticoid in humans, is commonly known as “the stress hormone”. 
This thesis examined associations between long-term cortisol as measured in scalp hair 
and different aspects of stress-related diseases and disorders. Research was conducted 
in two areas; associations between long-term cortisol and the mind, and associations 
between long-term cortisol and the body.
chapter 1 provides a general introduction to cortisol and the HPA-axis. The regulatory 
mechanisms of the HPA-axis are summarized, and different kinds of dysregulations are 
explained. Related, different methods to measure cortisol as product of the HPA-axis ac-
tivity are described. The term “stress” as well as its effect is introduced, and an overview 
of studies on long-term cortisol and chronic stress as well as stress-related disorders is 
given. Chapter 1 ends with the aims of the thesis.
In chapter 2, we used data of 760 participants without current psychopathology 
of the Netherlands Study of Depression and Anxiety (NESDA) and examined which 
sociodemographic, health and lifestyle, and hair (treatment) characteristics affect long-
term cortisol and cortisone levels measured in scalp hair. We evaluated the following 
characteristics in our analyses: sociodemographic factors: sex, age, educational level 
(years of attained education), and ancestry (North-European or not North-European); 
health and lifestyle factors: alcohol consumption, smoking behaviour, physical activity 
levels, waist and hip circumference, presence of diabetes mellitus, hypertension, other 
chronic diseases, and in women only: use of oral contraceptives, and pregnancy; hair 
(treatment) characteristics: natural hair colour, dyeing of hair, bleaching of hair, perming 
of hair, hair washing frequency, use of any products except for shampoo on the scalp on 
the day of sample collection, day of sample collection (indicative for season). For long-
term cortisol, age, diabetes mellitus, and use of oral contraceptives (in women) were 
the strongest determinants. For long-term cortisone, age and hair washing frequency 
were the strongest determinants. Therefore, these variables should be considered when 
examining long-term corticosteroid levels.
In chapter 3, we compared long-term corticosteroid levels of 245 persons without 
psychopathology with those of 655 persons with a remitted depressive and/or anxiety 
disorder and with those of 266 persons with a current depressive and/or anxiety disorder. 
Participants with a current comorbid depressive and anxiety disorder presented with 
significantly higher long-term cortisol. Long-term cortisol was not different in patients 
with a remitted disorder or with a current single diagnosis. Additional analyses revealed 
that the severity of current symptoms was associated with higher long-term cortisol 
levels. The intake of SSRIs was also associated with higher long-term cortisol. Long-term 
cortisone was associated with the presence of social phobia, but not with other current 
or remitted diagnoses. Interestingly, the significant results were found in participants 
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with a current diagnosis, whereas remitted persons did not show altered long-term cor-
ticosteroid levels. This poses a possible answer to the question whether a dysregulated 
HPA-axis in mentally ill patients is a state or trait phenomenon. A stronger association 
with active cortisol rather than inactivated cortisol (cortisone), as found in our study, 
may indicate that the alterations in long-term cortisol associated with psychopathologi-
cal characteristics seem to be a state rather than a trait. This would imply that during 
the episode of a disorder, the HPA-axis is dysregulated, but that the cortisol levels return 
to normal once the patient remits. This could be supported by the results that remitted 
patients showed long-term corticosteroid levels comparable to healthy controls.
In chapter 4, we examined the association between long-term cortisol of 71 patients 
with bipolar disorder and the number of stressful life events, the amount of social sup-
port, and mood in the three months prior to the hair assessment and between long-
term cortisol and mood in the subsequent three months. The total number of life events 
was not associated with long-term cortisol; however, the number of negative life events 
was associated with increased long-term cortisol. Social support showed an inverse as-
sociation with long-term cortisol in patients reporting negative life events. Long-term 
cortisol and mood were neither associated in the three months prior to hair sampling 
nor in the subsequent three months. This study indicates that patients who experienced 
recent negative life events have increased long-term cortisol levels, which seem to be 
attenuated by social support.
In chapter 5, we compared the long-term cortisol levels of 47 obese patients with 
those of 41 overweight and of 87 normal-weight participants, and found that obese 
participants had higher long-term cortisol levels than overweight and normal weight 
participants. Between overweight and normal weight participants, no difference in long-
term cortisol was detected. It may be that the association between increased weight 
and long-term cortisol only reveals itself in a more extreme phenotype of adiposity. It 
may also indicate that chronically elevated cortisol leads to obesity, although causality 
cannot be concluded from this study.
In chapter 6, we compared long-term cortisol levels of 132 patients with primary 
or secondary adrenal insufficiency on hydrocortisone replacement therapy with those 
of 42 patient controls with a pituitary disease without adrenal insufficiency and of 195 
healthy controls. We demonstrated that long-term cortisol levels were higher in patients 
with primary or secondary adrenal insufficiency on hydrocortisone replacement therapy 
than in patient controls and healthy controls. We further showed that the hydrocortisone 
dose correlated with long-term cortisol. Additional analyses revealed that male patients 
with adrenal insufficiency on hydrocortisone replacement had higher long-term cortisol 
levels than female patients, and that patients with adrenal insufficiency had higher body 
mass index (BMI) than healthy controls. The association between long-term cortisol and 
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BMI could suggest a mild overtreatment that may lead to adverse anthropometric side 
effects, especially in males.
chapter 7 describes the association between long-term cortisol, hydrocortisone 
intake, and quality of life (QoL) in 120 patients with stable adrenal insufficiency. Patients 
reported impairments in 14 of 15 QoL subscales. More impairment in physical aspects 
of QoL correlated with higher long-term cortisol and higher daily hydrocortisone intake, 
an effect that was more pronounced in female patients. These results show that patients 
with AI report several impairments in QoL which are associated with hydrocortisone in-
take, and to a lesser extent reflected by chronic systemic cortisol exposure as measured 
by hair cortisol. This suggests that QoL impairments in patients with AI are not per se the 
effect of overtreatment with hydrocortisone.
Finally, in chapter 8, the implications of the main findings are discussed, method-
ological considerations are reviewed, and suggestions for future research directions are 
provided.
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samenvatting
Cortisol, het belangrijkste glucocorticoïdhormoon bij de mens, staat ook wel bekend 
als “het stresshormoon”. In dit proefschrift werden de verbanden onderzocht tussen 
lange-termijn cortisol, zoals gemeten in hoofdhaar, en verschillende aspecten van 
stressgerelateerde ziekten en -stoornissen. Het onderzoek werd uitgevoerd op twee 
gebieden; associaties tussen lange-termijn cortisol en de psyche, en associaties tussen 
de lange-termijn cortisol en het lichaam.
In Hoofdstuk 1 wordt een algemene inleiding gegeven op het gebied van cortisol 
en de hypothalamus-hypofyse-bijnier (HPA)-as. De wijzen waarop de HPA-as wordt 
gereguleerd zijn hierin samengevat, en verschillende manieren waarop deze regulatie 
kan zijn verstoord. Verder worden verscheidene methoden beschreven waarop cortisol, 
het product van de HPA-as, kan worden gemeten. De term “stress” en de effecten hiervan 
worden ingeleid, en een overzicht van studies op het gebied van lange-termijn cortisol, 
chronische stress en stressgerelateerde stoornissen wordt gegeven. Hoofdstuk 1 eindigt 
met de doelstellingen van dit proefschrift.
In Hoofdstuk 2 onderzochten wij gegevens van 760 deelnemers zonder recente 
psychische stoornissen van de Nederlandse studie naar Depressie en Angst (NESDA), en 
onderzochten bij hen welke sociodemografische, gezondheids- en leefstijlaspecten, en 
eigenschappen van hoofdhaar van invloed zijn op lange-termijn corticosteroïd spiegels 
gemeten in hoofdhaar. Wij onderzochten in onze analyses de volgende eigenschappen: 
sociodemografische factoren: geslacht, leeftijd, opleidingsniveau (gevolgd onderwijs in 
jaren), en afkomst (Noord-Europese of niet Noord-Europese); gezondheid en leefstijl: 
alcoholconsumptie, roken, lichamelijke activiteit, taille- en heupomtrek, de aanwezig-
heid van diabetes mellitus, hypertensie, andere chronische aandoeningen, en alleen 
bij vrouwen het gebruik van orale anticonceptiva en zwangerschap; eigenschappen 
van hoofdhaar: natuurlijke haarkleur, verven, blonderen en permanenten van het haar, 
frequentie van haarwassen, gebruik van haar(styling)producten (met uitzondering 
van shampoo) op de dag van de haarverzameling, en de dag van de haarverzameling 
(als indicatie voor het seizoen). Leeftijd, diabetes mellitus en het gebruik van orale 
anticonceptiva (bij vrouwen) waren de sterkste invloeden op het lange-termijn cortisol. 
Leeftijd en frequentie van haarwassen waren de sterkste invloeden op het lange-termijn 
cortison. Daarom zou met deze variabelen rekening moeten worden gehouden bij de 
analyse van lange-termijn corticosteroïdwaarden.
In Hoofdstuk 3 vergeleken we de lange-termijn corticosteroïdwaarden van 245 
personen zonder psychische stoornissen met die van 655 mensen met een depressieve 
en/of angststoornis in het verleden, en 266 mensen met een actuele depressieve en/of 
angststoornis. Deelnemers met zowel een actuele depressie als angststoornis hadden 
een significant hoger lange-termijn cortisol dan andere deelnemers. Het lange-termijn 
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cortisol verschilde niet tussen patiënten met een aandoening in het verleden, of met 
een huidige diagnose van een enkele stoornis. Uit aanvullende analyses bleek dat de 
ernst van de huidige depressive en/of angstige symptomen geassocieerd was met een 
hoger lange-termijn cortisol. De inname van SSRI’s was ook geassocieerd met een hoger 
lange-termijn cortisol. Lange-termijn cortison was geassocieerd met de diagnose van 
een sociale fobie, maar niet met andere actuele of vroegere diagnoses. Wat opvalt, is 
dat de significante resultaten alleen werden gevonden in de deelnemers met een ac-
tuele stoornis, terwijl personen met een diagnose in het verleden geen verandering in 
lange-termijn corticosteroïdwaarden vertoonden. Deze resultaten geven een mogelijk 
antwoord op de vraag of een ontregelde HPA-as bij patiënten met een psychopatho-
logische diagnose een “state” of “trait” fenomeen is. Een sterkere associatie met actief 
cortisol, in plaats van geïnactiveerd cortisol (cortison), zoals in onze studie, zou kunnen 
aangeven dat de veranderingen op lange-termijn cortisol geassocieerd met psychopa-
thologische kenmerken meer wijzen in de richting van een “state” dan een “trait”. Dit 
impliceert dat de HPA-as ontregeld is tijdens een actuele episode van stoornis, maar 
dat de cortisolwaarden weer normaliseren zodra de patiënt is hersteld. Dit wordt verder 
ondersteund door de bevinding dat patienten met een diagnose in het verleden verge-
lijkbaare lange-termijn corticosteroïd waarden hebben met gezonde controles.
In Hoofdstuk 4 hebben we bij 71 patiënten met een bipolaire stoornis de as-
sociaties onderzocht tussen lange-termijn cortisol waarden en het aantal stressvolle 
levensgebeurtenissen, de hoevelheid sociale steun, de stemming in de drie maanden 
voorafgaand aan de haar verzameling, en de stemming in de drie maanden volgend op 
de haarverzameling. Het totale aantal levensgebeurtenissen hield geen verband met 
lange-termijn cortisolwaarden; het aantal negatieve gebeurtenissen was echter wel ge-
associeerd met een verhoogd lange-termijn cortisol. Sociale steun toonde een negatief 
verband met lange-termijn cortisol bij patiënten die negatieve levensgebeurtenissen 
hadden meegemaakt. Lange-termijn cortisol waarden waren niet geassocieerd met 
stemming in de drie maanden voorafgaand aan de haar verzameling, noch in de drie 
daaropvolgende maanden.
De resultaten van deze studie laten zien dat patiënten die recente negatieve levens-
gebeurtenissen hebben meegemaakt hogere lange-termijn cortisol levels hebben, wat 
echter lijkt te worden verminderd door een toename in sociale steun.
In Hoofdstuk 5 vergeleken we de lange-termijn cortisolwaarden van 47 obese patien-
ten, met die van 41 mensen met overgewicht en 87 mensen met normaal gewicht. Wij 
vonden dat obese mensen hogere lange-termijn cortisol waarden hebben dan mensen 
met overgewicht en normaal gewicht. Tussen mensen met overgewicht en een normaal 
gewicht werd geen verschil in lange-termijn cortisol gedetecteerd. Het zou kunnen zijn 
dat de associatie tussen hoger gewicht en lange-termijn cortisol waarden zich pas bij 
een ernstig overgewicht (obesitas) openbaart. Het zou tevens kunnen betekenen dat 
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chronisch verhoogde cortisol tot obesitas leidt, maar een oorzakelijk verband kan uit 
deze studie niet geconcludeerd worden.
In Hoofdstuk 6 vergeleken we de lange-termijn cortisolwaarden van 132 patiënten 
met primaire of secundaire bijnierschorsinsufficiëntie die werden behandeld met 
hydrocortisonsubstitutietherapie, met die van 42 controlepatiënten die een hypofyse-
aandoening zonder bijnierschorsinsufficiëntie, en 195 gezonde controles. We lieten 
zien dat lange-termijn cortisol waarden hoger waren bij patiënten met primaire of 
secundaire bijnierschorsinsufficiëntie onder hydrocortisonsubstitutietherapie dan 
controlepatiënten en gezonde controles. Daarnaast correleerde de dosis hydrocortison 
met lange-termijn cortisol. Uit aanvullende analyses bleek dat mannelijke patiënten 
met bijnierschorsinsufficiëntie onder hydrocortisonsubstitutietherapie een hoger 
lange-termijn cortisol hadden dan vrouwelijke patiënten. Patiënten met bijnierschorsin-
sufficiëntie hadden tevens een hogere body mass index (BMI) dan gezonde controles. 
Het verband tussen lange-termijn cortisol en BMI zou een milde overbehandeling 
kunnen suggereren, die zou kunnen leiden tot nadelige bijwerkingen op het gebied op 
lichaamssamenstelling, met name bij mannen.
Hoofdstuk 7 beschrijft het verband tussen lange-termijn cortisol, het gebruik van 
hydrocortison, en kwaliteit van leven (quality of life, QoL) bij 120 patiënten met stabiele 
bijnierschorsinsufficiëntie. Patiënten meldden afname in 14 van de 15 QoL subschalen. 
Een slechtere score op de fysieke aspecten van QoL correleerde met een hoger lange-
termijn cortisol, en een hogere dagelijkse inname van hydrocortison, een effect dat 
sterker was bij vrouwelijke patiënten. Deze resultaten tonen aan dat patiënten met 
bijnierinsufficiëntie meerdere beperkingen in levenskwaliteit rapporteren, welke geas-
socieerd zijn met hydrocortison inname, en in mindere mate worden gereflecteerd door 
een chronische systemische blootstelling aan cortisol zoals gemeten met haarcortisol. 
Dit suggereert dat de verminderde kwaliteit van leven bij patiënten met bijnierinsuf-
ficiëntie niet enkel het effect van overbehandeling met hydrocortison is.
Ten slotte worden in Hoofdstuk 8 de implicaties van de belangrijkste bevindingen 
besproken, methodologische beschouwingen worden samengevat, en worden aanbe-
velingen voor toekomstig onderzoek gegeven.
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